RNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

RNA-based vaccine compositions encoding HSV glycoproteins provide effective protection against HSV-1 and HSV-2 by inducing strong immune responses, addressing the lack of effective vaccines for genital herpes and reducing infection severity.

WO2024249967A1PCT designated stage expired Publication Date: 2024-12-05THE TRUSTEES OF THE UNIV OF PENNSYLVANIA +1

Patent Information

Application Number
PCT/US2024/032163
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-03
Filing Date
2024-06-02
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current vaccines do not effectively prevent genital herpes infections caused by herpes simplex virus (HSV) types 1 and 2, and there is a need for a prophylactic vaccine that can inhibit or treat these infections, particularly given the risk of transmission and severe complications such as neonatal herpes.

Method used

Development of pharmaceutical compositions comprising nucleoside modified RNAs that encode HSV glycoproteins, including gD, gC, and gE, which are administered to induce an immune response and prevent or treat HSV infections by encoding immunogenic fragments of these proteins.

Benefits of technology

The RNA-based vaccine compositions demonstrate significant protection against HSV-1 and HSV-2 infections by eliciting robust immune responses, including neutralizing antibodies and T-cell responses, effectively preventing the establishment of latent infections and reducing disease severity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2024032163_05122024_PF_FP_ABST
    Figure US2024032163_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present disclosure provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

P-627574-PC RNA VACCINES ENCODING HERPES SIMPLEX VIRUS GLYCOPROTEINS AND USES THEREOF SEQUENCE LISTING STATEMENT

[0001] The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy, created on June 2, 2024, is named P-627574-PC-SQL-02JUN24.xml and is 379 kilobytes in size. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with U.S. government support under AI139618 awarded by The National Institutes of Health. The government has certain rights in the invention. TECHNICAL FIELD

[0003] The present disclosure provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified RNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof. BACKGROUND

[0004] Herpes simplex type 1 (HSV-1) infections affect an estimated 3.7 billion people between the ages of 0-49 worldwide. Many people acquire HSV-1 during childhood from family members, friends, or peers at school. Orolabial HSV-1 infection is usually self-limited and although emotionally disturbing to some, does not pose a serious health risk to those infected. However, HSV-1 infection at other sites, such as the cornea or brain, may cause blindness and life- threatening encephalitis, respectively. In many resource-rich countries, reduced orolabial HSV-1 acquisition during childhood has resulted in adolescents and adults having a higher risk of acquiring first-time HSV-1 as a genital infection. Although genital HSV- 1 infections have a reduced risk of recurrences, genital transmission of HSV-1 from mother to newborn during labor 1 11979815v1P-627574-PC and delivery can be devastating. HSV-1 neonatal herpes is more common than HSV-2 neonatal herpes in resource rich-countries.

[0005] A prophylactic vaccine that prevents genital HSV-1 and HSV-2 infection and HSV-1 at non-genital sites is a public health priority. Despite major efforts from the scientific community, no FDA-approved vaccine is available to prevent HSV-1 or HSV-2 infection. SUMMARY

[0006] The present disclosure provides pharmaceutical compositions (e.g., immunogenic compositions, e.g., vaccines) for delivering a particular herpes simplex virus (HSV) glycoprotein or immunogenic fragment thereof (e.g., HSV-1 glycoprotein or immunogenic fragment thereof, an HSV-2 glycoprotein or immunogenic fragment thereof, or any combinations thereof) to a subject (e.g., a patient) and related technologies (e.g., methods). In particular, the present disclosure provides HSV (e.g., HSV-1, HSV-2, or both) vaccine compositions and related technologies (e.g., methods). Additionally, the present disclosure provides HSV (e.g., HSV-1, HSV-2, or both) vaccine compositions for inhibiting, preventing or treating an HSV infection (e.g., HSV-1, HSV-2, or both).

[0007] In some embodiments, the present disclosure provides a method of inhibiting an HSV-1 oral mucosal infection in a subject comprising the step of administering to said subject a composition comprising RNA encoding Herpes Simplex Virus (HSV) glycoprotein D (gD) or an immunogenic fragment thereof, a composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and a composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof.

[0008] In another embodiment, the present disclosure provides a method of preventing establishment of a latent HSV infection in a subject comprising the step of administering to said subject a composition comprising RNA encoding Herpes Simplex Virus (HSV) glycoprotein D (gD) or an immunogenic fragment thereof, a composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and a composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof.

[0009] Other features and advantages of the present disclosure will become apparent from the following detailed description examples and figures. It should be understood, however, that the detailed description and the specific examples while indicating preferred embodiments of the disclosure are given by way of illustration only, since various changes and modifications within 2 11979815v1P-627574-PC the spirit and scope of the disclosure will become apparent to those skilled in the art from this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present disclosure, the inventions of which can be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0011] Figures 1A-1C. Characterization of exemplary translational products of an immunogenic fragment of the ectodomain from HSV-2 gC (gC2)-, HSV-2 gD (gD2)- and HSV-2 gE (gE2)- modified RNA in Vero cells.

[0012] Figure 1A. Western blot showing expression of an immunogenic fragment of gC2 from an exemplary modified RNA.

[0013] Figure 1B. Western blot showing expression of an immunogenic fragment of gD2 from an exemplary modified RNA.

[0014] Figure 1C. Western blot showing expression of an immunogenic fragment of gE2 from an exemplary modified RNA.

[0015] Figure 2A. gC2 antibody (Ab) response as determined by antigen-specific ELISA in mice immunized with an exemplary gD2 RNA; or an exemplary combination of a gC2 RNA, a gD2 RNA and a gE2 RNA each given at a different intradermal site (Trivalent-I); or an exemplary combination of a gC2 RNA, a gD2 RNA and a gE2 RNA given in a single composition (Trivalent- C). I indicates first immunization; II indicates second immunization.

[0016] Figure 2B. gD2 Ab response as determined by antigen-specific ELISA in mice immunized with an exemplary gD2 RNA; or an exemplary combination of a gC2 RNA, a gD2 RNA and a gE2 RNA each given at a different intradermal site (Trivalent-I); or an exemplary combination of a gC2 RNA, a gD2 RNA and a gE2 RNA given in a single composition (Trivalent- C). I indicates first immunization; II indicates second immunization.

[0017] Figure 2C. gE2 Ab response as determined by antigen-specific ELISA in mice immunized with an exemplary gD2 RNA; or an exemplary combination of a gC2 RNA, a gD2 RNA and a gE2 RNA each given at a different intradermal site (Trivalent-I); or an exemplary 3 11979815v1P-627574-PC combination of a gC2 RNA, gD2 RNA and gE2 RNA given in a single composition (Trivalent- C). I indicates first immunization; II indicates second immunization.

[0018] Figure 3A. Antigen-specific IgG1 responses in mice vaccinated with exemplary RNA compositions. Antibodies were evaluated after the first and second immunization for IgG1 responses. I indicates first immunization; II indicates second immunization.

[0019] Figure 3B. Antigen-specific IgG2a responses in mice vaccinated with exemplary RNA compositions. Antibodies were evaluated after the first and second immunization for IgG2a responses. I indicates first immunization; II indicates second immunization.

[0020] Figure 4. Neutralizing antibody titers in RNA vaccinated mice. 50% endpoint neutralization titers of serum were obtained after the second immunization. Titers were performed using 10% human complement. Trivalent-I animals were immunized with an exemplary gC2 / lipid nanoparticle (LNP), an exemplary gD2 / LNP, and an exemplary gE2 / LNP, each given at a different site. Trivalent-C animals were immunized with an exemplary gC2, an exemplary gD2 and an exemplary gE2 combined into a single LNP. P values comparing 50% endpoint neutralizing titers: Trivalent-I versus gD2, p=0.04; Trivalent-C versus gD2, p=0.002; Trivalent-I versus Trivalent-C, p-0,026.

[0021] Figures 5A-5B. CD4+T cell responses to an exemplary gC2, an exemplary gD2 and an exemplary gE2 RNA each administered at a different intradermal site. Splenocytes were stimulated with subunit antigen glycoproteins (Figure 5A) or 15 amino acid peptides with 11 overlapping amino acids to stimulate HSV-2 specific T cell responses (Figure 5B). * indicates p<0.05 (t test) comparing gC, gD or gE with PBS stimulated CD4+T cells or DMSO stimulated CD4+T cells. Error bars represent SD.

[0022] Figures 6A-6B. CD8+T cell responses to an exemplary gC2, an exemplary gD2 and an exemplary gE2 RNA, each administered at a different intradermal site. Splenocytes were stimulated with subunit antigen glycoproteins (Figure 6A) or 15 amino acid peptides with 11 overlapping amino acids to stimulate HSV-2 specific T cell responses (Figure B). * indicates p<0.05 comparing gE pool 2 with DMSO control. Error bars represent SD.

[0023] Figure 7A. Survival in BALB / c mice immunized with exemplary RNA compositions twice at 28 day intervals and challenged intravaginally with HSV-2. Trivalent-I represents animals immunized with an exemplary gC2 RNA / LNP, an exemplary gD2 RNA / LNP, and an exemplary gE2 RNA / LNP each given at different intradermal sites. Trivalent-C represents 4 11979815v1P-627574-PC animals immunized with an exemplary gC2 RNA, an exemplary gD2 RNA and an exemplary gE2 RNA combined into a single LNP for immunization.

[0024] Figure 7B. Weight loss (-) or gain (+) and neurological signs in BALB / c mice immunized with exemplary RNA compositions twice at 28 day intervals and challenged intravaginally with HSV-2. Trivalent-I represents animals immunized with an exemplary gC2 RNA / LNP, an exemplary gD2 RNA / LNP, and an exemplary gE2 RNA / LNP each given at different intradermal sites. Trivalent-C represents animals immunized with an exemplary gC2 RNA, an exemplary gD2 RNA and an exemplary gE2 RNA combined into a single LNP for immunization.

[0025] Figures 8A-8B. Vaginal viral titers in mice vaccinated with exemplary RNA compositions after intravaginal challenge with HSV-2. Vaginal swab titers were obtained on Day 2 (Figure 8A) and Day 4 (Figure 8B) post-challenge. The dotted lines indicate the limit of detection of the assay at 7 PFU / ml.

[0026] Figure 9. Genital disease in mice vaccinated with exemplary RNA compositions after HSV-2 vaginal challenge. Mice were immunized with poly C as a control, or with an exemplary gD2 RNA / LNP, trivalent at individual sites for each exemplary glycoprotein RNA (Trivalent-I) or trivalent with all three exemplary RNAs combined (Trivalent-C). Genital disease was scored for 28 days. All animals in the poly C group died by day 10. ***, indicates p<0.001 comparing poly C with the other 3 groups.

[0027] Figure 10. HSV-2 DNA copies in dorsal root ganglia (DRG) in RNA vaccinated mice on day 4 post challenge. HSV-2 DNA in DRG was measured by qPCR. DRG from 4 to 5 animals per group were evaluated for HSV-2 DNA at 4 days post challenge. The bars represent the mean values per group.

[0028] Figure 11A. The exemplary trivalent RNA-LNP vaccine induces a potent T follicular helper cell response in mice. BALB / c female mice were left un-immunized as naïve control animals or immunized intradermally twice at 28 day intervals with poly C RNA-LNP or an exemplary trivalent modified RNA-LNP. The poly C RNA controls received 10μg Poly C RNA- LNP divided into 4 aliquots and administered at 4 separate sites. The exemplary trivalent modified RNA group received 10μg of an exemplary gC2 RNA-LNP, 10μg of an exemplary gD2 RNA- LNP, and 10μg of an exemplary gE2 RNA-LNP each divided into 2 aliquots and each given at 2 sites. Two weeks after the second immunization, spleens were harvested from 5 animals per group and flow cytometry performed to detect T follicular helper (Tfh) cell responses (*p<0.05). 5 11979815v1P-627574-PC

[0029] Figure 11B. The exemplary trivalent RNA-LNP vaccine induces a potent germinal center B cell response in mice. BALB / c female mice were left un-immunized as naïve control animals or immunized intradermally twice at 28 day intervals with poly C RNA-LNP or an exemplary trivalent modified RNA-LNP. The poly C RNA controls received 10μg Poly C RNA- LNP divided into 4 aliquots and administered at 4 separate sites. The trivalent modified RNA group received 10μg of an exemplary gC2 RNA-LNP, 10μg of an exemplary gD2 RNA-LNP, and 10μg of an exemplary gE2 RNA-LNP each divided into 2 aliquots and each given at 2 sites. Two weeks after the second immunization, spleens were harvested from 5 animals per group and flow cytometry performed to detect germinal center B cell responses (*p<0.05).

[0030] Figures 12A-12C. Genital mucosa IgG antibody responses. BALB / c mice were immunized intradermally twice at 28 day intervals with 10μg of poly C RNA-LNP, 10μg of an exemplary gD2 RNA-LNP or 10μg each of an exemplary gC2, an exemplary gD2, an exemplary gE2 trivalent modified RNA-LNP. The exemplary trivalent RNA was combined and administered as 10μg of an exemplary gC2 RNA & 10μg of an exemplary gD2 RNA & 10μg of an exemplary gE2 RNA combined into LNP and divided into 4 aliquots and given at 4 sites. One month after the second immunization, 60μl of media was introduced in the vaginal cavity and retrieved. IgG titers were determined at a 1:50 dilution of the vaginal wash fluids by ELISA to gC2 (Figure 12A), gD2 (Figure 12B), and gE2 (Figure 12C) (n=10 mice in the poly C group, n=10 in the gD2 RNA group and n=25 in the trivalent RNA group; ***p<0.001; **p<0.01).

[0031] Figure 13. The exemplary trivalent RNA-LNP vaccine produces antibodies that block gC2 binding to complement component C3b. BALB / c mice were left unimmunized as a source of non-immune IgG, or immunized intradermally with poly C RNA-LNP or an exemplary trivalent RNA-LNP. The poly C RNA controls received 10μg poly C RNA-LNP divided into 4 aliquots and administered at 4 separate sites. The gD2 RNA group received 10μg of an exemplary gD2 RNA- LNP administered as described for the poly C RNA-LNP. The trivalent modified RNA group received 10μg of an exemplary gC2 RNA-LNP, 10μg of an exemplary gD2 RNA-LNP, and 10μg of an exemplary gE2 RNA-LNP combined into LNP and divided into 4 aliquots and given at 4 sites. There were 10 mice in each group. Sera from the 10 mice were pooled and IgG was purified. The IgG was evaluated at 12μg / 200μl for its ability to block complement component C3b binding to gC2. (****p<0.0001).

[0032] Figures 14A-14F. The exemplary trivalent RNA vaccine provides outstanding protection in mice when the vaccine is administered intramuscularly. BALB / c mice were 6 11979815v1P-627574-PC immunized intramuscularly with poly C RNA-LNP as a control (15 / group) or with an exemplary trivalent RNA composition containing 10 μg each of an exemplary gC2, an exemplary gD2 and an exemplary gE2 RNA-LNP (20 / group). Figure 14A presents data on mouse survival; Figure 14B presents data on weight loss; Figure 14C presents data on genital disease. DRG were harvested from nine poly C animals at the time of euthanasia between days 7 and 12 post-infection or at the end of the experiment on day 28 in the trivalent RNA group. Figure 14D presents data on HSV-2 DNA in DRG. Figure 14E presents data on vaginal viral cultures on Day 2 and Figure 14F presents data on vaginal viral cultures on Day 4. Difference between poly C and trivalent groups are significant, p<0.001 for Figures 14A-14F.

[0033] Figures 15A-15C. The exemplary trivalent RNA vaccine is highly efficacious in the guinea pig genital infection model. Hartley Strain female guinea pigs were left unimmunized and uninfected (naive group, n=10), immunized three times intradermally at monthly intervals with 20μg poly C RNA-LNP (n=10) or with 20μg each of an exemplary gC2, an exemplary gD2, an exemplary gE modified RNA-LNP (n=10). One month after the final immunization, animals in the poly C and trivalent RNA groups were infected intravaginally with 5x105PFU of HSV-2 strain MS (50 LD50). Animals were observed for death, genital lesions during the acute phase of infection (days 1-14) and genital lesions during the recurrent phase of infection (days 15-60). Figure 15A presents data on survival; Figure 15B provides data on vaginal disease (acute phase); and Figure 15C provides data on vaginal disease (recurrent phase).

[0034] Figures 16A-16D. Exemplary tri-HSV-1 and exemplary tri-HSV-2 immunizations generate antibodies that bind to HSV-1 proteins and neutralize HSV-1. Mice were immunized twice with PBS, exemplary tri-HSV-1 RNA, or exemplary tri-HSV-2 RNA at 1 µg or 10 µg of total RNA. Figures 16A-16C. IgG ELISA endpoint titers against HSV-1 proteins. Figure 16D. HSV-1 neutralizing titers in the presence of 5% human serum as source of complement. N=10 mice per group. P values were calculated using the two-tailed Mann-Whitney test.

[0035] Figure 17. Gating strategy used in CD4 and CD8 T cell flow cytometry analysis. Singlet cells were gated, then live CD3+, then lymphocytes, and then CD4+ and CD8+ T-cells. Single cytokine positive CD8+ T-cells were gated using CD8+ and TNFα, IFNγ, or IL-2 parameters. Gate coordinates were set based on the DMSO treated cells and those gate coordinates were transferred to the peptide treated cells.

[0036] Figures 18A-18D. Exemplary tri-HSV-1 and exemplary tri-HSV-2 immunizations generate CD4+ and CD8+ T-cell responses to HSV-1 overlapping peptides. Mice were 7 11979815v1P-627574-PC immunized twice with 10 µg total of exemplary tri-HSV-1 RNA, exemplary tri-HSV-2 RNA, or PBS. Figure 18A. Proportion of CD8+ T-cells producing 0, 1, 2, or 3 cytokines. Numbers inside or adjacent to colored segments indicate percentage of total CD8+ T-cells producing the indicated number of cytokines. Figure 18B. Activation markers of CD8+ T-cells stimulated with gE1 overlapping peptide pool producing TNFα, IFNγ, and / or IL-2. Figure 18C. Proportion of CD8+ T-cells expressing CD107a when stimulated with gE1 overlapping peptides. Figure 18D. Proportion of CD4+ T-cells producing polyfunctional cytokines TNFα, IFNγ, and IL-2 following stimulation with a gD1 overlapping peptide pool. N=5 mice per group. P values in Figure 18B were calculated using 2-way ANOVA with Tukey’s correction for multiple comparisons. P values in Figure 18C and Figure 18D were calculated using the two-tailed Mann-Whitney test.

[0037] Figures 19A-19G. Exemplary tri-HSV-1 and tri-HSV-2 RNA compositions protect mice against acute and latent HSV-1 infection in the lip. Mice were immunized with PBS, exemplary tri-HSV-1 RNA, or tri-HSV-2 RNA compositions as in Figure 1. Mice were challenged with 2 ×106PFU of HSV-1 applied to the scarified lower lip. Figure 19A. HSV-1 virus titers in the lower lip. Figure 19B. HSV-1 DNA copy number in the lower lip. Figure 19C. HSV-1 virus titers in the trigeminal ganglia (TG). Figure 19D. HSV-1 DNA copy number in the TG. Figures 19A-19D. n=10 per group. Figure 19E. Mice were weighed daily for 13 days. Figure 19F. Mice were scored for lesions on the lip with a score of 1 for lesions or 0 for no lesions. Figure 19G. HSV-1 DNA genome copies in the TG 28 days post-challenge. Figures 19E-19G. n=24 mice for PBS group, n=15 mice per RNA immunization group. P values in Figures 19A-19D, and Figure 19G were calculated by the two-tailed Mann-Whitney test.

[0038] Figures 20A-20F. Exemplary tri-HSV-1 and exemplary tri-HSV-2 RNA compositions protect mice from intravaginal HSV-1 disease. Mice were immunized with PBS, exemplary tri- HSV-1 RNA, or exemplary tri-HSV-2 RNA. Mice were challenged with 2 ×106PFU of HSV-1 intravaginally and scored for clinical disease for 14 days. Figure 20A. Survival curve. P values were calculated by the log-rank test. Figure 20B. Weight loss. Figure 20C. Mean genital disease scores for each group. Figures 20D-20E. Vaginal swabs were obtained on days two and four for virus titers. Figure 20F. HSV-1 DNA copy number in DRG. N=5 mice for PBS group, n=5 mice for tri-HSV-1 group, and n=4 mice for tri-HSV-2 group. P values in Figures 20D-20F were calculated by the two-tailed Mann-Whitney test without adjustments for multiple comparisons.

[0039] Figure 21. Determination of LD50of HSV-1. Naïve (not vaccinated) 6 to 8-week-old female mice were inoculated intranasally with 5x103, 5x104, 5x105, 5x106plaque-forming units 8 11979815v1P-627574-PC (pfu) of HSV-1 strain H129, or with PBS as a control. Survival was evaluated over 28 days. Survival was 50% (2 of 4 mice) at 5x103pfu, establishing the 50% lethal dose (LD50) as 5x103pfu.

[0040] Figures 22A-22D. Trivalent HSV-2 vaccine (Tri-HSV-2) protects BALB / c mice against HSV-1 encephalitis. Female BALB / c mice were immunized twice with either 1 ^g (0.33 ^g of each mRNA) or 10 ^g (3.33 ^g each mRNA) trivalent HSV-2 mRNA vaccine at 1-month intervals or PBS as described above. One month after the 2ndimmunization, animals were infected intranasally with 5x105pfu (100 LD50) of HSV-1 strain H129. Figure 22A. Animals were monitored for survival; P<0.01 comparing 1 or 10 ^g Tri-HSV-2 vaccine group with PBS by Log- rank test. Figures 22B-22D. HSV-1 DNA copy number was determined on day 6 post-infection by qPCR in brains (Figure 22B), trigeminal ganglia (Figure 22C), and olfactory bulbs (Figure 22D); n=10 / group except n=9 for olfactory bulb in the 1 ^g Tri-HSV-2 vaccine group. P value comparing log10copy number (within the graph): ***, P<0.001; P values were calculated by two- tailed Mann-Whitney test. P value comparing number of animals positive for HSV-1 DNA (above the graph): **, P<0.01; P values were calculated by two-tailed Fisher’s exact test. CERTAIN DEFINITIONS

[0041] In general, terminology used herein is in accordance with its understood meaning in the art, unless clearly indicated otherwise. Explicit definitions of certain terms are provided below; meanings of these and other terms in particular instances throughout this specification will be clear to those skilled in the art from context.

[0042] In order that the present invention may be more readily understood, certain terms are first defined below. Additional definitions for the following terms and other terms are set forth throughout the specification.

[0043] About: The term “about”, when used herein in reference to a value, refers to a value that is similar, in context to the referenced value. In general, those skilled in the art, familiar with the context, will appreciate the relevant degree of variance encompassed by “about” in that context. For example, in some embodiments, the term “about” may encompass a range of values that within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the referred value.

[0044] Agent: As used herein, the term “agent”, may refer to a physical entity or phenomenon. In some embodiments, an agent may be characterized by a particular feature and / or effect. In some 9 11979815v1P-627574-PC embodiments, an agent may be a compound, molecule, or entity of any chemical class including, for example, a small molecule, polypeptide, nucleic acid, saccharide, lipid, metal, or a combination or complex thereof. In some embodiments, the term “agent” may refer to a compound, molecule, or entity that comprises a polymer. In some embodiments, the term may refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term “agent” may refer to a compound, molecule, or entity that is substantially free of a particular polymer or polymeric moiety. In some embodiments, the term may refer to a compound, molecule, or entity that lacks or is substantially free of any polymer or polymeric moiety.

[0045] Amino acid: In its broadest sense, as used herein, the term “amino acid” refers to a compound and / or substance that can be, is, or has been incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds. In some embodiments, an amino acid has the general structure H2N–C(H)(R)–COOH. In some embodiments, an amino acid is a naturally- occurring amino acid. In some embodiments, an amino acid is a non-natural amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L- amino acid. “Standard amino acid” refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. “Nonstandard amino acid” refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and / or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above. For example, in some embodiments, an amino acid may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and / or substitution (e.g., of the amino group, the carboxylic acid group, one or more protons, and / or the hydroxyl group) as compared with the general structure. In some embodiments, such modification may, for example, alter the circulating half-life of a polypeptide containing the modified amino acid as compared with one containing an otherwise identical unmodified amino acid. In some embodiments, such modification does not significantly alter a relevant activity of a polypeptide containing the modified amino acid, as compared with one containing an otherwise identical unmodified amino acid. As will be clear from context, in some embodiments, the term “amino acid” may be used to refer to a free amino acid; in some embodiments it may be used to refer to an amino acid residue of a polypeptide.

[0046] Antibody agent: As used herein, the term “antibody agent” refers to an agent that specifically binds to a particular antigen. In some embodiments, the term encompasses a 10 11979815v1P-627574-PC polypeptide or polypeptide complex that includes immunoglobulin structural elements sufficient to confer specific binding. For example, in some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those skilled in the art as a complementarity determining region (CDR); in some embodiments an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and / or at least one light chain CDR) that is substantially identical to one found in a reference antibody. In some embodiments an included CDR is substantially identical to a reference CDR in that it is either identical in sequence or contains between 1-5 amino acid substitutions as compared with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that it shows at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that at least one amino acid within the included CDR is substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical with that of the reference CDR. In some embodiments an included CDR is substantially identical to a reference CDR in that 1-5 amino acids within the included CDR are deleted, added, or substituted as compared with the reference CDR but the included CDR has an amino acid sequence that is otherwise identical to the reference CDR. In some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art as an immunoglobulin variable domain. In some embodiments, an antibody agent in or comprises a polypeptide whose amino acid sequence includes structural elements recognized by those skilled in the art to correspond to CDRs1, 2, and 3 of an antibody variable domain; in some such embodiments, an antibody agent in or comprises a polypeptide or set of polypeptides whose amino acid sequence(s) 11 11979815v1P-627574-PC together include structural elements recognized by those skilled in the art to correspond to both heavy chain and light chain variable region CDRs, e.g., heavy chain CDRs 1, 2, and / or 3 and light chain CDRs 1, 2, and / or 3. In some embodiments, an antibody agent is a polypeptide protein having a binding domain which is homologous or largely homologous to an immunoglobulin- binding domain. In some embodiments, an antibody agent may be or comprise a polyclonal antibody preparation. In some embodiments, an antibody agent may be or comprise a monoclonal antibody preparation. In some embodiments, an antibody agent may include one or more constant region sequences that are characteristic of a particular organism, such as a camel, human, mouse, primate, rabbit, rat; in many embodiments, an antibody agent may include one or more constant region sequences that are characteristic of a human. In some embodiments, an antibody agent may include one or more sequence elements that would be recognized by one skilled in the art as a humanized sequence, a primatized sequence, a chimeric sequence, etc. In some embodiments, an antibody agent may be a canonical antibody (e.g., may comprise two heavy chains and two light chains). In some embodiments, an antibody agent may be in a format selected from, but not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multi- specific antibodies (e.g., Zybodies®, etc); antibody fragments such as Fab fragments, Fab’ fragments, F(ab’)2 fragments, Fd’ fragments, Fd fragments, and isolated CDRs or sets thereof; single chain Fvs; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies such as IgNAR or fragments thereof); cameloid antibodies; masked antibodies (e.g., Probodies®); Small Modular ImmunoPharmaceuticals (“SMIPsTM”); single chain or Tandem diabodies (TandAb®); VHHs; Anticalins®; Nanobodies® minibodies; BiTE®s; ankyrin repeat proteins or DARPINs®; Avimers®; DARTs; TCR-like antibodies;, Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; MicroProteins; Fynomers®, Centyrins®; and KALBITOR®s. In some embodiments, an antibody may lack a covalent modification (e.g., attachment of a glycan) that it would have if produced naturally. In some embodiments, an antibody may contain a covalent modification (e.g., attachment of a glycan, a payload (e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc.), or other pendant group (e.g., poly-ethylene glycol, etc.)).

[0047] Antigen: Those skilled in the art, reading the present specification, will appreciate that the term “antigen” refers to a molecule that is recognized by the immune system, e.g., in particular embodiments the adaptive immune system, such that it elicits an antigen-specific immune response. In some embodiments, an antigen-specific immune response may be or comprise generation of antibodies and / or antigen-specific T cells. In some embodiments, an antigen is a 12 11979815v1P-627574-PC peptide or polypeptide that comprises at least one epitope against which an immune response can be generated. In some embodiments, an antigen is presented by cells of the immune system such as antigen presenting cells like dendritic cells or macrophages. In one embodiments, an antigen or a processed product thereof such as a T-cell epitope is bound by a T- or B-cell receptor, or by an immunoglobulin molecule such as an antibody. Accordingly, an antigen or a processed product thereof may react specifically with antibodies or T lymphocytes (T cells). In some embodiments, an antigen is a parasitic antigen. In accordance with the present disclosure, in some embodiments, an antigen may be delivered by RNA molecules as described herein. In some embodiments, a peptide or polypeptide antigen can be 2-100 amino acids, including for example, 5 amino acids, 10 amino acids, 15 amino acids, 20 amino acids, 25 amino acids, 30 amino acids, 35 amino acids, 40 amino acids, 45 amino acids, or 50 amino acids in length. In some embodiments, a peptide or polypeptide antigen can be greater than 50 amino acids. In some embodiments, a peptide or polypeptide antigen can be greater than 100 amino acids. In some embodiments, an antigen is recognized by an immune effector cell. In some embodiments, an antigen if recognized by an immune effector cell is able to induce in the presence of appropriate co-stimulatory signals, stimulation, priming and / or expansion of the immune effector cell carrying an antigen receptor recognizing the antigen. In the context of the embodiments of the present disclosure, in some embodiments, an antigen can be presented or present on the surface of a cell, e.g., an antigen presenting cell. In some embodiments, an antigen is presented by a diseased cell such as a virus- infected cell. In some embodiments, an antigen receptor is a TCR which binds to an epitope of an antigen presented in the context of MHC. In some embodiments, binding of a TCR when expressed by T cells and / or present on T cells to an antigen presented by cells such as antigen presenting cells results in stimulation, priming and / or expansion of said T cells. In some embodiments, binding of a TCR when expressed by T cells and / or present on T cells to an antigen presented on diseased cells results in cytolysis and / or apoptosis of the diseased cells, wherein said T cells preferably release cytotoxic factors, e.g., perforins and granzymes.

[0048] Associated: Two events or entities are “associated” with one another, as that term is used herein, if the presence, level, degree, type and / or form of one is correlated with that of the other. For example, a particular entity (e.g., polypeptide, genetic signature, metabolite, microbe, etc) is considered to be associated with a particular disease, disorder, or condition, if its presence, level and / or form correlates with incidence of, susceptibility to, severity of, stage of, etc. the disease, disorder, or condition (e.g., across a relevant population). In some embodiments, two or more 13 11979815v1P-627574-PC entities are physically “associated” with one another if they interact, directly or indirectly, so that they are and / or remain in physical proximity with one another. In some embodiments, two or more entities that are physically associated with one another are covalently linked to one another; in some embodiments, two or more entities that are physically associated with one another are not covalently linked to one another but are non-covalently associated, for example by means of hydrogen bonds, van der Waals interaction, hydrophobic interactions, magnetism, and combinations thereof.

[0049] Binding: Those skilled in the art, reading the present specification, will appreciate that the term “binding” typically refers to a non-covalent association between or among entities or moieties. In some embodiments, binding data are expressed in terms of “IC50”. As is understood in the art, IC50 is the concentration of an assessed agent in a binding assay at which 50% inhibition of binding of reference agent known to bind the relevant binding partner is observed. In some embodiments, assays are run under conditions in which the assays are run (e.g., limiting binding target and reference concentrations), these values approximate KDvalues. Assays for determining binding are well known in the art and are described in detail, for example, in PCT publications WO 94 / 20127 and WO 94 / 03205, and other publications such Sidney et al., Current Protocols in Immunology 18.3.1 (1998); Sidney, et al., J. Immunol. 154:247 (1995); and Sette, et al., Mol. Immunol.31:813 (1994). Alternatively, binding can be expressed relative to binding by a reference standard peptide. For example, can be based on its IC50, relative to the IC50 of a reference standard peptide. Binding can also be determined using other assay systems including those using: live cells (e.g., Ceppellini et al., Nature 339:392 (1989); Christnick et al., Nature 352:67 (1991); Busch et al., Int. Immunol. 2:443 (1990); Hill et al., J. Immunol. 147:189 (1991); del Guercio et al., J. Immunol. 154:685 (1995)), cell free systems using detergent lysates (e.g., Cerundolo et al., J. Immunol 21:2069 (1991)), immobilized purified MHC (e.g., Hill et al., J. Immunol. 152, 2890 (1994); Marshall et al., J. Immunol. 152:4946 (1994)), ELISA systems (e.g., Reay et al., EMBO J. 11:2829 (1992)), surface plasmon resonance (e.g., Khilko et al., J. Biol. Chem. 268:15425 (1993)); high flux soluble phase assays (Hammer et al., J. Exp. Med. 180:2353 (1994)), and measurement of class I MHC stabilization or assembly (e.g., Ljunggren et al., Nature 346:476 (1990); Schumacher et al., Cell 62:563 (1990); Townsend et al., Cell 62:285 (1990); Parker et al., J. Immunol.149:1896 (1992)).

[0050] Cap: As used herein, the term “cap” refers to a structure comprising or essentially consisting of a nucleoside-5 '-triphosphate that is typically joined to a 5'-end of an uncapped RNA 14 11979815v1P-627574-PC (e.g., an uncapped RNA having a 5'- diphosphate). In some embodiments, a cap is or comprises a guanine nucleotide. In some embodiments, a cap is or comprises a naturally-occurring RNA 5’ cap, including, e.g., but not limited to a 7- methylguanosine cap, which has a structure designated as “m7G.” In some embodiments, a cap is or comprises a synthetic cap analog that resembles an RNA cap structure and possesses the ability to stabilize RNA if attached thereto, including, e.g., but not limited to anti-reverse cap analogs (ARCAs) known in the art). Those skilled in the art will appreciate that methods for joining a cap to a 5’ end of an RNA are known in the art. For example, in some embodiments, a capped RNA may be obtained by in vitro capping of RNA that has a 5' triphosphate group or RNA that has a 5' diphosphate group with a capping enzyme system (including, e.g., but not limited to vaccinia capping enzyme system or Saccharomyces cerevisiae capping enzyme system). Alternatively, a capped RNA can be obtained by in vitro transcription (IVT) of a single-stranded DNA template in the presence of a dinucleotide or trinucleotide cap analog.

[0051] Cell-mediated immunity: “Cell-mediated immunity,” “cellular immunity,” “cellular immune response,” or similar terms are meant to include a cellular response directed to cells characterized by expression of an antigen, in particular characterized by presentation of an antigen with class I or class II MHC. A cellular response relates to immune effector cells, in particular to T cells or T lymphocytes which act as either “helpers” or “killers.” The helper T cells (also termed CD4+T cells or CD4 T cells) play a central role by regulating the immune response and the killer cells (also termed cytotoxic T cells, cytolytic T cells, CD8+T cells, CD8 T cells, or CTLs) kill diseased cells such as virus-infected cells, preventing the production of more diseased cells.

[0052] Co-administration: As used herein, the term “co-administration” refers to use of a pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine) described herein and an additional therapeutic agent. The combined use of a pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine) described herein and an additional therapeutic agent may be performed concurrently or separately (e.g., sequentially in any order). In some embodiments, a pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine) described herein and an additional therapeutic agent may be combined in one pharmaceutically-acceptable carrier, or they may be placed in separate carriers and delivered to a target cell or administered to a subject at different times. Each of these situations is contemplated as falling within the meaning of “co- administration” or “combination,” provided that a pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine) described herein and an additional therapeutic agent are delivered or 15 11979815v1P-627574-PC administered sufficiently close in time that there is at least some temporal overlap in biological effect(s) generated by each on a target cell or a subject being treated.

[0053] Codon-optimized: As used herein, the term “codon-optimized” refers to alteration of codons in a coding region of a nucleic acid molecule to reflect the typical codon usage of a host organism without preferably altering the amino acid sequence encoded by the nucleic acid molecule. Within the context of the present disclosure, in some embodiments coding regions are codon-optimized for optimal expression in a subject to be treated using the RNA molecules described herein. In some embodiments, codon-optimization may be performed such that codons for which frequently occurring tRNAs are available are inserted in place of “rare codons.” In some embodiments, codon-optimization may include increasing guanosine / cytosine (G / C) content of a coding region of RNA described herein as compared to the G / C content of the corresponding coding sequence of a wild type RNA, wherein the amino acid sequence encoded by the RNA is preferably not modified compared to the amino acid sequence.

[0054] Combination therapy: As used herein, the term “combination therapy” refers to those situations in which a subject is simultaneously exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents). In some embodiments, the two or more regimens may be administered simultaneously; in some embodiments, such regimens may be administered sequentially (e.g., all “doses” of a first regimen are administered prior to administration of any doses of a second regimen); in some embodiments, such agents are administered in overlapping dosing regimens. In some embodiments, “administration” of combination therapy may involve administration of one or more agent(s) or modality(ies) to a subject receiving the other agent(s) or modality(ies) in the combination. For clarity, combination therapy does not require that individual agents be administered together in a single composition (or even necessarily at the same time), although in some embodiments, two or more agents, or active moieties thereof, may be administered together in a combination composition.

[0055] Comparable: As used herein, the term “comparable” refers to two or more agents, entities, situations, sets of conditions, etc., that may not be identical to one another but that are sufficiently similar to permit comparison there between so that one skilled in the art will appreciate that conclusions may reasonably be drawn based on differences or similarities observed. In some embodiments, comparable sets of conditions, circumstances, individuals, or populations are characterized by a plurality of substantially identical features and one or a small number of varied features. Those of ordinary skill in the art will understand, in context, what degree of identity is 16 11979815v1P-627574-PC required in any given circumstance for two or more such agents, entities, situations, sets of conditions, etc. to be considered comparable. For example, those of ordinary skill in the art will appreciate that sets of circumstances, individuals, or populations are comparable to one another when characterized by a sufficient number and type of substantially identical features to warrant a reasonable conclusion that differences in results obtained or phenomena observed under or with different sets of circumstances, individuals, or populations are caused by or indicative of the variation in those features that are varied.

[0056] Corresponding to: As used herein, the term “corresponding to” refers to a relationship between two or more entities. For example, the term “corresponding to” may be used to designate the position / identity of a structural element in a compound or composition relative to another compound or composition (e.g., to an appropriate reference compound or composition). For example, in some embodiments, a monomeric residue in a polymer (e.g., an amino acid residue in a polypeptide or a nucleic acid residue in a polynucleotide) may be identified as “corresponding to” a residue in an appropriate reference polymer. For example, those of ordinary skill will appreciate that, for purposes of simplicity, residues in a polypeptide are often designated using a canonical numbering system based on a reference related polypeptide, so that an amino acid “corresponding to” a residue at position 190, for example, need not actually be the 190thamino acid in a particular amino acid chain but rather corresponds to the residue found at 190 in the reference polypeptide; those of ordinary skill in the art readily appreciate how to identify “corresponding” amino acids. For example, those skilled in the art will be aware of various sequence alignment strategies, including software programs such as, for example, BLAST, CS- BLAST, CUSASW++, DIAMOND, FASTA, GGSEARCH / GLSEARCH, Genoogle, HMMER, HHpred / HHsearch, IDF, Infernal, KLAST, USEARCH, parasail, PSI-BLAST, PSI-Search, ScalaBLAST, Sequilab, SAM, SSEARCH, SWAPHI, SWAPHI-LS, SWIMM, or SWIPE that can be utilized, for example, to identify “corresponding” residues in polypeptides and / or nucleic acids in accordance with the present disclosure. Those of skill in the art will also appreciate that, in some instances, the term “corresponding to” may be used to describe an event or entity that shares a relevant similarity with another event or entity (e.g., an appropriate reference event or entity). To give but one example, a gene or protein in one organism may be described as “corresponding to” a gene or protein from another organism in order to indicate, in some embodiments, that it plays an analogous role or performs an analogous function and / or that it shows a particular degree of sequence identity or homology, or shares a particular characteristic sequence element. 17 11979815v1P-627574-PC

[0057] Derived: In the context of an amino acid sequence (peptide or polypeptide) “derived from” a designated amino acid sequence (peptide or polypeptide), it refers to a structural analogue of a designated amino acid sequence. In some embodiments, an amino acid sequence which is derived from a particular amino acid sequence has an amino acid sequence that is identical, essentially identical or homologous to that particular sequence or a fragment thereof. Amino acid sequences derived from a particular amino acid sequence may be variants of that particular sequence or a fragment thereof. For example, it will be understood by one of ordinary skill in the art that the antigens suitable for use herein may be altered such that they vary in sequence from the naturally occurring or native sequences from which they were derived, while retaining the desirable activity of the native sequences.

[0058] Designed: As used herein, the term “designed” refers to an agent (i) whose structure is or was selected by the hand of man; (ii) that is produced by a process requiring the hand of man; and / or (iii) that is distinct from natural substances and other known agents.

[0059] Dosing regimen: Those skilled in the art will appreciate that the term “dosing regimen” may be used to refer to a set of unit doses (typically more than one) that are administered individually to a subject, typically separated by periods of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may involve one or more doses. In some embodiments, a dosing regimen comprises a plurality of doses each of which is separated in time from other doses. In some embodiments, individual doses are separated from one another by a time period of the same length; in some embodiments, a dosing regimen comprises a plurality of doses and at least two different time periods separating individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount different from the first dose amount. In some embodiments, a dosing regimen comprises a first dose in a first dose amount, followed by one or more additional doses in a second dose amount same as the first dose amount. In some embodiments, a dosing regimen is correlated with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).

[0060] Engineered: In general, the term “engineered” refers to the aspect of having been manipulated by the hand of man. For example, a polynucleotide is considered to be “engineered” when two or more sequences that are not linked together in that order in nature are manipulated 18 11979815v1P-627574-PC by the hand of man to be directly linked to one another in the engineered polynucleotide and / or when a particular residue in a polynucleotide is non-naturally occurring and / or is caused through action of the hand of man to be linked with an entity or moiety with which it is not linked in nature.

[0061] Epitope: As used herein, the term “epitope” refers to a moiety that is specifically recognized by an immunoglobulin (e.g., antibody or receptor) binding component. For example, an epitope may be recognized by a T cell, a B cell, or an antibody. In some embodiments, an epitope is comprised of a plurality of chemical atoms or groups on an antigen. In some embodiments, such chemical atoms or groups are surface-exposed when the antigen adopts a relevant three-dimensional conformation. In some embodiments, such chemical atoms or groups are physically near to each other in space when the antigen adopts such a conformation. In some embodiments, at least some such chemical atoms are groups are physically separated from one another when the antigen adopts an alternative conformation (e.g., is linearized). Accordingly, in some embodiments, an epitope of an antigen may include a continuous or discontinuous portion of the antigen. In some embodiments, an epitope is or comprises a T cell epitope. In some embodiments, an epitope may have a length of about 5 to about 30 amino acids, or about 10 to about 25 amino acids, or about 5 to about 15 amino acids, or about 5 to 12 amino acids, or about 6 to about 9 amino acids.

[0062] Expression: As used herein, the term “expression” of a nucleic acid sequence refers to the generation of a gene product from the nucleic acid sequence. In some embodiments, a gene product can be a transcript. In some embodiments, a gene product can be a polypeptide. In some embodiments, expression of a nucleic acid sequence involves one or more of the following: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, etc); (3) translation of an RNA into a polypeptide or protein; and / or (4) post-translational modification of a polypeptide or protein.

[0063] Five prime untranslated region: As used herein, the terms “five prime untranslated region” or “5' UTR” refer to a sequence of an RNA molecule between a transcription start site and a start codon of a coding region of an RNA. In some embodiments, “5’ UTR” refers to a sequence of an RNA molecule that begins at a transcription start site and ends one nucleotide (nt) before a start codon (usually AUG) of a coding region of an RNA molecule, e.g., in its natural context.

[0064] Humoral immunity: As used herein, the term “humoral immunity” or “humoral immune response” refers to antibody production and the accessory processes that accompany it, including: Th2 activation and cytokine production, germinal center formation and isotype switching, affinity 19 11979815v1P-627574-PC maturation and memory cell generation. It also refers to the effector functions of antibodies, which include pathogen neutralization, classical complement activation, and opsonin promotion of phagocytosis and pathogen elimination.

[0065] Identity: As used herein, the term “identity” refers to the overall relatedness between polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules. In some embodiments, polynucleotide molecules (e.g., DNA molecules and / or RNA molecules) and / or between polypeptide molecules are considered to be “substantially identical” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical. Calculation of the percent identity of two nucleic acid or polypeptide sequences, for example, can be performed by aligning the two sequences for optimal comparison purposes (e.g., gaps can be introduced in one or both of a first and a second sequence for optimal alignment and non-identical sequences can be disregarded for comparison purposes). In certain embodiments, the length of a sequence aligned for comparison purposes is at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or substantially 100% of the length of a reference sequence. The nucleotides at corresponding positions are then compared. When a position in the first sequence is occupied by the same residue (e.g., nucleotide or amino acid) as the corresponding position in the second sequence, then the molecules are identical at that position. The percent identity between the two sequences is a function of the number of identical positions shared by the sequences, taking into account the number of gaps, and the length of each gap, which needs to be introduced for optimal alignment of the two sequences. The comparison of sequences and determination of percent identity between two sequences can be accomplished using a mathematical algorithm. For example, the percent identity between two nucleotide sequences can be determined using the algorithm of Meyers and Miller, 1989, which has been incorporated into the ALIGN program (version 2.0). In some exemplary embodiments, nucleic acid sequence comparisons made with the ALIGN program use a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4. The percent identity between two nucleotide sequences can, alternatively, be determined using the GAP program in the GCG software package using an NWSgapdna.CMP matrix.

[0066] Immunologically equivalent: The term “immunologically equivalent” means that an immunologically equivalent molecule such as the immunologically equivalent amino acid sequence exhibits the same or essentially the same immunological properties and / or exerts the 20 11979815v1P-627574-PC same or essentially the same immunological effects, e.g., with respect to the type of the immunological effect. In the context of the present disclosure, in some embodiments, the term “immunologically equivalent” is used with respect to the immunological effects or properties of antigens or antigen variants used for immunization. For example, an amino acid sequence is immunologically equivalent to a reference amino acid sequence if said amino acid sequence when exposed to the immune system of a subject induces an immune reaction having a specificity of reacting with the reference amino acid sequence.

[0067] In some embodiments, an antigen receptor is an antibody or B cell receptor which binds to an epitope in an antigen. In some embodiments, an antibody or B cell receptor binds to native epitopes of an antigen.

[0068] Increased, Induced, or Reduced: As used herein, these terms or grammatically comparable comparative terms, indicate values that are relative to a comparable reference measurement. For example, in some embodiments, an assessed value achieved with a provided pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine) may be “increased” relative to that obtained with a comparable reference pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine). Alternatively or additionally, in some embodiments, an assessed value achieved in a subject may be “increased” relative to that obtained in the same subject under different conditions (e.g., prior to or after an event; or presence or absence of an event such as administration of a pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine) as described herein, or in a different, comparable subject (e.g., in a comparable subject that differs from the subject of interest in prior exposure to a condition, e.g., absence of administration of a pharmaceutical composition (e.g., immunogenic composition, e.g., vaccine) as described herein.). In some embodiments, comparative terms refer to statistically relevant differences (e.g., that are of a prevalence and / or magnitude sufficient to achieve statistical relevance). Those skilled in the art will be aware, or will readily be able to determine, in a given context, a degree and / or prevalence of difference that is required or sufficient to achieve such statistical significance. In some embodiments, the term “reduced” or equivalent terms refers to a reduction in the level of an assessed value by at least 5%, at least 10%, at least 20%, at least 50%, at least 75% or higher, as compared to a comparable reference. In some embodiments, the term “reduced” or equivalent terms refers to a complete or essentially complete inhibition, i.e., a reduction to zero or essentially to zero. In some embodiments, the term “increased” or “induced” refers to an increase in the level of an assessed value by at least 10%, at least 20%, at least 30%, 21 11979815v1P-627574-PC at least 40%, at least 50%, at least 80%, at least 100%, at least 200%, at least 500%, or higher, as compared to a comparable reference.

[0069] Ionizable: The term “ionizable” refers to a compound or group or atom that is charged at a certain pH. In the context of an ionizable amino lipid, such a lipid or a function group or atom thereof bears a positive charge at a certain pH. In some embodiments, an ionizable amino lipid is positively charged at an acidic pH. In some embodiments, an ionizable amino lipid is predominately neutral at physiological pH values, e.g., in some embodiments about 7.0-7.4, but becomes positively charged at lower pH values. In some embodiments, an ionizable amino lipid may have a pKa within a range of about 5 to about 7.

[0070] Isolated: The term “isolated” means altered or removed from the natural state. For example, a nucleic acid or a peptide naturally present in a living animal is not “isolated”, but the same nucleic acid or peptide partially or completely separated from the coexisting materials of its natural state is “isolated”. An isolated nucleic acid or protein can exist in substantially purified form

[0071] Nucleic acid / Polynucleotide: As used herein, the term “nucleic acid” refers to a polymer of at least 10 nucleotides or more. In some embodiments, a nucleic acid is or comprises DNA. In some embodiments, a nucleic acid is or comprises RNA. In some embodiments, a nucleic acid is or comprises peptide nucleic acid (PNA). In some embodiments, a nucleic acid is or comprises a single stranded nucleic acid. In some embodiments, a nucleic acid is or comprises a double- stranded nucleic acid. In some embodiments, a nucleic acid comprises both single and double- stranded portions. In some embodiments, a nucleic acid comprises a backbone that comprises one or more phosphodiester linkages. In some embodiments, a nucleic acid comprises a backbone that comprises both phosphodiester and non-phosphodiester linkages. For example, in some embodiments, a nucleic acid may comprise a backbone that comprises one or more phosphorothioate or 5'-N-phosphoramidite linkages and / or one or more peptide bonds, e.g., as in a “peptide nucleic acid”. In some embodiments, a nucleic acid comprises one or more, or all, natural residues (e.g., adenine, cytosine, deoxyadenosine, deoxycytidine, deoxyguanosine, deoxythymidine, guanine, thymine, uracil). In some embodiments, a nucleic acid comprises on or more, or all, non-natural residues. In some embodiments, a non-natural residue comprises a nucleoside analog (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3 - methyl adenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2- aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5 - 22 11979815v1P-627574-PC propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, 6-O-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, a non-natural residue comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) as compared to those in natural residues. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or polypeptide. In some embodiments, a nucleic acid has a nucleotide sequence that comprises one or more introns. In some embodiments, a nucleic acid may be prepared by isolation from a natural source, enzymatic synthesis (e.g., by polymerization based on a complementary template, e.g., in vivo or in vitro, reproduction in a recombinant cell or system, or chemical synthesis. In some embodiments, a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000, 9500, 10,000, 10,500, 11,000, 11,500, 12,000, 12,500, 13,000, 13,500, 14,000, 14,500, 15,000, 15,500, 16,000, 16,500, 17,000, 17,500, 18,000, 18,500, 19,000, 19,500, or 20,000 or more residues or nucleotides long.

[0072] Nucleotide: As used herein, the term “nucleotide” refers to its art-recognized meaning. When a number of nucleotides is used as an indication of size, e.g., of a polynucleotide, a certain number of nucleotides refers to the number of nucleotides on a single strand, e.g., of a polynucleotide.

[0073] Patient: As used herein, the term “patient” refers to any organism who is suffering or at risk of a disease or disorder or condition. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, a patient is a human. In some embodiments, a patient is suffering from or susceptible to one or more diseases or disorders or conditions. In some embodiments, a patient displays one or more symptoms of a disease or disorder or condition. In some embodiments, a patient has been diagnosed with one or more diseases or disorders or conditions. In some embodiments, a disease or disorder or condition that is amenable to provided technologies is or includes an HSV infection. In some embodiments, a patient is receiving or has received certain therapy to diagnose and / or to treat a disease, disorder, or condition. In some embodiments, a patient is a patient suffering from or susceptible to an HSV infection. 23 11979815v1P-627574-PC

[0074] Pharmaceutical composition: As used herein, the term “pharmaceutical composition” refers to an active agent, formulated together with one or more pharmaceutically acceptable carriers. In some embodiments, active agent is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In some embodiments, pharmaceutical compositions may be specially formulated for parenteral administration, for example, by subcutaneous, intramuscular, or intravenous injection as, for example, a sterile solution or suspension formulation.

[0075] Pharmaceutically effective amount: The term “pharmaceutically effective amount” or “therapeutically effective amount” refers to the amount which achieves a desired reaction or a desired effect alone or together with further doses. In the case of the treatment of a particular disease, a desired reaction in some embodiments relates to inhibition of the course of the disease. In some embodiments, such inhibition may comprise slowing down the progress of a disease and / or interrupting or reversing the progress of the disease. In some embodiments, a desired reaction in a treatment of a disease may be or comprise delay or prevention of the onset of a disease or a condition. An effective amount of pharmaceutical compositions (e.g., immunogenic compositions, e.g., vaccines) described herein will depend, for example, on a disease or condition to be treated, the severity of such a disease or condition, individual parameters of the patient, including, e.g., age, physiological condition, size and weight, the duration of treatment, the type of an accompanying therapy (if present), the specific route of administration and similar factors. Accordingly, doses of pharmaceutical compositions (e.g., immunogenic compositions, e.g., vaccines) described herein may depend on various of such parameters. In the case that a reaction in a patient is insufficient with an initial dose, higher doses (or effectively higher doses achieved by a different, more localized route of administration) may be used.

[0076] Poly(A) sequence: As used herein, the term “poly(A) sequence” or “poly-A tail” refers to an uninterrupted or interrupted sequence of adenylate residues which is typically located at the 3'- end of an RNA molecule. Poly(A) sequences are known to those of skill in the art and may follow the 3’-UTR in the RNAs described herein. An uninterrupted poly(A) sequence is characterized by consecutive adenylate residues. In nature, an uninterrupted poly(A) sequence is typical. RNAs disclosed herein can have a poly(A) sequence attached to the free 3'-end of the RNA by a template- independent RNA polymerase after transcription or a poly(A) sequence encoded by DNA and transcribed by a template-dependent RNA polymerase. 24 11979815v1P-627574-PC

[0077] Prevent: As used herein, the term “prevent” or “prevention” when used in connection with the occurrence of a disease, disorder, and / or condition, refers to reducing the risk of developing the disease, disorder and / or condition and / or to delaying onset of one or more characteristics or symptoms of the disease, disorder or condition. Prevention may be considered complete when onset of a disease, disorder or condition has been delayed for a predefined period of time.

[0078] Recombinant: The term “recombinant” in the context of the present disclosure means “made through genetic engineering”. In some embodiments, a “recombinant” entity such as a recombinant nucleic acid in the context of the present disclosure is not naturally occurring.

[0079] Reference: As used herein, the term “reference” describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and / or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and / or comparison to a particular possible reference or control.

[0080] Risk: As will be understood from context, “risk” of a disease, disorder, and / or condition refers to a likelihood that a particular individual will develop the disease, disorder, and / or condition. In some embodiments, risk is expressed as a percentage. In some embodiments, risk is from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 40, 50, 60, 70, 80, 90 up to 100%. In some embodiments risk is expressed as a risk relative to a risk associated with a reference sample or group of reference samples. In some embodiments, a reference sample or group of reference samples have a known risk of a disease, disorder, condition and / or event. In some embodiments a reference sample or group of reference samples are from individuals comparable to a particular individual. In some embodiments, relative risk is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more. In some embodiments, risk may reflect one or more genetic attributes, e.g., which may predispose an individual toward development (or not) of a particular disease, disorder and / or condition. In some embodiments, risk may reflect one or more epigenetic events or attributes and / or one or more lifestyle or environmental events or attributes. 25 11979815v1P-627574-PC

[0081] Selective or specific: The term “selective” or “specific”, when used herein in reference to an agent having an activity, is understood by those skilled in the art to mean that the agent discriminates between potential target entities, states, or cells. For example, in some embodiments, an agent is said to bind “specifically” to its target if it binds preferentially with that target in the presence of one or more competing alternative targets. In many embodiments, specific interaction is dependent upon the presence of a particular structural feature of the target entity (e.g., an epitope, a cleft, a binding site). It is to be understood that specificity need not be absolute. In some embodiments, specificity may be evaluated relative to that of a target-binding moiety for one or more other potential target entities (e.g., competitors). In some embodiments, specificity is evaluated relative to that of a reference specific binding moiety. In some embodiments, specificity is evaluated relative to that of a reference non-specific binding moiety.

[0082] Subject: As used herein, the term “subject” refers to an organism to be administered with a composition described herein, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, domestic pets, etc.) and humans. In some embodiments, a subject is a human subject. In some embodiments, a subject is suffering from a disease, disorder, or condition (e.g., an HSV infection). In some embodiments, a subject is susceptible to a disease, disorder, or condition (e.g., an HSV infection). In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder, or condition (e.g., an HSV infection). In some embodiments, a subject displays one or more non-specific symptoms of a disease, disorder, or condition (e.g., an HSV infection). In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition (e.g., an HSV infection). In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition (e.g., an HSV infection). In some embodiments, a subject is a patient. In some embodiments, a subject is an individual to whom diagnosis and / or therapy is and / or has been administered.

[0083] Suffering from: An individual who is “suffering from” a disease, disorder, and / or condition has been diagnosed with and / or displays one or more symptoms of a disease, disorder, and / or condition.

[0084] Susceptible to: An individual who is “susceptible to” a disease, disorder, and / or condition is one who has a higher risk of developing the disease, disorder, and / or condition than does a member of the general public. In some embodiments, an individual who is susceptible to a disease, 26 11979815v1P-627574-PC disorder and / or condition may not have been diagnosed with the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may exhibit symptoms of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may not exhibit symptoms of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will develop the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition will not develop the disease, disorder, and / or condition.

[0085] Synthetic: As used herein, the term “synthetic” refers to an entity that is artificial, or that is made with human intervention, or that results from synthesis rather than naturally occurring. For example, in some embodiments, a synthetic nucleic acid or polynucleotide refers to a nucleic acid molecule that is chemically synthesized, e.g., in some embodiments by solid-phase synthesis. In some embodiments, the term “synthetic” refers to an entity that is made outside of biological cells. For example, in some embodiments, a synthetic nucleic acid or polynucleotide refers to a nucleic acid molecule (e.g., an RNA) that is produced by in vitro transcription using a template.

[0086] Therapy: The term “therapy” refers to an administration or delivery of an agent or intervention that has a therapeutic effect and / or elicits a desired biological and / or pharmacological effect (e.g., has been demonstrated to be statistically likely to have such effect when administered to a relevant population). In some embodiments, a therapeutic agent or therapy is any substance that can be used to alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition. In some embodiments, a therapeutic agent or therapy is a medical intervention (e.g., surgery, radiation, phototherapy) that can be performed to alleviate, relieve, inhibit, present, delay onset of, reduce severity of, and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition.

[0087] Three prime untranslated region: As used herein, the terms “three prime untranslated region” or “3' UTR” refer to a sequence of an RNA molecule that begins following a stop codon of a coding region of an open reading frame sequence. In some embodiments, the 3' UTR begins immediately after a stop codon of a coding region of an open reading frame sequence, e.g., in its natural context. In other embodiments, the 3' UTR does not begin immediately after stop codon of the coding region of an open reading frame sequence, e.g., in its natural context. 27 11979815v1P-627574-PC

[0088] Threshold level (e.g., acceptance criteria): As used herein, the term “threshold level” refers to a level that are used as a reference to attain information on and / or classify the results of a measurement, for example, the results of a measurement attained in an assay. For example, in some embodiments, a threshold level means a value measured in an assay that defines the dividing line between two subsets of a population (e.g. a batch that satisfy quality control criteria vs. a batch that does not satisfy quality control criteria). Thus, a value that is equal to or higher than the threshold level defines one subset of the population, and a value that is lower than the threshold level defines the other subset of the population. A threshold level can be determined based on one or more control samples or across a population of control samples. A threshold level can be determined prior to, concurrently with, or after the measurement of interest is taken. In some embodiments, a threshold level can be a range of values.

[0089] Treat: As used herein, the term “treat,” “treatment,” or “treating” refers to any method used to partially or completely alleviate, ameliorate, relieve, inhibit, prevent, delay onset of, reduce severity of, and / or reduce incidence of one or more symptoms or features of a disease, disorder, and / or condition. Treatment may be administered to a subject who does not exhibit signs of a disease, disorder, and / or condition. In some embodiments, treatment may be administered to a subject who exhibits only early signs of the disease, disorder, and / or condition, for example for the purpose of decreasing the risk of developing pathology associated with the disease, disorder, and / or condition. In some embodiments, treatment may be administered to a subject at a later-stage of disease, disorder, and / or condition.

[0090] Vaccination: As used herein, the term “vaccination” refers to the administration of a composition intended to generate an immune response, for example to a disease-associated (e.g., disease-causing) agent. In some embodiments, vaccination can be administered before, during, and / or after exposure to a disease-associated agent, and in certain embodiments, before, during, and / or shortly after exposure to the agent. In some embodiments, vaccination includes multiple administrations, appropriately spaced in time, of a vaccine composition. In some embodiments, vaccination generates an immune response to an infectious agent.

[0091] Vaccine: As used herein, the term “vaccine” refers to a composition that induces an immune response upon administration to a subject. In some embodiments, an induced immune response provides protective immunity.

[0092] Variant: As used herein in the context of molecules, e.g., nucleic acids, proteins, or small molecules, the term “variant” refers to a molecule that shows significant structural identity with a 28 11979815v1P-627574-PC reference molecule but differs structurally from the reference molecule, e.g., in the presence or absence or in the level of one or more chemical moieties as compared to the reference entity. In some embodiments, a variant also differs functionally from its reference molecule. In general, whether a particular molecule is properly considered to be a “variant” of a reference molecule is based on its degree of structural identity with the reference molecule. As will be appreciated by those skilled in the art, any biological or chemical reference molecule has certain characteristic structural elements. A variant, by definition, is a distinct molecule that shares one or more such characteristic structural elements but differs in at least one aspect from the reference molecule. In some embodiments, a variant polypeptide or nucleic acid may differ from a reference polypeptide or nucleic acid as a result of one or more differences in amino acid or nucleotide sequence and / or one or more differences in chemical moieties (e.g., carbohydrates, lipids, phosphate groups) that are covalently components of the polypeptide or nucleic acid (e.g., that are attached to the polypeptide or nucleic acid backbone). In some embodiments, a variant polypeptide or nucleic acid shows an overall sequence identity with a reference polypeptide or nucleic acid that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, or 99%. In some embodiments, a variant polypeptide or nucleic acid does not share at least one characteristic sequence element with a reference polypeptide or nucleic acid. In some embodiments, a reference polypeptide or nucleic acid has one or more biological activities. In some embodiments, a variant polypeptide or nucleic acid shares one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid lacks one or more of the biological activities of the reference polypeptide or nucleic acid. In some embodiments, a variant polypeptide or nucleic acid shows a reduced level of one or more biological activities as compared to the reference polypeptide or nucleic acid. In some embodiments, a polypeptide or nucleic acid of interest is considered to be a “variant” of a reference polypeptide or nucleic acid if it has an amino acid or nucleotide sequence that is identical to that of the reference but for a small number of sequence alterations at particular positions. Typically, fewer than about 20%, about 15%, about 10%, about 9%, about 8%, about 7%, about 6%, about 5%, about 4%, about 3%, or about 2% of the residues in a variant are substituted, inserted, or deleted, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises about 10, about 9, about 8, about 7, about 6, about 5, about 4, about 3, about 2, or about 1 substituted residues as compared to a reference. Often, a variant polypeptide or nucleic acid comprises a very small number (e.g., fewer than about 5, about 4, about 3, about 2, or about 1) 29 11979815v1P-627574-PC number of substituted, inserted, or deleted, functional residues (i.e., residues that participate in a particular biological activity) relative to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises not more than about 5, about 4, about 3, about 2, or about 1 addition or deletion, and, in some embodiments, comprises no additions or deletions, as compared to the reference. In some embodiments, a variant polypeptide or nucleic acid comprises fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly fewer than about 5, about 4, about 3, or about 2 additions or deletions as compared to the reference. In some embodiments, a reference polypeptide or nucleic acid is one found in nature.

[0093] Vector: as used herein, refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments may be ligated. Another type of vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression vectors.” In some embodiments, known techniques may be used, for example, for generation or manipulation of recombinant DNA, for oligonucleotide synthesis, and for tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques may be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures may be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)), which is incorporated herein by reference for any purpose.

[0094] All literature and similar material cited in this application, including, but not limited to, patents, patent applications, articles, books, treatises, and web pages, regardless of the format of such literature and similar materials, are expressly incorporated by reference in their entirety. In the event that one or more of the incorporated literature and similar materials differs from or 30 11979815v1P-627574-PC contradicts this application, including but not limited to defined terms, term usage, described techniques, or the like, this application controls. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described in any way. DETAILED DESCRIPTION Compositions

[0095] In some embodiments, the present disclosure provides compositions comprising one or more RNAs (also referred to herein as “polyribonucleotides”). In some embodiments, one or more RNAs encodes a Herpes Simplex Virus (HSV) glycoprotein or immunogenic fragment thereof. In some embodiments, an RNA is a modified RNA as described herein below.

[0096] In some embodiments, an immunogenic fragment of an HSV glycoprotein comprises the ectodomain of the glycoprotein, or portion thereof. In another embodiment, an immunogenic fragment consists of the ectodomain of the glycoprotein, or portion thereof.

[0097] In some embodiments, the present disclosure provides a composition comprising one or more nucleoside modified RNAs. In some embodiments, a modified RNA encodes a Herpes Simplex Virus (HSV) glycoprotein or immunogenic fragment thereof. In some embodiments, modified RNA comprises one or more pseudouridine or pseudouridine family residues.

[0098] In some embodiments, an HSV glycoprotein comprises glycoprotein D (gD), glycoprotein C (gC), glycoprotein E (gE), glycoprotein B (gB), glycoprotein H (gH), glycoprotein L (gL), glycoprotein I (gI), or any combinations thereof.

[0099] In some embodiments, the present disclosure provides a composition comprising one or more modified RNAs encoding HSV gD, gC, gE, gB, gH, gL, gI, or immunogenic fragments thereof. In some embodiments, the modified RNAs comprise pseudouridine-modified RNAs.

[0100] In some embodiments, the present disclosure provides compositions comprising an RNA encoding HSV gD or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV gC or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV gE or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV gB or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV gH or an immunogenic fragment thereof. In 31 11979815v1P-627574-PC another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV gL or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV gI or an immunogenic fragment thereof.

[0101] In some embodiments, the present disclosure provides a composition comprising: (a) an RNA encoding HSV gD or an immunogenic fragment thereof; and (b) an RNA encoding HSV gC or an immunogenic fragment thereof.

[0102] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV gD or an immunogenic fragment thereof; and (b) an RNA encoding HSV gE or an immunogenic fragment thereof.

[0103] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV gC or an immunogenic fragment thereof; and (b) an RNA encoding HSV gE or an immunogenic fragment thereof.

[0104] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV gD or an immunogenic fragment thereof; (b) an RNA encoding HSV gC or an immunogenic fragment thereof, and (c) an RNA encoding HSV gE or an immunogenic fragment thereof.

[0105] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV gD or an immunogenic fragment thereof; (b) an RNA encoding HSV gC or an immunogenic fragment thereof, (c) an RNA encoding HSV gE or an immunogenic fragment thereof; and (d) an RNA encoding HSV gB or an immunogenic fragment thereof.

[0106] In some embodiments, the HSV glycoproteins are HSV-2 glycoproteins or immunogenic fragments thereof. In another embodiment, the HSV glycoproteins are HSV-1 glycoproteins or immunogenic fragments thereof. In some embodiments, the HSV glycoproteins comprise both HSV-2 glycoproteins and HSV-1 glycoproteins or immunogenic fragments thereof. In another embodiment, the HSV glycoproteins comprise a mixture of HSV-2 glycoproteins and HSV-1 glycoproteins or immunogenic fragments thereof.

[0107] In some embodiments, the present disclosure provides compositions comprising an RNA encoding HSV-2 gD or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-2 gC or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-2 gE or an immunogenic fragment thereof. In another 32 11979815v1P-627574-PC embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-2 gE or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-2 gB or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-2 gH or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-2 gL or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-2 gI or an immunogenic fragment thereof.

[0108] In some embodiments, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-2 gD or an immunogenic fragment thereof; and (b) an RNA encoding HSV- 2 gC or an immunogenic fragment thereof.

[0109] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-2 gD or an immunogenic fragment thereof; and (b) an RNA encoding HSV- 2 gE or an immunogenic fragment thereof.

[0110] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-2 gC or an immunogenic fragment thereof; and (b) an RNA encoding HSV- 2 gE or an immunogenic fragment thereof.

[0111] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-2 gD or an immunogenic fragment thereof; (b) an RNA encoding HSV-2 gC or an immunogenic fragment thereof, and (c) an RNA encoding HSV-2 gE or an immunogenic fragment thereof.

[0112] In some embodiments, the present disclosure provides compositions comprising an RNA encoding HSV-1 gD or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-1 gC or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-1 gE or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-1 gE or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-1 gB or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-1 gH or an immunogenic fragment thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-1 gL or an immunogenic fragment 33 11979815v1P-627574-PC thereof. In another embodiment, the present disclosure provides compositions comprising an RNA encoding HSV-1 gI or an immunogenic fragment thereof.

[0113] In some embodiments, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-1 gD or fragment thereof; and (b) an RNA encoding HSV-1 gC or fragment thereof.

[0114] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-1 gD or an immunogenic fragment thereof; and (b) an RNA encoding HSV- 1 gE or an immunogenic fragment thereof.

[0115] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-1 gC or an immunogenic fragment thereof; and (b) an RNA encoding HSV- 1 gE or an immunogenic fragment thereof.

[0116] In another embodiment, the present disclosure provides a composition comprising: (a) an RNA encoding HSV-1 gD or an immunogenic fragment thereof; (b) an RNA encoding HSV-1 gC or an immunogenic fragment thereof, and (c) an RNA encoding HSV-1 gE or an immunogenic fragment thereof.

[0117] In some embodiments, any of the compositions as described herein consists essentially of one or more RNAs, wherein each of said RNAs encodes an HSV glycoprotein or immunogenic fragment thereof. In another embodiment, any of the compositions as described herein consists of one or more RNAs, wherein each of said RNAs encodes an HSV glycoprotein or immunogenic fragment thereof.

[0118] In another embodiment, the present disclosure provides compositions comprising an RNA encoding an HSV gD protein or immunogenic fragment thereof, an RNA encoding an HSV gC protein or immunogenic fragment thereof, an RNA encoding an HSV gE protein or immunogenic fragment thereof, and RNAs encoding one or more additional HSV glycoproteins. In some embodiments, said additional HSV glycoproteins comprise gB or immunogenic fragment thereof, gH or immunogenic fragment thereof, gL or immunogenic fragment thereof, gI or immunogenic fragment thereof, or any combination thereof. In some embodiments, said additional HSV glycoproteins comprise glycoprotein M (gM), glycoprotein N (gN), glycoprotein K (gK), glycoprotein G (gG), glycoprotein J (gJ), or an immunogenic fragment thereof.

[0119] In some embodiments, compositions of the present disclosure and for use in the methods of the present disclosure comprise both HSV-2 glycoproteins or glycoprotein fragments and HSV- 1 glycoproteins or glycoprotein fragments. In another embodiment, compositions of the present 34 11979815v1P-627574-PC disclosure and for use in the methods of the present disclosure comprise a mixture of HSV-2 glycoproteins or glycoprotein fragments and HSV-1 glycoproteins or glycoprotein fragments. For example, in some embodiments, a composition of the present disclosure comprises HSV-2 gC, HSV-1 gD, and HSV-2 gE, or immunogenic fragments thereof. In another embodiment, a composition of the present disclosure comprises HSV-1 gC, HSV-2 gD, and HSV-2 gE, or immunogenic fragments thereof. In another embodiment, a composition of the present disclosure comprises HSV-2 gC, HSV-2 gD, and HSV-1 gE, or immunogenic fragments thereof. In another embodiment, a composition of the present disclosure comprises HSV-1 gC, HSV-1 gD, and HSV- 2 gE, or immunogenic fragments thereof. In another embodiment, a composition of the present disclosure comprises HSV-1 gC, HSV-2 gD, and HSV-1 gE, or immunogenic fragments thereof. In another embodiment, a composition of the present disclosure comprises HSV-2 gC, HSV-1 gD, and HSV-1 gE, or immunogenic fragments thereof.

[0120] In another embodiment, the compositions of the present disclosure comprise one or more additional (i) HSV-1 glycoproteins or immunogenic fragments thereof, (ii) HSV-2 glycoproteins or immunogenic fragments thereof, or (iii) both HSV-1 or immunogenic fragments thereof and HSV-2 glycoproteins or immunogenic fragments thereof, as described herein. For example, in some embodiments, a composition of the present disclosure comprising HSV-2 gC, HSV-1 gD, and HSV-2 gE may further comprise HSV-1 gI. In another embodiment, a composition of the present disclosure comprising HSV-2 gC, HSV-2 gD, and HSV-2 gE may further comprise HSV- 1 gB. Each of the possible combinations of HSV-1 and HSV-2 glycoproteins represents a separate embodiment of the disclosure.

[0121] As used herein, “encoding” refers to an RNA molecule that contains a gene that encodes a protein of interest or a fragment thereof. In another embodiment, an RNA molecule comprises a coding sequence that encodes a protein of interest or a fragment thereof. In another embodiment, one or more other proteins or fragments thereof is also encoded. In another embodiment, the protein of interest or a fragment thereof is the only protein encoded. Each possibility represents a separate embodiment of the present disclosure.

[0122] “Immunogenic fragment” refers to a portion of a protein that is immunogenic and elicits a protective immune response when administered to a subject.

[0123] “Immunogenicity” or “immunogenic” is used herein to refer to the innate ability of a protein, peptide, protein fragment, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, nucleic acid, antigen or organism is administered to the 35 11979815v1P-627574-PC animal. Thus, “enhancing the immunogenicity” refers to increasing the ability of a protein, peptide, protein fragment, nucleic acid, antigen or organism to elicit an immune response in an animal when the protein, peptide, protein fragment, nucleic acid, antigen or organism is administered to an animal. The increased ability of a protein, peptide, protein fragment, nucleic acid, antigen or organism to elicit an immune response can be measured by, in some embodiments, a greater number of antibodies to a protein, peptide, protein fragment, nucleic acid, antigen or organism, a greater diversity of antibodies to an antigen or organism, a greater number of T-cells specific for a protein, peptide, protein fragment, nucleic acid, antigen or organism, a greater cytotoxic or helper T-cell response to a protein, peptide, protein fragment, nucleic acid, antigen or organism, and the like.

[0124] In some embodiments, a protein, peptide, protein fragment, nucleic acid or organism can be antigenic. “Antigenic” refers to a protein, peptide, protein fragment, nucleic acid, or organism capable of specifically interacting with an antigen recognition molecule of the immune system, e.g., an immunoglobulin (antibody) or T cell antigen receptor. An antigenic protein, peptide, protein fragment contains, in another embodiment, an epitope of at least about 8 amino acids (AA). An antigenic portion of a protein, peptide, protein fragment, nucleic acid, or organism, also called herein an “epitope” can be a portion that is immunodominant for antibody or T cell receptor recognition, or it can be a portion used to generate an antibody to the molecule by conjugating an antigenic portion to a carrier (e.g., a carrier polypeptide) for immunization. A molecule that is antigenic need not be itself immunogenic, i.e., capable of eliciting an immune response without a carrier.

[0125] “Functional” is used herein to refer to the innate ability of a protein, peptide, nucleic acid, fragment or a variant thereof to exhibit a biological activity or function. In some embodiments, such a biological function is its binding property to an interaction partner, e.g., a membrane- associated receptor, and in another embodiment, its trimerization property. In the case of functional fragments and the functional variants of the disclosure, these biological functions may in fact be changed, e.g., with respect to their specificity or selectivity, but with retention of the basic biological function.

[0126] In some embodiments, the term “fragment” is used herein to refer to a protein or polypeptide that is shorter or comprises fewer amino acids than the full length protein or polypeptide. In another embodiment, fragment refers to a nucleic acid encoding the protein fragment that is shorter or comprises fewer nucleotides than the full length nucleic acid. In another 36 11979815v1P-627574-PC embodiment, the fragment is an N-terminal fragment. In another embodiment, the fragment is a C-terminal fragment. In some embodiments, the fragment is an intrasequential section of the protein, peptide, or nucleic acid. In another embodiment, the fragment is an immunogenic intrasequential section of the protein, peptide or nucleic acid. In another embodiment, the fragment is a functional intrasequential section within the protein, peptide or nucleic acid. In another embodiment, the fragment is an N-terminal immunogenic fragment. In some embodiments, the fragment is a C-terminal immunogenic fragment. In another embodiment, the fragment is an N- terminal functional fragment. In another embodiment, the fragment is a C-terminal functional fragment. In another embodiment, the fragment contains pieces of the protein linked together or pieces of multiple proteins linked together. In some embodiments, a fragment is a domain (e.g., an ectodomain).

[0127] Thus, in some embodiments, an “immunogenic fragment” of a protein as described in the present disclosure refers to a portion of the protein that is immunogenic, in one embodiment and in another embodiment, elicits a protective immune response when administered to a subject.

[0128] In another aspect, the present disclosure provides compositions comprising RNAs, wherein each of said RNAs encodes a) HSV glycoprotein D (gD) or an immunogenic fragment thereof, b) HSV glycoprotein C (gC) or an immunogenic fragment thereof, c) HSV glycoprotein E (gE) or an immunogenic fragment thereof, or any combination thereof.

[0129] In some embodiments, the present disclosure provides a composition comprising an RNA encoding an HSV gD or an immunogenic fragment thereof, an RNA encoding an HSV gC or an immunogenic fragment thereof, and an RNA encoding an HSV gE or an immunogenic fragment thereof.

[0130] In some embodiments, compositions of RNA encoding HSV-1 gD (gD1) or an immunogenic fragment thereof are protective against HSV-1 infection. In some embodiments, combination compositions of RNA encoding HSV gC (gC1) or an immunogenic fragment thereof / HSV-1 gD (gD1) or an immunogenic fragment thereof / HSV-1 gE (gE1) or an immunogenic fragment thereof can are protective against HSV-1. Further, as provided herein, compositions of RNA encoding gD2 or an immunogenic fragment thereof can be protective against HSV-2 infection (Figures 7-10). Further, combination compositions of RNA encoding gC2 or an immunogenic fragment thereof / gD2 or an immunogenic fragment thereof / gE2 or an immunogenic fragment thereof can confer superior protection compared with compositions containing RNA encoding gC2 alone, gD2 alone, or gE2 alone. 37 11979815v1P-627574-PC

[0131] In some embodiments, inclusion of an RNA encoding gC or an immunogenic fragment thereof, and / or an RNA encoding gE or an immunogenic fragment thereof in the composition of the present disclosure can increase the efficaciousness of anti-gD antibodies elicited by the composition. In some embodiments, inclusion of an RNA encoding gC or an immunogenic fragment thereof, and / or an RNA encoding gE or an immunogenic fragment thereof in the composition of the present disclosure can increase the dose of RNA encoding gD or an immunogenic fragment thereof required to elicit antibodies that inhibit binding of gD to a cellular receptor. In another embodiment, inclusion of an RNA encoding gC or an immunogenic fragment thereof, and / or an RNA encoding gE or an immunogenic fragment thereof in the composition of the present disclosure can decrease the dose of RNA encoding gD or an immunogenic fragment thereof required to elicit antibodies that inhibit binding of gD or an immunogenic fragment thereof to a cellular receptor when a dose of RNA encoding a gD or an immunogenic fragment thereof is administered separately from RNAs encoding the gC protein, gE protein or immunogenic fragments thereof.

[0132] In another embodiment, inclusion of an RNA encoding gC or an immunogenic fragment thereof, and / or an RNA encoding gE or an immunogenic fragment thereof in the composition of the present disclosure enhances the effectiveness of an innate immune response. In another embodiment, the innate immune response is an antibody-mediated immune response. In another embodiment, the innate immune response is a non-antibody-mediated immune response. In another embodiment, the innate immune response is an NK (natural killer) cell response. In another embodiment, the innate immune response is any other innate immune response known in the art.

[0133] In another embodiment, inclusion of an RNA encoding gC or an immunogenic fragment thereof, and / or an RNA encoding gE or an immunogenic fragment thereof in the composition of the present disclosure increases the efficaciousness of antibodies elicited by the composition against one of the above glycoproteins. In another embodiment, inclusion of an RNA encoding gC or an immunogenic fragment thereof, and / or an RNA encoding gE or an immunogenic fragment thereof in the composition of the present disclosure decreases the dose of one of the above glycoproteins required to elicit antibodies that inhibit binding of the glycoprotein to a cellular receptor thereof, when a dose of one of the glycoproteins is administered separately from one of the other glycoproteins. 38 11979815v1P-627574-PC

[0134] In some embodiments, a composition comprises (i) one or more RNAs encoding HSV glycoproteins or immunogenic fragments thereof and (ii) lipid nanoparticles, polyplexes (PLX), lipidated polyplexes (LPLX), or liposomes. Glycoprotein D HSV-1 gD

[0135] In some embodiments, a composition of the present disclosure comprises an RNA encoding HSV-1 gD protein. In some embodiments, a composition comprises an RNA encoding a fragment of an HSV-1 gD protein (e.g., an immunogenic fragment).

[0136] In some embodiments, a nucleotide sequence of the RNA encoding an HSV-1 gD fragment comprises: GGAAUAAAAGUCUCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUC AAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAAG CAAUUUUCUGAAAAUUUUCACCAUUUACGAACGAUAGCAUGCGCAUGCAGCU GCUGCUGCUGAUCGCCCUGUCCCUGGCCCUGGUGACCAACUCCAAGUACGC CCUGGCCGACGCCUCCCUGAAGAUGGCCGACCCCAACCGCUUCCGCGGCAAGG ACCUGCCCGUGCUGGACCAGCUGACCGACCCCCCCGGCGUGCGCCGCGUGUAC CACAUCCAGGCCGGCCUGCCCGACCCCUUCCAGCCCCCCUCCCUGCCCAUCACC GUGUACUACGCCGUGCUGGAGCGCGCCUGCCGCUCCGUGCUGCUGAACGCCCC CUCCGAGGCCCCCCAGAUCGUGCGCGGCGCCUCCGAGGACGUGCGCAAGCAGC CCUACAACCUGACCAUCGCCUGGUUCCGCAUGGGCGGCAACUGCGCCAUCCCC AUCACCGUGAUGGAGUACACCGAGUGCUCCUACAACAAGUCCCUGGGCGCCUG CCCCAUCCGCACCCAGCCCCGCUGGAACUACUACGACUCCUUCUCCGCCGUGU CCGAGGACAACCUGGGCUUCCUGAUGCACGCCCCCGCCUUCGAGACCGCCGGC ACCUACCUGCGCCUGGUGAAGAUCAACGACUGGACCGAGAUCACCCAGUUCAU CCUGGAGCACCGCGCCAAGGGCUCCUGCAAGUACGCCCUGCCCCUGCGCAUCC CCCCCUCCGCCUGCCUGUCCCCCCAGGCCUACCAGCAGGGCGUGACCGUGGAC UCCAUCGGCAUGCUGCCCCGCUUCAUCCCCGAGAACCAGCGCACCGUGGCCGU GUACUCCCUGAAGAUCGCCGGCUGGCACGGCCCCAAGGCCCCCUACACCUCCA CCCUGCUGCCCCCCGAGCUGUCCGAGACCCCCAACGCCACCCAGCCCGAGCUGG CCCCCGAGGACCCCGAGGACUCCGCCCUGCUGGAGGACCCCGUGGGCACCGUG GCCCCCCAGAUCCCCCCCAACUGGCACAUCCCCUCCAUCCAGGACGCCGCCACC CCCUACUAACUAGUAGUGACUGACUAGGAUCUGGUUACCACUAAACCAGCCUCAA 39 11979815v1P-627574-PC GAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUACAAAAUGU UGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUC ACAUUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAC (SEQ ID NO: 1)

[0137] In some embodiments, all uridine residues are 1-methyl-pseudouridine. In some embodiments, underlined residues represent 5’ untranslated sequences (SEQ ID NO: 243). In some embodiments, bold residues represent a signal sequence (leader sequence) (SEQ ID NO: 19) to assist expression of the HSV-1 gD fragment. In some embodiments, italicized residues represent 3’ untranslated sequences (SEQ ID NO: 244) and poly adenylation tail (SEQ ID NO: 264).

[0138] In another embodiment, a nucleotide sequence of the RNA encoding an HSV-1 gD fragment lacks the 5’ untranslated sequences, the signal sequence, the 3’ untranslated sequences, the poly adenylation tail, or any combinations thereof. In some embodiments, the sequence of the HSV-1 gD fragment is as set forth in SEQ ID NO: 22.

[0139] In some embodiments, an HSV-1 gD fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 26-331 of gD (e.g., from HSV- 1 Patton strain), as set forth in the following amino acid sequence: KYALADASLKMADPNRFRGKDLPVLDQLTDPPGVRRVYHIQAGLPDPFQPPSLPITV YYAVLERACRSVLLNAPSEAPQIVRGASEDVRKQPYNLTIAWFRMGGNCAIPITVME YTECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKIN DWTEITQFILEHRAKGSCKYALPLRIPPSACLSPQAYQQGVTVDSIGMLPRFIPENQRT VAVYSLKIAGWHGPKAPYTSTLLPPELSETPNATQPELAPEDPEDSALLEDPVGTVAP QIPPNWHIPSIQDAATPY (SEQ ID NO: 2 )

[0140] In some embodiments, an HSV-1 gD fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 2. In some embodiments, an HSV-1 gD fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 2.

[0141] In some embodiments, the HSV-1 gD fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 26-333 of gD (e.g., from HSV- 1 Patton strain), as set forth in the following amino acid sequence: KYALADASLKMADPNRFRGKDLPVLDQLTDPPGVRRVYHIQAGLPDPFQPPSLPITV YYAVLERACRSVLLNAPSEAPQIVRGASEDVRKQPYNLTIAWFRMGGNCAIPITVME 40 11979815v1P-627574-PC YTECSYNKSLGACPIRTQPRWNYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKIN DWTEITQFILEHRAKGSCKYALPLRIPPSACLSPQAYQQGVTVDSIGMLPRFIPENQRT VAVYSLKIAGWHGPKAPYTSTLLPPELSETPNATQPELAPEDPEDSALLEDPVGTVAP QIPPNWHIPSIQDAATPYHP (SEQ ID NO: 134)

[0142] In some embodiments, an HSV-1 gD fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 134. In some embodiments, an HSV-1 gD fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 134.

[0143] In some embodiments, full length HSV-1 gD encoded by RNA utilized in the methods and compositions of the present disclosure comprises the following amino acid sequence: MGGAAARLGAVILFVVIVGLHGVRGKYALADASLKLADPNRFRRKDLPVLDQLTDP PGVRRVYHIQAGLPDPFQPPSLPITVYYAVLERACRSVLLNAPSEAPQIVRGASEDVR KQPYNLTIAWFRMGGNCAIPITVMEYTECSYNKSLGACPIRTQPRWNYYDSFSAVSE DNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRAKGSCKYALPLRIPPSACLS PQAYQQGVTVDSIGMLPRFIPENQRTVAVYSLKIAGWHGPKAPYTSTLLPPELSETPN ATQPELAPEAPEDSALLEDPVGTVAPQIPPNWHIPSIQDAATPYHPPATPNNMGLIAG AVGGSLLAALVICGIVYWMRRRTQKAPKRIRLPHIREDDQPSSHQPLFY (SEQ ID NO: 3)

[0144] In some embodiments, an HSV-1 gD fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 3. In some embodiments, an HSV-1 gD fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 3.

[0145] In another embodiment, an HSV-1 gD, or immunogenic fragment thereof, encoded by RNA utilized in the methods and compositions of the present disclosure comprises the amino acid sequences as set forth in any one of the following GenBank Accession Numbers: AAL90884.1 (KHS2 strain), AAL90883.1 (KHS1 strain), AAK93950.1 (F strain), AAB59754.1 (F strain), AAA19631.1 (mutant strain not identified), AAA19630.1 (mutant strain not identified), or AAA19629.1 (strain not identified).

[0146] In another embodiment, an HSV-1 gD, or immunogenic fragment thereof, encoded by RNA utilized in the methods and compositions of the present disclosure comprises the amino acid 41 11979815v1P-627574-PC sequences as set forth in any of the following GenBank Accession Numbers: A1Z0Q5.2, AAA45780.1, AAA45785.1, AAA45786.1, AAA96682.1, AAK19597.1, AAN74642.1, ABI63524.1, ABM52978.1, ABM52979.1, ABM52980.1, ABM52981.1, ABM66847.1, ABM66848.1, ACM62295.1, ADD60053.1, ADD60130.1, ADM22389.1, ADM22466.1, ADM22542.1, ADM22619.1, ADM22696.1, ADM22773.1, ADM22849.1, ADM22926.1, ADM23003.1, ADM23079.1, ADM23155.1, ADM23231.1, ADM23309.1, ADM23383.1, ADM23457.1, ADM23531.1, ADM23605.1, ADM23680.1, ADM23755.1, ADM23831.1, AEQ77097.1, AER37647.1, AER37715.1, AER37786.1, AER37857.1, AER37929.1, AER38000.1, AER38070.1, AFE62894.1, AFH41180.1, AFI23657.1, AFK50415.1, AFP86430.1, AGZ01928.1, AIR95858.1, AJE60009.1, AJE60080.1, AJE60151.1, AJE60222.1, AJE60293.1, AJE60439.1, AKE48645.1, AKG59246.1, AKG59318.1, AKG59391.1, AKG59462.1, AKG59536.1, AKG59609.1, AKG59682.1, AKG59755.1, AKG59826.1, AKG59898.1, AKG59972.1, AKG60046.1, AKG60118.1, AKG60189.1, AKG60261.1, AKG60334.1, AKG60404.1, AKG60474.1, AKG60546.1, AKG60620.1, AKG60692.1, AKG60763.1, AKG60835.1, AKG60906.1, AKG60978.1, AKG61050.1, AKG61123.1, AKG61194.1, AKG61267.1, AKG61339.1, AKG61411.1, AKG61484.1, AKG61556.1, AKG61629.1, AKG61703.1, AKG61774.1, AKG61847.1, AKG61920.1, AKG61993.1, AKH80463.1, AKH80536.1, ALM22635.1, ALM22709.1, ALM22783.1, ALM22857.1, ALO18662.1, ALO18738.1, AMB65662.1, AMB65735.1, AMB65809.1, AMB65885.1, AMB65956.1, AMN09832.1, ANN83964.1, ANN84041.1, ANN84117.1, ANN84194.1, ANN84271.1, ANN84348.1, ANN84424.1, ANN84500.1, ANN84577.1, ANN84653.1, ANN84730.1, ANN84806.1, ANN84883.1, ANN84959.1, ANN85036.1, ANN85112.1, ANN85187.1, ANN85264.1, ANN85341.1, ANN85416.1, ANN85494.1, ANN85571.1, ANN85648.1, ANN85724.1, ANN85801.1, AOY34093.1, AOY34141.1, AOY34243.1, AOY34271.1, AOY34337.1, AOY36685.1, ARB08957.1, ARO37961.1, ARO37962.1, ARO37963.1, ARO37964.1, ARO37965.1, ARO37966.1, ARO37967.1, ARO37968.1, ARO37969.1, ARO37970.1, ARO37971.1, ARO37972.1, ARO37973.1, ARO37974.1, ARO37975.1, ARO37976.1, ARO37977.1, ARO37978.1, ARO37979.1, ARO37980.1, ARO37981.1, ARO37982.1, ARO37983.1, ARO37984.1, ARO37985.1, ARO37986.1, ARO37987.1, ARO37988.1, ARO37989.1, ARO37990.1, ARO37991.1, ARO37992.1, ARO37993.1, ARO37994.1, ARO37995.1, ARO37996.1, ARO37997.1, ARO37998.1, ARO37999.1, ASM47664.1, ASM47741.1, ASM47818.1, ASM47893.1, BAM73419.1, CAA26060.1, 42 11979815v1P-627574-PC CAA32283.1, CAA32284.1, CAA32289.1, CAA38245.1, CAT05431.1, P06476.1, P36318.1, P57083.1, P68331.1, Q05059.1, Q69091.1, SBO07792.1, SBO07819.1, SBO07855.1, SBO07869.1, SBO07887.1, SBO07908.1, SBS69553.1, SBS69561.1, SBS69579.1, SBS69625.1, SBS69688.1, SBS69694.1, SBS69717.1, SBS69727.1, SBS69811.1, SBT69395.1, SCL76902.1, VGBEDZ, or YP_009137141.1. HSV-2 gD

[0147] In another embodiment, a composition comprises an RNA encoding an HSV-2 gD protein. In another embodiment, a composition comprises an RNA encoding a fragment of an HSV-2 gD protein (e.g., an immunogenic fragment).

[0148] In some embodiments, a nucleotide sequence of the RNA encoding an HSV-2 gD fragment comprises: GGAAUAAAAGUCUCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUCAA GCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAAGCAAU UUUCUGAAAAUUUUCACCAUUUACGAACGAUAGCAUGACCCGCCUGACCGUGCU GGCCCUGCUGGCCGGCCUGCUGGCCUCCUCCCGCGCCAAGUACGCCCUGGCCG ACCCCUCCCUGAAGAUGGCCGACCCCAACCGCUUCCGCGGCAAGAACCUGCCCGU GCUGGACCAGCUGACCGACCCCCCCGGCGUGAAGCGCGUGUACCACAUCCAGCCC UCCCUGGAGGACCCCUUCCAGCCCCCCUCCAUCCCCAUCACCGUGUACUACGCCGU GCUGGAGCGCGCCUGCCGCUCCGUGCUGCUGCACGCCCCCUCCGAGGCCCCCCAGA UCGUGCGCGGCGCCUCCGACGAGGCCCGCAAGCACACCUACAACCUGACCAUCGC CUGGUACCGCAUGGGCGACAACUGCGCCAUCCCCAUCACCGUGAUGGAGUACACC GAGUGCCCCUACAACAAGUCCCUGGGCGUGUGCCCCAUCCGCACCCAGCCCCGCU GGUCCUACUACGACUCCUUCUCCGCCGUGUCCGAGGACAACCUGGGCUUCCUGAU GCACGCCCCCGCCUUCGAGACCGCCGGCACCUACCUGCGCCUGGUGAAGAUCAAC GACUGGACCGAGAUCACCCAGUUCAUCCUGGAGCACCGCGCCCGCGCCUCCUGCA AGUACGCCCUGCCCCUGCGCAUCCCCCCCGCCGCCUGCCUGACCUCCAAGGCCUAC CAGCAGGGCGUGACCGUGGACUCCAUCGGCAUGCUGCCCCGCUUCAUCCCCGAGA ACCAGCGCACCGUGGCCCUGUACUCCCUGAAGAUCGCCGGCUGGCACGGCCCCAA GCCCCCCUACACCUCCACCCUGCUGCCCCCCGAGCUGUCCGACACCACCAACGCCA CCCAGCCCGAGCUGGUGCCCGAGGACCCCGAGGACUCCGCCCUGCUGGAGGACCC CGCCGGCACCGUGUCCUCCCAGAUCCCCCCCAACUGGCACAUCCCCUCCAUCCAGG ACGUGGCCCCCCACCACUAACUAGUAGUGACUGACUAGGAUCUGGUUACCACUAAAC 43 11979815v1P-627574-PC CAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUACACUUAC AAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAAGAAAGUUU CUUCACAUUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAC (SEQ ID NO: 4)

[0149] In some embodiments, all uridine residues are 1-methyl-pseudouridine. In some embodiments, underlined residues represent 5’ untranslated sequence (SEQ ID NO: 243). In some embodiments, bold residues represent a signal sequence (leader sequence) (SEQ ID NO: 20) to assist expression of the HSV-2 gD fragment. In some embodiments, italicized residues represent 3’ untranslated sequences (SEQ ID NO: 244) and poly adenylation tail (SEQ ID NO: 264).

[0150] In another embodiment, a nucleotide sequence of the RNA encoding an HSV-2 gD fragment lacks the 5’ untranslated sequences, the signal sequence, the 3’ untranslated sequences, the poly adenylation tail, or any combinations thereof. In some embodiments, the sequence of the HSV-2 gD fragment is as set forth in SEQ ID NO: 23.

[0151] In some embodiments, an HSV-2 gD fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 26-331 of gD (e.g., from HSV- 2 strain 333 or US6), as set forth in the following amino acid sequence: KYALADPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVY YAVLERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVME YTECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKIN DWTEITQFILEHRARASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQR TVALYSLKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVS SQIPPNWHIPSIQDVAPHH (SEQ ID NO: 5).

[0152] In some embodiments, an HSV-2 gD fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 5. In some embodiments, an HSV-2 gD fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 5.

[0153] In some embodiments, an HSV-2 gD fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 30-331 of gD from HSV-2 (e.g., strain 333 or US6), as set forth in the following amino acid sequence: ADPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVL ERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEYTECP 44 11979815v1P-627574-PC YNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEI TQFILEHRARASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALY SLKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPN WHIPSIQDVAPHH (SEQ ID NO: 234).

[0154] In some embodiments, an HSV-2 gD fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 234. In some embodiments, an HSV-2 gD fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 234.

[0155] In some embodiments, an HSV-2 gD fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 31-331 of gD from HSV-2 (e.g., strain 333 or US6), as set forth in the following amino acid sequence: DPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLE RACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEYTECPY NKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEIT QFILEHRARASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYS LKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPN WHIPSIQDVAPHH (SEQ ID NO: 110).

[0156] In some embodiments, an HSV-2 gD fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 110. In some embodiments, an HSV-2 gD fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 110.

[0157] In some embodiments, an HSV-2 gD fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 26-333 of gD from HSV-2 (e.g., strain 333 or US6), as set forth in the following amino acid sequence: DPSLKMADPNRFRGKNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLE RACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEYTECPY NKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEIT QFILEHRARASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYS LKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPN WHIPSIQDVAPHHAP (SEQ ID NO: 120). 45 11979815v1P-627574-PC

[0158] In some embodiments, an HSV-2 gD fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 120. In some embodiments, an HSV-2 gD fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 120.

[0159] In some embodiments, the full length HSV-2 gD encoded by RNA utilized in the methods and compositions of the present disclosure comprises the following amino acid sequence:

[0160] MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLDQ LTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQIVRGASDEA RKHTYNLTIAWYRMGDNCAIPITVMEYTECPYNKSLGVCPIRTQPRWSYYDSFSAVSED NLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRARASCKYALPLRIPPAACLTSKA YQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTLLPPELSDTTNATQPE LVPEDPEDSALLEDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALAGSTLAV LVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQPLFY (SEQ ID NO: 6).

[0161] In some embodiments, an HSV-2 gC comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 6. In some embodiments, an HSV-2 gC has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 6.

[0162] In another embodiment, an HSV-2 gD, or immunogenic fragment thereof, encoded by RNA utilized in the methods and compositions of the present disclosure comprises the amino acid sequences as set forth in GenBank Accession Numbers: 1003204A, AAA45841.1, AAA45842.1, AAB60552.1, AAB60553.1, AAB60554.1, AAB60555.1, AAB72102.1, AAS01730.1, AAW23130.1, AAW23131.1, AAW23132.1, AAW23133.1, AAW23134.1, ABS84899.1, ABU45433.1, ABU45434.1, ABU45435.1, ABU45461.1, ABU45462.1, ACA28831.1, AEV91405.1, AFM93876.1, AFS18198.1, AFS18199.1, AFS18200.1, AFS18201.1, AFS18202.1, AFS18203.1, AFS18204.1, AFS18205.1, AFS18206.1, AFS18207.1, AFS18208.1, AFS18209.1, AFS18210.1, AFS18211.1, AFS18212.1, AFS18213.1, AFS18214.1, AFS18215.1, AFS18216.1, AFS18217.1, AFS18218.1, AFS18219.1, AFS18220.1, AFS18221.1, AHG54730.1, AIL27720.1, AIL27721.1, AIL27722.1, AIL27723.1, AIL27724.1, AIL27725.1, AIL27726.1, AIL27727.1, AIL27728.1, AIL27729.1, AIL27730.1, AIL27731.1, AIL28069.1, AIL28070.1, AKC42828.1, AKC59305.1, AKC59376.1, AKC59447.1, AKC59518.1, AKC59589.1, 46 11979815v1P-627574-PC AMB66102.1, AMB66171.1, AMB66244.1, AMB66321.1, AMB66394.1, AMB66463.1, AQZ55754.1, AQZ55825.1, AQZ55896.1, AQZ55967.1, AQZ56038.1, AQZ56109.1, AQZ56180.1, AQZ56251.1, AQZ56322.1, AQZ56393.1, AQZ56464.1, AQZ56535.1, AQZ56606.1, AQZ56677.1, AQZ56748.1, AQZ56819.1, AQZ56890.1, AQZ56961.1, AQZ57032.1, AQZ57103.1, AQZ57174.1, AQZ57245.1, AQZ57316.1, AQZ57387.1, AQZ57458.1, AQZ57529.1, AQZ57600.1, AQZ57671.1, AQZ57742.1, AQZ57813.1, AQZ57884.1, AQZ57955.1, AQZ58026.1, AQZ58097.1, AQZ58168.1, AQZ58239.1, AQZ58310.1, AQZ58381.1, AQZ58452.1, AQZ58523.1, AQZ58594.1, AQZ58665.1, AQZ58736.1, AQZ58807.1, AQZ58878.1, AQZ58949.1, AQZ59020.1, AQZ59091.1, AQZ59162.1, ARO38000.1, ARO38001.1, ARO38002.1, ARO38003.1, ARO38004.1, ARO38005.1, ARO38006.1, ARO38007.1, ARO38008.1, ARO38009.1, ARO38010.1, ARO38011.1, ARO38012.1, ARO38013.1, ARO38014.1, ARO38015.1, ARO38016.1, ARO38017.1, ARO38018.1, ARO38019.1, ARO38020.1, ARO38021.1, ARO38022.1, ARO38023.1, ARO38024.1, ARO38025.1, ARO38026.1, ARO38027.1, ARO38028.1, ARO38029.1, ARO38030.1, ARO38031.1, ARO38032.1, ARO38033.1, ARO38034.1, ARO38035.1, ARO38036.1, ARO38037.1, ARO38038.1, ARO38039.1, ARO38040.1, ARO38041.1, ARO38042.1, ARO38043.1, ARO38044.1, CAA26025.1, CAB06713.1, CAC33573.1, CAT05432.1, P03172.2, Q69467.1, or YP_009137218.1.

[0163] In another embodiment, the gD protein or fragment (e.g., immunogenic fragment) includes Y63. In another embodiment, the gD protein or fragment (e.g., immunogenic fragment) includes R159. In another embodiment, the gD protein or fragment (e.g., immunogenic fragment) includes D240. In another embodiment, the gD protein or fragment (e.g., immunogenic fragment) includes P246. In another embodiment, the gD protein or fragment (e.g., immunogenic fragment) includes a residue selected from Y63, R159, D240, and P246. In another embodiment, inclusion of one of these residues elicits antibodies that inhibit binding to nectin-1.

[0164] The nomenclature used herein for gD amino acid residues includes the residues of the signal peptide encoded by the signal sequence. Thus, residue one of the mature protein is referred to as “26.”

[0165] Each RNA encoding HSV-1 gD and HSV-2 gD protein or immunogenic fragment thereof represents a separate embodiment of the present disclosure. 47 11979815v1P-627574-PC

[0166] In some embodiments, an HSV gD, gC, and gE proteins, or immunogenic fragments thereof, encoded by the modified RNA as disclosed herein are described in US Patent Publication No.2013-0028925-A1, which is incorporated by reference herein in its entirety.

[0167] In another embodiment, a gD protein fragment encoded by RNA utilized in the methods and compositions of the present disclosure is an immunogenic fragment. In another embodiment, a gD immunoprotective antigen need not be the entire protein. The protective immune response generally involves, in another embodiment, an antibody response. In another embodiment, mutants, sequence conservative variants, and functional conservative variants of gD are useful in methods and compositions of the present disclosure, provided that all such variants retain the required immuno-protective effect. In another embodiment, the immunogenic fragment can comprise an immuno-protective gD antigen from any strain of HSV. In another embodiment, the immunogenic fragment can comprise sequence variants of HSV, as found in infected individuals. Glycoprotein C HSV-1 gC

[0168] In another embodiment, a composition of the present disclosure comprises an RNA encoding HSV-1 gC protein. In another embodiment, a composition comprises an RNA encoding a fragment of an HSV-1 gC protein (e.g., an immunogenic fragment).

[0169] In some embodiments, a nucleotide sequence of the RNA encoding an HSV-1 gC fragment comprises: GGAAUAAAAGUCUCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUC AAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAAG CAAUUUUCUGAAAAUUUUCACCAUUUACGAACGAUAGCAUGGCCAUCUCCGG CGUGCCCGUGCUGGGCUUCUUCAUCAUCGCCGUGCUGAUGUCCGCCCAGG AGUCCUGGGCCGAGACCGCCUCCACCGGCCCCACCAUCACCGCCGGCGCCGUG ACCAACGCCUCCGAGGCCCCCACCUCCGGCUCCCCCGGCUCCGCCGCCUCCCCC GAGGUGACCCCCACCUCCACCCCCAACCCCAACAACGUGACCCAGAACAAGAC CACCCCCACCGAGCCCGCCUCCCCCCCCACCACCCCCAAGCCCACCUCCACCCC CAAGUCCCCCCCCACCUCCACCCCCGACCCCAAGCCCAAGAACAACACCACCCC CGCCAAGUCCGGCCGCCCCACCAAGCCCCCCGGCCCCGUGUGGUGCGACCGCCG CGACCCCCUGGCCCGCUACGGCUCCCGCGUGCAGAUCCGCUGCCGCUUCCGCA ACUCCACCCGCAUGGAGUUCCGCCUGCAGAUCUGGCGCUACUCCAUGGGCCCC UCCCCCCCCAUCGCCCCCGCCCCCGACCUGGAGGAGGUGCUGACCAACAUCACC 48 11979815v1P-627574-PC GCCCCCCCCGGCGGCCUGCUGGUGUACGACUCCGCCCCCAACCUGACCGACCCC CACGUGCUGUGGGCCGAGGGCGCCGGCCCCGGCGCCGACCCCCCCCUGUACUC CGUGACCGGCCCCCUGCCCACCCAGCGCCUGAUCAUCGGCGAGGUGACCCCCG CCACCCAGGGCAUGUACUACCUGGCCUGGGGCCGCAUGGACUCCCCCCACGAG UACGGCACCUGGGUGCGCGUGCGCAUGUUCCGCCCCCCCUCCCUGACCCUGCA GCCCCACGCCGUGAUGGAGGGCCAGCCCUUCAAGGCCACCUGCACCGCCGCCG CCUACUACCCCCGCAACCCCGUGGAGUUCGACUGGUUCGAGGACGACCGCCAG GUGUUCAACCCCGGCCAGAUCGACACCCAGACCCACGAGCACCCCGACGGCUU CACCACCGUGUCCACCGUGACCUCCGAGGCCGUGGGCGGCCAGGUGCCCCCCC GCACCUUCACCUGCCAGAUGACCUGGCACCGCGACUCCGUGACCUUCUCCCGC CGCAACGCCACCGGCCUGGCCCUGGUGCUGCCCCGCCCCACCAUCACCAUGGA GUUCGGCGUGCGCCACGUGGUGUGCACCGCCGGCUGCGUGCCCGAGGGCGUGA CCUUCGCCUGGUUCCUGGGCGACGACCCCUCCCCCGCCGCCAAGUCCGCCGUG ACCGCCCAGGAGUCCUGCGACCACCCCGGCCUGGCCACCGUGCGCUCCACCCU GCCCAUCUCCUACGACUACUCCGAGUACAUCUGCCGCCUGACCGGCUACCCCG CCGGCAUCCCCGUGCUGGAGCACCACUAACUAGUAGUGACUGACUAGGAUCUGG UUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUAC CAACUUACACUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCC UAAUAAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAC (SEQ ID NO: 7)

[0170] In some embodiments, all uridine residues are 1-methyl-pseudouridine. In some embodiments, underlined residues represent 5’ untranslated sequences (SEQ ID NO: 243). In some embodiments, bold residues represent a signal sequence (leader sequence) (SEQ ID NO: 21) to assist expression of the HSV-1 gC fragment. In some embodiments, italicized residues represent 3’ untranslated sequences (SEQ ID NO: 244) and poly adenylation tail (SEQ ID NO: 264).

[0171] In another embodiment, a nucleotide sequence of the RNA encoding an HSV-1 gC fragment lacks the 5’ untranslated sequences, the signal sequence, the 3’ untranslated sequences, the poly adenylation tail, or any combinations thereof. In some embodiments, the sequence of the HSV-1 gC fragment is as set forth in SEQ ID NO: 24. 49 11979815v1P-627574-PC

[0172] In some embodiments, an HSV-1 gC fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 27-457 of gC from HSV-1 (e.g., KOS strain), as set forth in the following amino acid sequence: ETASTGPTITAGAVTNASEAPTSGSPGSAASPEVTPTSTPNPNNVTQNKTTPTEPASPP TTPKPTSTPKSPPTSTPDPKPKNNTTPAKSGRPTKPPGPVWCDRRDPLARYGSRVQIR CRFRNSTRMEFRLQIWRYSMGPSPPIAPAPDLEEVLTNITAPPGGLLVYDSAPNLTDP HVLWAEGAGPGADPPLYSVTGPLPTQRLIIGEVTPATQGMYYLAWGRMDSPHEYGT WVRVRMFRPPSLTLQPHAVMEGQPFKATCTAAAYYPRNPVEFDWFEDDRQVFNPG QIDTQTHEHPDGFTTVSTVTSEAVGGQVPPRTFTCQMTWHRDSVTFSRRNATGLAL VLPRPTITMEFGVRHVVCTAGCVPEGVTFAWFLGDDPSPAAKSAVTAQESCDHPGL ATVRSTLPISYDYSEYICRLTGYPAGIPVLEHH (SEQ ID NO: 8).

[0173] In some embodiments, an HSV-1 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 8. In some embodiments, an HSV-1 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 8.

[0174] In some embodiments, the HSV-1 gC fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 25-457 of gC from HSV-1 (e.g., KOS strain), as set forth in the following amino acid sequence: GSETASTGPTITAGAVTNASEAPTSGSPGSAASPEVTPTSTPNPNNVTQNKTTPTEPAS PPTTPKPTSTPKSPPTSTPDPKPKNNTTPAKSGRPTKPPGPVWCDRRDPLARYGSRVQ IRCRFRNSTRMEFRLQIWRYSMGPSPPIAPAPDLEEVLTNITAPPGGLLVYDSAPNLTD PHVLWAEGAGPGADPPLYSVTGPLPTQRLIIGEVTPATQGMYYLAWGRMDSPHEYG TWVRVRMFRPPSLTLQPHAVMEGQPFKATCTAAAYYPRNPVEFDWFEDDRQVFNP GQIDTQTHEHPDGFTTVSTVTSEAVGGQVPPRTFTCQMTWHRDSVTFSRRNATGLA LVLPRPTITMEFGVRHVVCTAGCVPEGVTFAWFLGDDPSPAAKSAVTAQESCDHPG LATVRSTLPISYDYSEYICRLTGYPAGIPVLEHH (SEQ ID NO: 240).

[0175] In some embodiments, an HSV-1 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 240. In some embodiments, an HSV-1 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 240. 50 11979815v1P-627574-PC

[0176] In some embodiments, a gC fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 27-457 of gC from an HSV-1 strain.

[0177] In some embodiments, the full length HSV-1 gC encoded by RNA utilized in the methods and compositions of the present disclosure comprises the following amino acid sequence: MAPGRVGLAVVLWGLLWLGAGVAGGSETASTGPTITAGAVTNASEAPTSGSPGSA ASPEVTPTSTPNPNNVTQNKTTPTEPASPPTTPKPTSTPKSPPTSTPDPKPKNNTTPAKS GRPTKPPGPVWCDRRDPLARYGSRVQIRCRFRNSTRMEFRLQIWRYSMGPSPPIAPA PDLEEVLTNITAPPGGLLVYDSAPNLTDPHVLWAEGAGPGADPPLYSVTGPLPTQRLI IGEVTPATQGMYYLAWGRMDSPHEYGTWVRVRMFRPPSLTLQPHAVMEGQPFKAT CTAAAYYPRNPVEFDWFEDDRQVFNPGQIDTQTHEHPDGFTTVSTVTSEAVGGQVP PRTFTCQMTWHRDSVTFSRRNATGLALVLPRPTITMEFGVRHVVCTAGCVPEGVTF AWFLGDDPSPAAKSAVTAQESCDHPGLATVRSTLPISYDYSEYICRLTGYPAGIPVLE HHGSHQPPPRDPTERQVIEAIEWVGIGIGVLAAGVLVVTAIVYVVRTSQSRQRHRR (SEQ ID NO:9).

[0178] In some embodiments, an HSV-2 gC comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 9. In some embodiments, an HSV-2 gC has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 9.

[0179] In another embodiment, an HSV-1 gC encoded by RNA utilized in the methods and compositions of the present disclosure comprises the amino acid sequences as set forth in any of the following GenBank Accession Numbers: AAA45779.1, AAA96680.1, ABI63505.1, ABM52973.1, ABM52976.1, ABM52977.1, ACM62267.1, ADD60042.1, ADD60119.1, ADM22367.1, ADM22444.1, ADM22520.1, ADM22597.1, ADM22674.1, ADM22751.1, ADM22827.1, ADM22904.1, ADM22981.1, ADM23057.1, ADM23133.1, ADM23210.1, ADM23287.1, ADM23361.1, ADM23435.1, ADM23509.1, ADM23583.1, ADM23658.1, ADM23733.1, ADM23809.1, AEQ77075.1, AEQ77099.1, AER37628.1, AER37697.1, AER37767.1, AER37838.1, AER37910.1, AER37981.1, AER38051.2, AFA36179.1, AFA36180.1, AFA36181.1, AFA36182.1, AFA36183.1, AFA36184.1, AFA36185.1, AFA36186.1, AFA36187.1, AFA36188.1, AFA36189.1, AFA36190.1, AFA36191.1, AFA36192.1, AFA36193.1, AFA36194.1, AFA36195.1, AFA36196.1, AFA36197.1, AFA36198.1, AFA36199.1, AFA36200.1, AFA36201.1, AFA36202.1, AFA36203.1, 51 11979815v1P-627574-PC AFE62872.1, AFH78104.1, AFI23635.1, AFK50391.1, AFP86408.1, AGZ01906.1, AIR95840.1, AJE59989.1, AJE60060.1, AJE60131.1, AJE60202.1, AKE48623.1, AKE98415.1, AKE98416.1, AKE98417.1, AKE98418.1, AKE98419.1, AKE98420.1, AKE98421.1, AKE98422.1, AKE98423.1, AKE98424.1, AKE98425.1, AKE98426.1, AKE98427.1, AKE98428.1, AKE98429.1, AKE98430.1, AKE98431.1, AKE98432.1, AKE98433.1, AKE98434.1, AKE98435.1, AKG59227.1, AKG59299.1, AKG59372.1, AKG59444.1, AKG59516.1, AKG59591.1, AKG59663.1, AKG59736.1, AKG59807.1, AKG59879.1, AKG59953.1, AKG60027.1, AKG60099.1, AKG60170.1, AKG60243.1, AKG60316.1, AKG60386.1, AKG60456.1, AKG60528.1, AKG60601.1, AKG60674.1, AKG60745.1, AKG60817.1, AKG60887.1, AKG60959.1, AKG61032.1, AKG61104.1, AKG61175.1, AKG61248.1, AKG61321.1, AKG61392.1, AKG61464.1, AKG61537.1, AKG61611.1, AKG61684.1, AKG61756.1, AKG61828.1, AKG61902.1, AKG61974.1, AKH80444.1, AKH80517.1, AKM76368.1, ALM22613.1, ALM22687.1, ALM22761.1, ALM22835.1, ALO18641.1, ALO18717.1, AMB65642.1, AMB65715.1, AMB65862.1, AMN09813.1, ANN83942.1, ANN84019.1, ANN84095.1, ANN84172.1, ANN84249.1, ANN84326.1, ANN84403.1, ANN84478.1, ANN84555.1, ANN84632.1, ANN84708.1, ANN84785.1, ANN84861.1, ANN84938.1, ANN85014.1, ANN85091.1, ANN85167.1, ANN85242.1, ANN85319.1, ANN85396.1, ANN85472.1, ANN85549.1, ANN85626.1, ANN85703.1, ANN85779.1, AOY34308.1, AOY36663.1, AOY36687.1, ARB08935.1, ARO38059.1, ARO38060.1, ARO38061.1, ARO38062.1, ARO38063.1, ARO38064.1, ARO38065.1, ARO38066.1, ASM47642.1, ASM47719.1, ASM47796.1, ASM47871.1, BAM73394.1, CAA32294.1, CAB40083.1, CAD13356.1, CAD13357.1, CAD13358.1, CAD13359.1, CAD13360.1, CAD13361.1, CAD13362.1, CAD13363.1, CAD13364.1, CAD13365.1, CAD13366.1, CAD13367.1, CAD13368.1, CAD13369.1, CAD13370.1, CAD13371.1, CAD13372.1, CAD13373.1, CAD13374.1, CAD13375.1, CAD13376.1, CAD13377.1, CAD13378.1, P04290.1, P04488.1, P09855.1, P10228.1, P28986.1, SBO07729.1, SBO07793.1, SBO07798.1, SBO07812.1, SBO07880.1, SBS69375.1, SBS69379.1, SBS69440.1, SBS69448.1, SBS69560.1, SBS69599.1, SBS69602.1, SBS69637.1, SBS69790.1, SBT69374.1, SCL76887.1, YP_009137119.1, or YP_009137143.1. 52 11979815v1P-627574-PC HSV-2 gC

[0180] In some embodiments, a composition comprises an RNA encoding an HSV-2 gC protein. In another embodiment, a composition comprises an RNA encoding a fragment of an HSV-2 gC protein (e.g., immunogenic fragment).

[0181] In some embodiments, a nucleotide sequence of the RNA encoding an HSV-2 gC fragment comprises: GGAAUAAAAGUCUCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUC AAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAAG CAAUUUUCUGAAAAUUUUCACCAUUUACGAACGAUAGCAUGCGCAUGCAGCU GCUGCUGCUGAUCGCCCUGUCCCUGGCCCUGGUGACCAACUCCGCCUCCCC CGGCCGCACCAUCACCGUGGGCCCCCGCGGCAACGCCUCCAACGCCGCCCCCUC CGCCUCCCCCCGCAACGCCUCCGCCCCCCGCACCACCCCCACCCCCCCCCAGCCC CGCAAGGCCACCAAGUCCAAGGCCUCCACCGCCAAGCCCGCCCCCCCCCCCAAG ACCGGCCCCCCCAAGACCUCCUCCGAGCCCGUGCGCUGCAACCGCCACGACCCC CUGGCCCGCUACGGCUCCCGCGUGCAGAUCCGCUGCCGCUUCCCCAACUCCAC CCGCACCGAGUUCCGCCUGCAGAUCUGGCGCUACGCCACCGCCACCGACGCCG AGAUCGGCACCGCCCCCUCCCUGGAGGAGGUGAUGGUGAACGUGUCCGCCCCC CCCGGCGGCCAGCUGGUGUACGACUCCGCCCCCAACCGCACCGACCCCCACGU GAUCUGGGCCGAGGGCGCCGGCCCCGGCGCCUCCCCCCGCCUGUACUCCGUGG UGGGCCCCCUGGGCCGCCAGCGCCUGAUCAUCGAGGAGCUGACCCUGGAGACC CAGGGCAUGUACUACUGGGUGUGGGGCCGCACCGACCGCCCCUCCGCCUACGG CACCUGGGUGCGCGUGCGCGUGUUCCGCCCCCCCUCCCUGACCAUCCACCCCCA CGCCGUGCUGGAGGGCCAGCCCUUCAAGGCCACCUGCACCGCCGCCACCUACU ACCCCGGCAACCGCGCCGAGUUCGUGUGGUUCGAGGACGGCCGCCGCGUGUUC GACCCCGCCCAGAUCCACACCCAGACCCAGGAGAACCCCGACGGCUUCUCCAC CGUGUCCACCGUGACCUCCGCCGCCGUGGGCGGCCAGGGCCCCCCCCGCACCU UCACCUGCCAGCUGACCUGGCACCGCGACUCCGUGUCCUUCUCCCGCCGCAAC GCCUCCGGCACCGCCUCCGUGCUGCCCCGCCCCACCAUCACCAUGGAGUUCACC GGCGACCACGCCGUGUGCACCGCCGGCUGCGUGCCCGAGGGCGUGACCUUCGC CUGGUUCCUGGGCGACGACUCCUCCCCCGCCGAGAAGGUGGCCGUGGCCUCCC AGACCUCCUGCGGCCGCCCCGGCACCGCCACCAUCCGCUCCACCCUGCCCGUGU CCUACGAGCAGACCGAGUACAUCUGCCGCCUGGCCGGCUACCCCGACGGCAUC 53 11979815v1P-627574-PC CCCGUGCUGGAGCACCACUAACUAGUAGUGACUGACUAGGAUCUGGUUACCACU AAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACUUAC ACUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUAAAAA GAAAGUUUCUUCACAUUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA C (SEQ ID NO: 10).

[0182] In some embodiments, all uridine residues are 1-methyl-pseudouridine. In some embodiments, underlined residues represent 5’ untranslated sequences (SEQ ID NO: 243). In some embodiments, bold residues represent a signal sequence (leader sequence) (SEQ ID NO: 19) to assist expression of the HSV-2 gC fragment. In some embodiments, italicized residues represent 3’ untranslated sequences and a poly adenylation tail (SEQ ID NO: 244).

[0183] In another embodiment, a nucleotide sequence of the RNA encoding an HSV-2 gC fragment lacks the 5’ untranslated sequences, the signal sequence, the 3’ untranslated sequences, the poly adenylation tail, or any combinations thereof. In some embodiments, the sequence of the HSV-2 gC fragment is as set forth in SEQ ID NO: 25.

[0184] In some embodiments, an HSV-2 gC fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 27-426 of gC from HSV-2 (e.g. strain 333 or UL44), as set forth in the following amino acid sequence: ASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATKSKASTAKPAPPPKT GPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTESRLQIWRYATATDAEIGTAP SLEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRL IIEELTLETQGMYYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATC TAATYYPGNRAEFVWFEDGRRVFDPAQIHTQTQENPDGFSTVSTVTSAAVGGQGPP RTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCTAGCVPEGVTFA WFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEH H (SEQ ID NO: 11).

[0185] In some embodiments, an HSV-2 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 11. In some embodiments, an HSV-2 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 11. 54 11979815v1P-627574-PC

[0186] In some embodiments, an HSV-2 gC fragment comprises the following amino acid sequence: ASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATKSKASTAKPAPPPKT GPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTEFRLQIWRYATATDAEIGTAP SLEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRL IIEELTLETQGMYYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATC TAATYYPGNRAEFVWFEDGRRVFDPAQIHTQTQENPDGFSTVSTVTSAAVGGQGPP RTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCTAGCVPEGVTFA WFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEH H (SEQ ID NO: 28).

[0187] In some embodiments, an HSV-2 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 28. In some embodiments, an HSV-2 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 28.

[0188] In some embodiments, the HSV-2 gC fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 28-426 of gC from HSV-2 (e.g., strain 333 or UL44), as set forth in the following amino acid sequence: SPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATKSKASTAKPAPPPKTG PPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTESRLQIWRYATATDAEIGTAPS LEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRLII EELTLETQGMYYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATCT AATYYPGNRAEFVWFEDGRRVFDPAQIHTQTQENPDGFSTVSTVTSAAVGGQGPPR TFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCTAGCVPEGVTFAWF LGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEHH (SEQ ID NO: 223).

[0189] In some embodiments, an HSV-2 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 223. In some embodiments, an HSV-2 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 223. 55 11979815v1P-627574-PC

[0190] In some embodiments, an HSV-2 gC fragment comprises the following amino acid sequence: SPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATKSKASTAKPAPPPKTG PPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTEFRLQIWRYATATDAEIGTAPS LEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRLII EELTLETQGMYYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATCT AATYYPGNRAEFVWFEDGRRVFDPAQIHTQTQENPDGFSTVSTVTSAAVGGQGPPR TFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCTAGCVPEGVTFAWF LGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEHH (SEQ ID NO: 224).

[0191] In some embodiments, an HSV-2 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 224. In some embodiments, an HSV-2 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 224.

[0192] In some embodiments, the HSV-2 gC fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 26-426 of gC from HSV-2 (e.g., strain 333 or UL44), as set forth in the following amino acid sequence: SASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATKSKASTAKPAPPPK TGPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTESRLQIWRYATATDAEIGTA PSLEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQR LIIEELTLETQGMYYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKAT CTAATYYPGNRAEFVWFEDGRRVFDPAQIHTQTQENPDGFSTVSTVTSAAVGGQGP PRTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCTAGCVPEGVTFA WFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEH H (SEQ ID NO: 241).

[0193] In some embodiments, an HSV-2 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 241. In some embodiments, an HSV-2 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 241. 56 11979815v1P-627574-PC

[0194] In some embodiments, an HSV-2 gC fragment comprises the following amino acid sequence: SASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKATKSKASTAKPAPPPK TGPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTEFRLQIWRYATATDAEIGTA PSLEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQR LIIEELTLETQGMYYWVWGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKAT CTAATYYPGNRAEFVWFEDGRRVFDPAQIHTQTQENPDGFSTVSTVTSAAVGGQGP PRTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCTAGCVPEGVTFA WFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEH H (SEQ ID NO: 242).

[0195] In some embodiments, an HSV-2 gC fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 242. In some embodiments, an HSV-2 gC fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 242.

[0196] In some embodiments, the full length HSV-2 gC encoded by RNA utilized in the methods and compositions of the present disclosure comprises the following amino acid sequence: MALGRVGLAVGLWGLLWVGVVVVLANASPGRTITVGPRGNASNAAPSASPRNASA PRTTPTPPQPRKATKSKASTAKPAPPPKTGPPKTSSEPVRCNRHDPLARYGSRVQIRC RFPNSTRTEFRLQIWRYATATDAEIGTAPSLEEVMVNVSAPPGGQLVYDSAPNRTDP HVIWAEGAGPGASPRLYSVVGPLGRQRLIIEELTLETQGMYYWVWGRTDRPSAYGT WVRVRVFRPPSLTIHPHAVLEGQPFKATCTAATYYPGNRAEFVWFEDGRRVFDPAQI HTQTQENPDGFSTVSTVTSAAVGGQGPPRTFTCQLTWHRDSVSFSRRNASGTASVLP RPTITMEFTGDHAVCTAGCVPEGVTFAWFLGDDSSPAEKVAVASQTSCGRPGTATIR STLPVSYEQTEYICRLAGYPDGIPVLEHHGSHQPPPRDPTERQVIRAVEGAGIGVAVL VAVVLAGTAVVYLTHASSVRYRRLR (SEQ ID NO: 12).

[0197] In some embodiments, an HSV-2 gC comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 12. In some embodiments, an HSV-2 gC has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 12. 57 11979815v1P-627574-PC

[0198] In some embodiments, an HSV-2 gC encoded by RNA utilized in the methods and compositions of the present disclosure comprises the amino acid sequences as set forth in any of the following GenBank Accession Numbers: AAA20532.1, AAA66442.1, AAB60549.1, AAB60550.1, AAB60551.1, AAB72101.1, ABU45429.1, ABU45430.1, ABU45431.1, ABU45432.1, ABU45459.1, ABU45460.1, AEV91348.1, AEV91383.1, AEV91407.1, AFM93864.1, AHG54708.1, AKC42808.1, AKC59285.1, AKC59357.1, AKC59428.1, AKC59499.1, AKC59570.1, AMB66008.1, AMB66079.1, AMB66151.1, AMB66224.1, AMB66252.1, AMB66253.1, AMB66368.1, AMB66441.1, AQZ55735.2, AQZ55806.1, AQZ55877.1, AQZ55948.1, AQZ56019.1, AQZ56090.1, AQZ56161.2, AQZ56232.2, AQZ56303.2, AQZ56374.2, AQZ56445.1, AQZ56516.1, AQZ56587.1, AQZ56658.1, AQZ56729.2, AQZ56800.1, AQZ56871.1, AQZ56942.2, AQZ57013.1, AQZ57084.2, AQZ57155.1, AQZ57226.1, AQZ57297.1, AQZ57368.1, AQZ57439.1, AQZ57510.1, AQZ57581.1, AQZ57652.1, AQZ57723.1, AQZ57794.2, AQZ57865.2, AQZ57936.1, AQZ58007.2, AQZ58078.1, AQZ58149.2, AQZ58220.1, AQZ58291.1, AQZ58362.1, AQZ58433.1, AQZ58504.1, AQZ58575.1, AQZ58646.1, AQZ58717.2, AQZ58788.2, AQZ58859.2, AQZ58930.1, AQZ59001.2, AQZ59072.1, AQZ59143.1, ARO38067.1, ARO38068.1, ARO38069.1, ARO38070.1, ARO38071.1, ARO38072.1, CAA25687.1, CAA26025.1, CAB06730.1, CAB06734.1, CAB96544.1, P03173.1, P06475.1, P89475.1, Q89730.1, YP_009137161.1, YP_009137196.1, or YP_009137220.1.

[0199] In other embodiments, an HSV gC protein fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises a properdin interfering domain “Properdin-interfering domain” refers, in some embodiments, to a domain that blocks or inhibits binding of a host C3b molecule with a host properdin molecule. In another embodiment, the term refers to a domain that blocks or inhibits an interaction of a host C3b molecule with a host properdin molecule.

[0200] In another embodiment, an HSV gC protein fragment encoded by RNA utilized in the methods and compositions of the present disclosure is a C5 interfering domain. In another embodiment, the gC protein fragment is a portion of a C5 interfering domain. “C5-interfering domain” refers, in another embodiment, to a domain that interferes with binding of a host C3b molecule with a host C5 molecule. In another embodiment, the term refers to a domain that interferes with the interaction of a host C3b molecule with a host C5 molecule. 58 11979815v1P-627574-PC

[0201] Each RNA encoding HSV-1 gCor HSV-2 gC protein or fragment thereof represents a separate embodiment of the present disclosure.

[0202] In another embodiment, a gC protein fragment encoded by RNA utilized in the methods and compositions of the present disclosure is an immunogenic fragment. In another embodiment, a gC immunoprotective antigen need not be the entire protein. The protective immune response generally involves, in another embodiment, an antibody response. In another embodiment, mutants, sequence conservative variants, and functional conservative variants of gC are useful in methods and compositions of the present disclosure, provided that all such variants retain the required immuno-protective effect. In another embodiment, the immunogenic fragment can comprise an immuno-protective gC antigen from any strain of HSV. In another embodiment, the immunogenic fragment can comprise sequence variants of HSV, as found in infected individuals. Glycoprotein E HSV-1 gE

[0203] In another embodiment, a composition of the present disclosure comprises an RNA encoding HSV-1 gE protein. In another embodiment, a composition comprises an RNA encoding a fragment of an HSV-1 gE protein (e.g., immunogenic fragment).

[0204] In some embodiments, a nucleotide sequence of the RNA encoding an HSV-1 gE fragment comprises: GGAAUAAAAGUCUCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUC AAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAAG CAAUUUUCUGAAAAUUUUCACCAUUUACGAACGAUAGCAUGCGCAUGCAGCU GCUGCUGCUGAUCGCCCUGUCCCUGGCCCUGGUGACCAACUCCAAGACCUC CUGGCGCCGCGUGUCCGUGGGCGAGGACGUGUCCCUGCUGCCCGCCCCCGGCC CCACCGGCCGCGGCCCCACCCAGAAGCUGCUGUGGGCCGUGGAGCCCCUGGAC GGCUGCGGCCCCCUGCACCCCUCCUGGGUGUCCCUGAUGCCCCCCAAGCAGGU GCCCGAGACCGUGGUGGACGCCGCCUGCAUGCGCGCCCCCGUGCCCCUGGCCA UGGCCUACGCCCCCCCCGCCCCCUCCGCCACCGGCGGCCUGCGCACCGACUUCG UGUGGCAGGAGCGCGCCGCCGUGGUGAACCGCUCCCUGGUGAUCUACGGCGUG CGCGAGACCGACUCCGGCCUGUACACCCUGUCCGUGGGCGACAUCAAGGACCC CGCCCGCCAGGUGGCCUCCGUGGUGCUGGUGGUGCAGCCCGCCCCCGUGCCCA CCCCCCCCCCCACCCCCGCCGACUACGACGAGGACGACAACGACGAGGGCGAG GGCGAGGACGAGUCCCUGGCCGGCACCCCCGCCUCCGGCACCCCCCGCCUGCCC 59 11979815v1P-627574-PC CCCUCCCCCGCCCCCCCCCGCUCCUGGCCCUCCGCCCCCGAGGUGUCCCACGUG CGCGGCGUGACCGUGCGCAUGGAGACCCCCGAGGCCAUCCUGUUCUCCCCCGG CGAGGCCUUCUCCACCAACGUGUCCAUCCACGCCAUCGCCCACGACGACCAGA CCUACACCAUGGACGUGGUGUGGCUGCGCUUCGACGUGCCCACCUCCUGCGCC GAGAUGCGCAUCUACGAGUCCUGCCUGUACCACCCCCAGCUGCCCGAGUGCCU GUCCCCCGCCGACGCCCCCUGCGCCGCCUCCACCUGGACCUCCCGCCUGGCCGU GCGCUCCUACGCCGGCUGCUCCCGCACCAACCCCCCCCCCCGCUGCUCCGCCGA GGCCCACAUGGAGCCCUUCCCCGGCCUGGCCUGGCAGGCCGCCUCCGUGAACC UGGAGUUCCGCGACGCCUCCCCCCAGCACUCCGGCCUGUACCUGUGCGUGGUG UACGUGAACGACCACAUCCACGCCUGGGGCCACAUCACCAUCAACACCGCCGC CCAGUACCGCAACGCCGUGGUGGAGCAGCCCCUGCCCCAGCGCGGCGCCGACC UGGCCGAGCCCACCCACCCCCACGUGGGCGCCUAACUAGUAGUGACUGACUAGG AUCUGGUUACCACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACA UAAUACCAACUUACACUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUC UGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAC (SEQ ID NO: 13).

[0205] In some embodiments, all uridine residues are 1-methyl-pseudouridine. In some embodiments, underlined residues represent 5’ untranslated sequences (SEQ ID NO: 243). In some embodiments, bold residues represent a signal sequence (leader sequence) (SEQ ID NO: 19) to assist expression of the HSV-1 gE fragment. In some embodiments, italicized residues represent 3’ untranslated sequences (SEQ ID NO: 244) and poly adenylation tail (SEQ ID NO: 264).

[0206] In another embodiment, a nucleotide sequence of the RNA encoding an HSV-1 gE fragment lacks the 5’ untranslated sequences, the signal sequence, the 3’ untranslated sequences, the poly adenylation tail, or a combination thereof. In some embodiments, the sequence of the HSV-1 gE fragment is as set forth in SEQ ID NO: 26.

[0207] In some embodiments, an HSV-1 gE fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 24-409 of gE from HSV-1 (e.g., NS strain), as set forth in the following amino acid sequence: KTSWRRVSVGEDVSLLPAPGPTGRGPTQKLLWAVEPLDGCGPLHPSWVSLMPPKQV PETVVDAACMRAPVPLAMAYAPPAPSATGGLRTDFVWQERAAVVNRSLVIYGVRE TDSGLYTLSVGDIKDPARQVASVVLVVQPAPVPTPPPTPADYDEDDNDEGEGEDESL 60 11979815v1P-627574-PC AGTPASGTPRLPPSPAPPRSWPSAPEVSHVRGVTVRMETPEAILFSPGEAFSTNVSIHA IAHDDQTYTMDVVWLRFDVPTSCAEMRIYESCLYHPQLPECLSPADAPCAASTWTS RLAVRSYAGCSRTNPPPRCSAEAHMEPFPGLAWQAASVNLEFRDASPQHSGLYLCV VYVNDHIHAWGHITINTAAQYRNAVVEQPLPQRGADLAEPTHPHVGA (SEQ ID NO: 14).

[0208] In some embodiments, an HSV-1 gE fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 14. In some embodiments, an HSV-1 gE fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 14.

[0209] In some embodiments, a gE fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 24-409 of gE from an HSV-1 strain (SEQ ID NO: 14).

[0210] In some embodiments, an HSV-1 gE fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 21-409 of gE from HSV-1 (e.g., NS strain or US8), as set forth in the following amino acid sequence: GTPKTSWRRVSVGEDVSLLPAPGPTGRGPTQKLLWAVEPLDGCGPLHPSWVSLMPP KQVPETVVDAACMRAPVPLAMAYAPPAPSATGGLRTDFVWQERAAVVNRSLVIYG VRETDSGLYTLSVGDIKDPARQVASVVLVVQPAPVPTPPPTPADYDEDDNDEGEGE DESLAGTPASGTPRLPPSPAPPRSWPSAPEVSHVRGVTVRMETPEAILFSPGEAFSTNV SIHAIAHDDQTYTMDVVWLRFDVPTSCAEMRIYESCLYHPQLPECLSPADAPCAAST WTSRLAVRSYAGCSRTNPPPRCSAEAHMEPFPGLAWQAASVNLEFRDASPQHSGLY LCVVYVNDHIHAWGHITINTAAQYRNAVVEQPLPQRGADLAEPTHPHVGA (SEQ ID NO: 248).

[0211] In some embodiments, an HSV-1 gE fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 248. In some embodiments, an HSV-1 gE fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 248.

[0212] In some embodiments, an HSV-1 gE fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 21-409 of gE from an HSV-1 strain. 61 11979815v1P-627574-PC

[0213] In some embodiments, an HSV-1 gE fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 24-309 of gE from HSV-1 (e.g., NS strain or US8), as set forth in the following amino acid sequence: GTPKTSWRRVSVGEDVSLLPAPGPTGRGPTQKLLWAVEPLDGCGPLHPSWVSLMPP KQVPETVVDAACMRAPVPLAMAYAPPAPSATGGLRTDFVWQERAAVVNRSLVIYG VRETDSGLYTLSVGDIKDPARQVASVVLVVQPAPVPTPPPTPADYDEDDNDEGEGE DESLAGTPASGTPRLPPSPAPPRSWPSAPEVSHVRGVTVRMETPEAILFSPGEAFSTNV SIHAIAHDDQTYTMDVVWLRFDVPTSCAEMRIYESCLYHPQLPECLSPADAPCAAST WTSRLAVRSYAGCSRTNPPPRCSAEAHMEPFPGLAWQAASVNLEFRDASPQHSGLY LCVVYVNDHIHAWGHITINTAAQYRNAVVEQPLPQRGADLAEPTHPHVGA (SEQ ID NO: 248).

[0214] In some embodiments, an HSV-1 gE fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 248. In some embodiments, an HSV-1 gE fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 248.

[0215] In some embodiments, a full length HSV-1 gE encoded by RNA utilized in the methods and compositions of the present disclosure comprises the following amino acid sequence: MDRGAVVGFLLGVCVVSCLAGTPKTSWRRVSVGEDVSLLPAPGPTGRGPTQKLLW AVEPLDGCGPLHPSWVSLMPPKQVPETVVDAACMRAPVPLAMAYAPPAPSATGGL RTDFVWQERAAVVNRSLVIYGVRETDSGLYTLSVGDIKDPARQVASVVLVVQPAPV PTPPPTPADYDEDDNDEGEGEDESLAGTPASGTPRLPPSPAPPRSWPSAPEVSHVRGV TVRMETPEAILFSPGEAFSTNVSIHAIAHDDQTYTMDVVWLRFDVPTSCAEMRIYES CLYHPQLPECLSPADAPCAASTWTSRLAVRSYAGCSRTNPPPRCSAEAHMEPFPGLA WQAASVNLEFRDASPQHSGLYLCVVYVNDHIHAWGHITINTAAQYRNAVVEQPLP QRGADLAEPTHPHVGAPPHAPPTHGALRLGAVMGAALLLSALGLSVWACMTCWR RRAWRAVKSRASGKGPTYIRVADSELYADWSSDSEGERDQVPWLAPPERPDSPSTN GSGFEILSPTAPSVYPRSDGHQSRRQLTTFGSGRPDRRYSQASDSSVFW (SEQ ID NO: 15).

[0216] In some embodiments, an HSV-1 gE comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ 62 11979815v1P-627574-PC ID NO: 15. In some embodiments, an HSV-1 gE has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO:15.

[0217] In another embodiment, an HSV-1 gE encoded by RNA utilized in the methods and compositions of the present disclosure comprises the amino acid sequences as set forth in any of the following GenBank Accession Numbers: AAA45779.1, AAA96680.1, ABI63526.1, ACM62297.1, ADD60055.1, ADD60132.1, ADM22391.1, ADM22468.1, ADM22544.1, ADM22621.1, ADM22698.1, ADM22775.1, ADM22851.1, ADM22928.1, ADM23005.1, ADM23081.1, ADM23157.1, ADM23233.1, ADM23311.1, ADM23385.1, ADM23459.1, ADM23533.1, ADM23607.1, ADM23682.1, ADM23757.1, ADM23833.1, ADN34689.1, ADN34692.1, ADN34695.1, AEQ77099.1, AER37649.1, AER37717.1, AER37788.1, AER37859.1, AER37931.1, AER38002.1, AER38072.1, AFA36179.1, AFA36180.1, AFA36181.1, AFA36182.1, AFA36183.1, AFA36184.1, AFA36185.1, AFA36186.1, AFA36187.1, AFA36188.1, AFA36189.1, AFA36190.1, AFA36191.1, AFA36192.1, AFA36193.1, AFA36194.1, AFA36195.1, AFA36196.1, AFA36197.1, AFA36198.1, AFA36199.1, AFA36200.1, AFA36201.1, AFA36202.1, AFA36203.1, AFE62896.1, AFI23659.1, AFK50417.1, AFP86432.1, AGZ01930.1, AIR95859.1, AJE60011.1, AJE60082.1, AJE60153.1, AJE60224.1, AJE60295.1, AKE48647.1, AKE98373.1, AKE98374.1, AKE98375.1, AKE98376.1, AKE98377.1, AKE98378.1, AKE98379.1, AKE98380.1, AKE98381.1, AKE98382.1, AKE98383.1, AKE98384.1, AKE98385.1, AKE98386.1, AKE98387.1, AKE98388.1, AKE98389.1, AKE98390.1, AKE98391.1, AKE98392.1, AKE98393.1, AKG59248.1, AKG59320.1, AKG59393.1, AKG59464.1, AKG59538.1, AKG59611.1, AKG59684.1, AKG59757.1, AKG59828.1, AKG59900.1, AKG59974.1, AKG60048.1, AKG60120.1, AKG60191.1, AKG60263.1, AKG60336.1, AKG60406.1, AKG60476.1, AKG60548.1, AKG60622.1, AKG60694.1, AKG60765.1, AKG60837.1, AKG60908.1, AKG60980.1, AKG61052.1, AKG61125.1, AKG61196.1, AKG61269.1, AKG61341.1, AKG61413.1, AKG61486.1, AKG61558.1, AKG61631.1, AKG61705.1, AKG61776.1, AKG61849.1, AKG61922.1, AKG61995.1, AKH80465.1, AKH80538.1, ALM22637.1, ALM22711.1, ALM22785.1, ALM22859.1, ALO18664.1, ALO18740.1, AMB65664.1, AMB65737.1, AMB65811.1, AMB65887.1, AMB65958.1, AMN09834.1, ANN83966.1, ANN84043.1, ANN84119.1, ANN84196.1, ANN84273.1, ANN84350.1, ANN84426.1, ANN84502.1, ANN84579.1, ANN84655.1, ANN84732.1, ANN84808.1, ANN84885.1, ANN84961.1, ANN85038.1, ANN85114.1, ANN85189.1, ANN85266.1, 63 11979815v1P-627574-PC ANN85343.1, ANN85418.1, ANN85496.1, ANN85573.1, ANN85650.1, ANN85726.1, ANN85803.1, AOY34085.1, AOY36687.1, ARB08959.1, ARO38073.1, ARO38074.1, ARO38075.1, ARO38076.1, ARO38077.1, ARO38078.1, ARO38079.1, ARO38080.1, ASM47642.1, ASM47666.1, ASM47743.1, ASM47820.1, ASM47895.1, BAM73421.1, CAA26062.1, CAA32272.1, CAF24756.1, CAF24757.1, CAF24758.1, CAF24759.1, CAF24760.1, CAF24761.1, CAF24762.1, CAF24763.1, CAF24764.1, CAF24765.1, CAF24766.1, CAF24767.1, CAF24768.1, CAF24769.1, CAF24770.1, CAF24771.1, CAF24772.1, CAF24773.1, CAF24774.1, CAF24775.1, CAF24776.1, CAF24777.1, CAF24778.1, CAF24779.1, CAF24780.1, CAF24781.1, CAF24782.1, CAF24783.1, CAF24784.1, CAF24785.1, P04290.1, P04488.1, P28986.1, Q703F0.1, SBO07910.1, SBS69571.1, SBS69576.1, SBS69595.1, SBS69636.1, SBS69693.1, SBS69701.1, SBS69722.1, SBS69732.1, SBS69813.1, SBT69397.1, or YP_009137143.1. HSV-2 gE

[0218] In some embodiments, a composition comprises an RNA encoding an HSV-2 gE protein. In another embodiment, a composition comprises an RNA encoding a fragment of an HSV-2 gE protein (e.g., immunogenic fragment).

[0219] In some embodiments, a nucleotide sequence of the RNA encoding an HSV-2 gE fragment comprises: GGAAUAAAAGUCUCAACACAACAUAUACAAAACAAACGAAUCUCAAGCAAUC AAGCAUUCUACUUCUAUUGCAGCAAUUUAAAUCAUUUCUUUUAAAGCAAAAG CAAUUUUCUGAAAAUUUUCACCAUUUACGAACGAUAGCAUGCGCAUGCAGCU GCUGCUGCUGAUCGCCCUGUCCCUGGCCCUGGUGACCAACUCCCGCACCUC CUGGAAGCGCGUGACCUCCGGCGAGGACGUGGUGCUGCUGCCCGCCCCCGCCG GCCCCGAGGAGCGCACCCGCGCCCACAAGCUGCUGUGGGCCGCCGAGCCCCUG GACGCCUGCGGCCCCCUGCGCCCCUCCUGGGUGGCCCUGUGGCCCCCCCGCCGC GUGCUGGAGACCGUGGUGGACGCCGCCUGCAUGCGCGCCCCCGAGCCCCUGGC CAUCGCCUACUCCCCCCCCUUCCCCGCCGGCGACGAGGGCCUGUACUCCGAGC UGGCCUGGCGCGACCGCGUGGCCGUGGUGAACGAGUCCCUGGUGAUCUACGGC GCCCUGGAGACCGACUCCGGCCUGUACACCCUGUCCGUGGUGGGCCUGUCCGA CGAGGCCCGCCAGGUGGCCUCCGUGGUGCUGGUGGUGGAGCCCGCCCCCGUGC CCACCCCCACCCCCGACGACUACGACGAGGAGGACGACGCCGGCGUGUCCGAG CGCACCCCCGUGUCCGUGCCCCCCCCCACCCCCCCCCGCCGCCCCCCCGUGGCC 64 11979815v1P-627574-PC CCCCCCACCCACCCCCGCGUGAUCCCCGAGGUGUCCCACGUGCGCGGCGUGACC GUGCACAUGGAGACCCCCGAGGCCAUCCUGUUCGCCCCCGGCGAGACCUUCGG CACCAACGUGUCCAUCCACGCCAUCGCCCACGACGACGGCCCCUACGCCAUGG ACGUGGUGUGGAUGCGCUUCGACGUGCCCUCCUCCUGCGCCGAGAUGCGCAUC UACGAGGCCUGCCUGUACCACCCCCAGCUGCCCGAGUGCCUGUCCCCCGCCGA CGCCCCCUGCGCCGUGUCCUCCUGGGCCUACCGCCUGGCCGUGCGCUCCUACG CCGGCUGCUCCCGCACCACCCCCCCCCCCCGCUGCUUCGCCGAGGCCCGCAUGG AGCCCGUGCCCGGCCUGGCCUGGCUGGCCUCCACCGUGAACCUGGAGUUCCAG CACGCCUCCCCCCAGCACGCCGGCCUGUACCUGUGCGUGGUGUACGUGGACGA CCACAUCCACGCCUGGGGCCACAUGACCAUCUCCACCGCCGCCCAGUACCGCA ACGCCGUGGUGGAGCAGCACCUGCCCCAGCGCCAGCCCGAGCCCGUGGAGCCC ACCCGCCCCCACGUGCGCGCCUAACUAGUAGUGACUGACUAGGAUCUGGUUACC ACUAAACCAGCCUCAAGAACACCCGAAUGGAGUCUCUAAGCUACAUAAUACCAACU UACACUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGUAUCUGCUCCUAAUA AAAAGAAAGUUUCUUCACAUUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAC (SEQ ID NO: 16)

[0220] In some embodiments, all uridine residues are 1-methyl-pseudouridine. In some embodiments, underlined residues represent 5’ untranslated sequences (SEQ ID NO: 243). In some embodiments, bold residues represent a signal sequence (leader sequence) (SEQ ID NO: 19) to assist expression of the HSV-2 gE fragment. In some embodiments, italicized residues represent 3’ untranslated sequences (SEQ ID NO: 244) and poly adenylation tail (SEQ ID NO: 264).

[0221] In another embodiment, a nucleotide sequence of the RNA encoding an HSV-2 gE fragment lacks the 5’ untranslated sequences, the signal sequence, the 3’ untranslated sequences, the poly adenylation tail, or a combination thereof. In some embodiments, the sequence of the HSV-2 gE fragment is as set forth in SEQ ID NO: 27.

[0222] In some embodiments, an HSV-2 gE fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises amino acids 24-405 of gE from HSV-2 (e.g., strain 2.12 or US8) as set forth in the following amino acid sequence: RTSWKRVTSGEDVVLLPAPAGPEERTRAHKLLWAAEPLDACGPLRPSWVALWPPR RVLETVVDAACMRAPEPLAIAYSPPFPAGDEGLYSELAWRDRVAVVNESLVIYGAL ETDSGLYTLSVVGLSDEARQVASVVLVVEPAPVPTPTPDDYDEEDDAGVSERTPVSV 65 11979815v1P-627574-PC PPPTPPRRPPVAPPTHPRVIPEVSHVRGVTVHMETPEAILFAPGETFGTNVSIHAIAHD DGPYAMDVVWMRFDVPSSCAEMRIYEACLYHPQLPECLSPADAPCAVSSWAYRLA VRSYAGCSRTTPPPRCFAEARMEPVPGLAWLASTVNLEFQHASPQHAGLYLCVVYV DDHIHAWGHMTISTAAQYRNAVVEQHLPQRQPEPVEPTRPHVRA (SEQ ID NO: 17).

[0223] In some embodiments, an HSV-2 gE fragment comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 17. In some embodiments, an HSV-2 gE fragment has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 17.

[0224] In some embodiments, full length HSV-2 gE encoded by RNA utilized in the methods and compositions of the present disclosure comprises the following amino acid sequence: MARGAGLVFFVGVWVVSCLAAAPRTSWKRVTSGEDVVLLPAPAERTRAHKLLWA AEPLDACGPLRPSWVALWPPRRVLETVVDAACMRAPEPLAIAYSPPFPAGDEGLYSE LAWRDRVAVVNESLVIYGALETDSGLYTLSVVGLSDEARQVASVVLVVEPAPVPTP TPDDYDEEDDAGVTNARRSAFPPQPPPRRPPVAPPTHPRVIPEVSHVRGVTVHMETL EAILFAPGETFGTNVSIHAIAHDDGPYAMDVVWMRFDVPSSCADMRIYEACLYHPQ LPECLSPADAPCAVSSWAYRLAVRSYAGCSRTTPPPRCFAEARMEPVPGLAWLAST VNLEFQHASPQHAGLYLCVVYVDDHIHAWGHMTISTAAQYRNAVVEQHLPQRQPE PVEPTRPHVRAPHPAPSARGPLRLGAVLGAALLLAALGLSAWACMTCWRRRSWRA VKSRASATGPTYIRVADSELYADWSSDSEGERDGSLWQDPPERPDSPSTNGSGFEILS PTAPSVYPHSEGRKSRRPLTTFGSGSPGRRHSQASYPSVLW (SEQ ID NO: 18).

[0225] In some embodiments, an HSV-2 gE comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to the amino acid sequence SEQ ID NO: 18. In some embodiments, an HSV-2 gE has an amino acid sequence that is identical to the amino acid sequence SEQ ID NO: 18.

[0226] In another embodiment, an HSV-2 gE encoded by RNA utilized in the methods and compositions of the present disclosure comprises the amino acid sequences as set forth in any of the following GenBank Accession Numbers: ABU45436.1, ABU45437.1, ABU45438.1, ABU45439.1, ABW83306.1, ABW83308.1, ABW83310.1, ABW83312.1, ABW83314.1, ABW83316.1, ABW83318.1, ABW83320.1, ABW83322.1, ABW83324.1, ABW83326.1, ABW83328.1, ABW83330.1, ABW83332.1, ABW83334.1, ABW83336.1, ABW83338.1, 66 11979815v1P-627574-PC ABW83340.1, ABW83342.1, ABW83344.1, ABW83346.1, ABW83348.1, ABW83350.1, ABW83352.1, ABW83354.1, ABW83356.1, ABW83358.1, ABW83360.1, ABW83362.1, ABW83364.1, ABW83366.1, ABW83368.1, ABW83370.1, ABW83372.1, ABW83374.1, ABW83376.1, ABW83378.1, ABW83380.1, ABW83382.1, ABW83384.1, ABW83386.1, ABW83388.1, ABW83390.1, ABW83392.1, ABW83394.1, ABW83396.1, ABW83398.1, ABW83400.1, ABZ04069.1, AEV91407.1, AHG54732.1, AKC42830.1, AKC59307.1, AKC59378.1, AKC59449.1, AKC59520.1, AKC59591.1, AMB66104.1, AMB66173.1, AMB66246.1, AMB66465.1, AQZ55756.1, AQZ55827.1, AQZ55898.1, AQZ55969.2, AQZ56040.2, AQZ56111.2, AQZ56182.1, AQZ56253.2, AQZ56324.1, AQZ56395.1, AQZ56466.2, AQZ56537.1, AQZ56608.1, AQZ56679.1, AQZ56750.1, AQZ56821.2, AQZ56892.1, AQZ56963.2, AQZ57034.2, AQZ57105.1, AQZ57176.1, AQZ57247.2, AQZ57318.2, AQZ57389.2, AQZ57460.2, AQZ57531.2, AQZ57602.2, AQZ57673.1, AQZ57744.2, AQZ57815.1, AQZ57886.1, AQZ57957.2, AQZ58028.2, AQZ58099.1, AQZ58170.2, AQZ58241.2, AQZ58312.2, AQZ58383.2, AQZ58454.2, AQZ58525.2, AQZ58596.1, AQZ58667.1, AQZ58738.2, AQZ58809.2, AQZ58880.2, AQZ58951.2, AQZ59022.2, AQZ59093.1, AQZ59164.1, ARO38081.1, ARO38082.1, ARO38083.1, ARO38084.1, ARO38085.1, ARO38086.1, CAB06715.1, P89436.1, P89475.1, or YP_009137220.1.

[0227] In another embodiment, an HSV gE fragment encoded by RNA utilized in the methods and compositions of the present disclosure comprises an IgG Fc-binding domain of the gE protein. In another embodiment, the gE domain encoded by RNA utilized in the methods and compositions of the present disclosure is any other gE domain known in the art to mediate binding to IgG Fc.

[0228] In another embodiment, an HSV gE protein encoded by RNA utilized in the methods and compositions of the present disclosure comprises a gE domain involved in cell-to-cell spread.

[0229] In another embodiment, an HSV gE fragment encoded by RNA fragment utilized in the methods and compositions of the present disclosure comprises an immune evasion domain. In another embodiment, the gE fragment encoded by RNA fragment utilized in the methods and compositions of the present disclosure comprises a portion of an immune evasion domain.

[0230] Each RNA encoding HSV-1 gE or HSV-2 gE protein or fragment thereof represents a separate embodiment of the present disclosure.

[0231] In another embodiment, an HSV gE protein fragment encoded by RNA utilized in the methods and compositions of the present disclosure is an immunogenic fragment. In another 67 11979815v1P-627574-PC embodiment, a gE immunoprotective antigen need not be the entire protein. The protective immune response generally involves, in another embodiment, an antibody response. In another embodiment, mutants, sequence conservative variants, and functional conservative variants of gE are useful in methods and compositions of the present disclosure, provided that all such variants retain the required immuno-protective effect. In another embodiment, the immunogenic fragment can comprise an immuno-protective gE antigen from any strain of HSV. In another embodiment, the immunogenic fragment can comprise sequence variants of HSV, as found in infected individuals.

[0232] In some embodiments, an RNA of the present disclosure encodes an HSV polypeptide, or fragment thereof, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 1.

[0233] In some embodiments, methods of the present disclosure comprise administering to a subject an HSV polypeptide, or fragment thereof, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 1. Table 1: Exemplary amino acid sequences of HSV immunogens Sequence Amino acid sequence SEQ ID NO:11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name69 11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name70 11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name11979815v1P-627574-PC Sequence Amino acid sequence SEQ ID NO: Name [ ence a, , , , , , %, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 2.

[0235] In some embodiments, methods of the present disclosure comprise administering to a subject an RNA comprising a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 2. Table 2: Exemplary nucleic acid sequences of HSV immunogens HSV-1 gD AAGUACGCCCUGGCCGACGCCUCCCUGAAGAUGGC 2211979815v1P-627574-PC GCCCCCGCCUUCGAGACCGCCGGCACCUACCUGCGC CUGGUGAAGAUCAACGACUGGACCGAGAUCACCCA11979815v1P-627574-PC CCGAGAACCAGCGCACCGUGGCCCUGUACUCCCUG AAGAUCGCCGGCUGGCACGGCCCCAAGCCCCCCUAC11979815v1P-627574-PC UAACUGGCACAUCCCCAGCAUCCAGGAUGUGGCCC CUCAUCAUUGA11979815v1P-627574-PC Version CGCGUCUACCACAUACAGCCUAGUCUUGAGGACCC 2.1 UUUUCAGCCACCGUCUAUCCCCAUUACCGUGUACU11979815v1P-627574-PC ACCUCACAAUAGCGUGGUAUCGAAUGGGCGAUAAC UGCGCAAUUCCCAUCACAGUCAUGGAGUACACGGA11979815v1P-627574-PC AUGCACGCCCCCGCCUUCGAAACCGCCGGCACCUAC CUGAGACUGGUGAAAAUCAACGAUUGGACCGAAAU11979815v1P-627574-PC AGCAUUGGCAUGCUGCCUCGUUUCAUUCCCGAGAA UCAACGGACAGUGGCUCUGUAUUCCCUGAAGAUCG11979815v1P-627574-PC GCCAGAUCGACACCCAGACCCACGAGCACCCCGACG GCUUCACCACCGUGUCCACCGUGACCUCCGAGGCC11979815v1P-627574-PC AGGCCAGCCUUUCAAGGCCACAUGUACCGCCGCCA CCUACUAUCCCGGAAACAGAGCCGAGUUCGUUUGG11979815v1P-627574-PC GCACCGACCGCCCCUCCGCCUACGGCACCUGGGUGC GCGUGCGCGUGUUCCGCCCCCCCUCCCUGACCAUCC11979815v1P-627574-PC UUGGCCCGCUUGGACGACAGAGACUCAUCAUCGAG GAACUGACACUGGAGACACAGGGGAUGUACUACUG11979815v1P-627574-PC CAGGAGGACAGCUGGUCUAUGACUCAGCGCCCAAU AGGACCGAUCCCCACGUGAUCUGGGCAGAAGGAGC11979815v1P-627574-PC UGAGUUUCGGCUGCAGAUCUGGCGUUAUGCCACAG CUACUGACGCAGAGAUUGGUACCGCCCCCAGUUUG11979815v1P-627574-PC CCCAAAGACAAGUAGCGAACCAGUUCGGUGCAACA GGCAUGACCCACUUGCACGCUAUGGGUCAAGAGUC11979815v1P-627574-PC (28-426) GGAAUGCUUCUGCCCCAAGAACUACCCCCACUCCU Version CCUCAACCCAGGAAAGCGACAAAGUCCAAGGCCAG92 11979815v1P-627574-PC UGGCCGGCUAUCCCGAUGGGAUUCCAGUCCUGGAG CACCACUGA11979815v1P-627574-PC AGAAAGUGGCUGUGGCCUCUCAGACGAGCUGCGGU CGACCAGGAACAGCUACCAUUCGCAGCACUCUGCC11979815v1P-627574-PC CCAUGGAAUUCACCGGCGAUCACGCCGUGUGCACC GCCGGCUGCGUGCCCGAAGGCGUGACCUUCGCCUG11979815v1P-627574-PC CCUUCACCUGCCAGCUGACCUGGCACCGCGACUCCG UGUCCUUCUCCCGCCGCAACGCCUCCGGCACCGCCU11979815v1P-627574-PC ACACAGACCCAAGAGAACCCCGACGGCUUUAGCAC CGUGUCCACAGUGACAUCUGCCGCCGUUGGAGGAC11979815v1P-627574-PC CCUUUCAAGGCCACAUGUACCGCCGCCACCUACUA UCCCGGAAACAGAGCCGAGUUCGUUUGGUUCGAGG11979815v1P-627574-PC UGGGGCCGUACUGACCGCCCUUCCGCAUAUGGCAC UUGGGUGAGAGUUCGCGUCUUUCGGCCCCCUUCUC11979815v1P-627574-PC CCUGGGGCCUCUCCACGGCUGUACUCAGUUGUUGG CCCGCUUGGACGACAGAGACUCAUCAUCGAAGAGC11979815v1P-627574-PC AGAAGUGAUGGUGAACGUGUCCGCCCCUCCUGGCG GCCAGCUGGUGUACGAUUCCGCCCCCAACAGAACC11979815v1P-627574-PC GCAGAUCAGAUGCAGAUUUCCAAAUUCCACCAGAA CAGAAUUCAGACUCCAGAUCUGGAGAUAUGCAACA11979815v1P-627574-PC CGGCCAAACCCGCCCCUCCACCCAAAACCGGACCUC CUAAGACCAGCUCUGAACCGGUGCGGUGUAAUAGG103 11979815v1P-627574-PC HSV-2 gC AGUCCAGGAAGGACGAUUACGGUGGGACCCAGAGG 130 [UL44] UAAUGCGUCCAAUGCUGCGCCAUCCGCUUCUCCAC104 11979815v1P-627574-PC GUUUCCUACGAACAGACCGAGUAUAUCUGCCGAUU GGCCGGUUACCCCGAUGGGAUACCAGUCCUGGAGC11979815v1P-627574-PC CGCCUGGUUUCUCGGUGAUGACUCCUCUCCUGCUG AAAAGGUGGCUGUAGCCUCCCAAACAAGCUGUGGU11979815v1P-627574-PC UGCGUCAGGGACCGCCUCCGUGCUUCCUCGGCCAA CCAUCACAAUGGAAUUCACGGGUGAUCACGCUGUC11979815v1P-627574-PC CGUGUCAACGGUCACAUCUGCCGCCGUCGGAGGAC AAGGGCCACCCAGAACCUUCACAUGCCAGCUGACC11979815v1P-627574-PC UGGACGUGGUGUGGCUGCGCUUCGACGUGCCCACC UCCUGCGCCGAGAUGCGCAUCUACGAGUCCUGCCU11979815v1P-627574-PC CGCCCACGACGACGGCCCCUACGCCAUGGACGUGG UGUGGAUGCGCUUCGACGUGCCCUCCUCCUGCGCC11979815v1P-627574-PC CUGGCGAGACAUUUGGCACCAACGUGUCCAUCCAC GCUAUCGCCCACGACGAUGGCCCUUACGCCAUGGA11979815v1P-627574-PC GCACAUGGAAACACCUGAGGCCAUCCUGUUCGCCC CUGGCGAGACAUUUGGCACCAACGUGUCCAUCCAC11979815v1P-627574-PC AUUCCCGAGGUCAGCCAUGUGCGCGGCGUAACUGU GCACAUGGAGACGCCCGAAGCGAUACUGUUUGCCC11979815v1P-627574-PC GACCCCCAGUAGCACCUCCAACCCAUCCGAGAGUG AUUCCCGAGGUCAGCCAUGUGCGCGGCGUAACUGU11979815v1P-627574-PC ACCGGUGAGUGUGCCACCUCCCACACCGCCAAGGA GACCCCCAGUAGCACCUCCAACCCAUCCGAGAGUG11979815v1P-627574-PC UGAAGAAGAUGAUGCCGGCGUGUCCGAAAGAACCC CCGUGUCCGUGCCCCCUCCCACCCCUCCCCGCAGAC11979815v1P-627574-PC CCAGCUCCAGUGCCAACCCCAACCCCAGAUGAUUA UGAUGAAGAAGAUGAUGCUGGAGUGUCUGAAAGA11979815v1P-627574-PC ACGGCAAGUGGCUUCCGUGGUACUGGUCGUAGAGC CCGCACCAGUUCCCACACCCACCCCGGAUGACUACG11979815v1P-627574-PC CCUCCCUGCCCAUCACCGUGUACUACGCCGUGCUG GAGCGCGCCUGCCGCUCCGUGCUGCUGAACGCCCCC11979815v1P-627574-PC AAUUUUCUGAAAAUUUUCACCAUUUACGAACGAUA GCAUGACCCGCCUGACCGUGCUGGCCCUGCUGGC0 11979815v1P-627574-PC UUCGUAUCUGCUCCUAAUAAAAAGAAAGUUUCUUCAC AUUCUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA11979815v1P-627574-PC ACCUGCACCGCCGCCGCCUACUACCCCCGCAACCCC GUGGAGUUCGACUGGUUCGAGGACGACCGCCAGGU11979815v1P-627574-PC GCCCGCCCCCCCCCCCAAGACCGGCCCCCCCAAGAC CUCCUCCGAGCCCGUGCGCUGCAACCGCCACGACCC3 11979815v1P-627574-PC CUUACAAAAUGUUGUCCCCCAAAAUGUAGCCAUUCGU AUCUGCUCCUAAUAAAAAGAAAGUUUCUUCACAUUCU11979815v1P-627574-PC CCGAGAUGCGCAUCUACGAGUCCUGCCUGUACCAC CCCCAGCUGCCCGAGUGCCUGUCCCCCGCCGACGCC11979815v1P-627574-PC GGCCUGUACUCCGAGCUGGCCUGGCGCGACCGCGU GGCCGUGGUGAACGAGUCCCUGGUGAUCUACGGCG126 11979815v1P-627574-PC AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAC [ odedof a sequence provided herein. In another embodiment, an HSV glycoprotein, or immunogenic fragment thereof, encoded by RNA utilized in the methods and compositions of the present disclosure is an isoform of the sequence provided herein. In another embodiment, an HSV glycoprotein, or immunogenic fragment thereof, encoded by RNA utilized in the methods and compositions of the present disclosure is a variant of the sequence provided herein. In another embodiment, an HSV glycoprotein, or immunogenic fragment thereof, encoded by RNA utilized in the methods and compositions of the present disclosure is a fragment of the sequence provided herein.

[0237] In another embodiment, a glycoprotein fragment encoded by RNA of the methods and compositions of the present disclosure comprises the ectodomain of the glycoprotein. In another embodiment, a glycoprotein fragment encoded by RNA of the methods and compositions of the present disclosure consists of the ectodomain of the glycoprotein. In another embodiment, a glycoprotein fragment encoded by RNA of the methods and compositions of the present disclosure comprises a fragment of the ectodomain of the glycoprotein. In another embodiment, the glycoprotein fragment may be any glycoprotein fragment known in the art.

[0238] In another embodiment, a glycoprotein or immunogenic fragment encoded by an RNA utilized in the methods and compositions of the present disclosure may be from any strain of HSV. In another embodiment, an immunogenic fragment encoded by RNA utilized in the methods and compositions of the present disclosure may comprise sequence variants of HSV, as found in infected individuals.

[0239] In some embodiments, “variant” refers to an amino acid or nucleic acid sequence (or in other embodiments, an organism or tissue) that is different from the majority of the population but is still sufficiently similar to the common mode to be considered to be one of them, for example splice variants. In some embodiments, the variant may a sequence conservative variant, while in another embodiment, the variant may be a functional conservative variant. In some embodiments, a variant may comprise an addition, deletion or substitution of one or more amino acids.

[0240] “Immune evasion domain” refers, in some embodiments, to a domain that interferes with or reduces in vivo anti-HSV efficacy of anti-HSV antibodies (e.g., anti-gD antibodies). In another 127 11979815v1P-627574-PC embodiment, the domain interferes or reduces in vivo anti-HSV efficacy of an anti-HSV immune response. In another embodiment, the domain reduces the immunogenicity of an HSV protein (e.g. gD) during subsequent infection. In another embodiment, the domain reduces the immunogenicity of an HSV protein during subsequent challenge. In another embodiment, the domain reduces the immunogenicity of HSV during subsequent challenge. In another embodiment, the domain reduces the immunogenicity of an HSV protein in the context of ongoing HSV infection. In another embodiment, the domain reduces the immunogenicity of HSV in the context of ongoing HSV infection. In another embodiment, the domain functions as an IgG Fc receptor. In another embodiment, the domain promotes antibody bipolar bridging, which in some embodiments, is a term that refers to an antibody molecule binding by its Fab domain to an HSV antigen and by its Fc domain to a separate HSV antigen, such as in some embodiments, gE, thereby blocking the ability of the Fc domain to activate complement.

[0241] The present disclosure also provides for modified RNA encoding analogs of HSV proteins or polypeptides, or fragments thereof. Analogs may differ from naturally occurring proteins or peptides by conservative amino acid sequence substitutions or by modifications which do not affect sequence, or by both.

[0242] In another embodiment, an HSV glycoprotein, or an immunogenic fragment thereof, encoded by modified RNA of the present disclosure is homologous to a sequence set forth hereinabove, either expressly or by reference to a GenBank entry. The terms “homology,” “homologous,” etc., when in reference to any protein or peptide, refer, in some embodiments, to a percentage of amino acid residues in the candidate sequence that are identical with the residues of a corresponding native polypeptide, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Methods and computer programs for the alignment are well known in the art.

[0243] In another embodiment, “homology” refers to identity of a protein sequence encoded by an RNA to a sequence disclosed herein of greater than 70%. In another embodiment, the identity is greater than 72%. In another embodiment, the identity is greater than 75%. In another embodiment, the identity is greater than 78%. In another embodiment, the identity is greater than 80%. In another embodiment, the identity is greater than 82%. In another embodiment, the identity is greater than 83%. In another embodiment, the identity is greater than 85%. In another embodiment, the identity is greater than 87%. In another embodiment, the identity is greater than 128 11979815v1P-627574-PC 88%. In another embodiment, the identity is greater than 90%. In another embodiment, the identity is greater than 92%. In another embodiment, the identity is greater than 93%. In another embodiment, the identity is greater than 95%. In another embodiment, the identity is greater than 96%. In another embodiment, the identity is greater than 97%. In another embodiment, the identity is greater than 98%. In another embodiment, the identity is greater than 99%. In another embodiment, the identity is 100%.

[0244] In some embodiments, “isoform” refers to a version of a molecule, for example, a protein, with only slight differences to another isoform of the same protein. In some embodiments, isoforms may be produced from different but related genes, or in another embodiment, may arise from the same gene by alternative splicing. In another embodiment, isoforms are caused by single nucleotide polymorphisms.

[0245] In another embodiment, the RNA encoding a glycoprotein or glycoprotein fragment as described herein further encodes an antigenic tag. In some embodiments, the tag is a histidine (“His”) tag. In some embodiments, the His tag comprises 5 histidine residues. In another embodiment, the His tag comprises 6 histidine residues.

[0246] In another embodiment, methods and compositions of the present disclosure utilize a chimeric molecule, comprising a fusion of an RNA encoding an HSV protein, or an immunogenic fragment thereof, with an RNA encoding a tag polypeptide that provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is placed, in other embodiments, at the amino- or carboxyl-terminus of the protein or in an internal location therein. The presence of such epitope-tagged forms of the recombinant HSV protein, or an immunogenic fragment thereof, is detected, in another embodiment, using an antibody against the tag polypeptide. In another embodiment, inclusion of the epitope tag enables the recombinant HSV protein, or an immunogenic fragment thereof, to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. Various tag polypeptides and their respective antibodies are known in the art.

[0247] In some embodiments, the compositions of the present disclosure comprise an adjuvant, while in another embodiment, the compositions do not comprise an adjuvant. “Adjuvant” refers, in another embodiment, to compounds that, when administered to an individual or tested in vitro, increase the immune response to an antigen in the individual or test system to which the antigen is administered. In another embodiment, an immune adjuvant enhances an immune response to an antigen that is weakly immunogenic when administered alone, i.e., inducing no or weak antibody 129 11979815v1P-627574-PC titers or cell-mediated immune response. In another embodiment, the adjuvant increases antibody titers to the antigen. In another embodiment, the adjuvant lowers the dose of the antigen effective to achieve an immune response in the individual. Multiple types of adjuvants are known in the art and described in detail in U. S. Patent Publication 2013 / 0028925 which is hereby incorporated by reference herein. Signal Sequence and Signal Peptides

[0248] In some embodiments, an RNA encoding a glycoprotein as described herein comprises a signal sequence encoding a signal peptide, e.g., that is functional in mammalian cells. In some embodiments, a signal sequence encodes a modified signal peptide (e.g., comprising amino acid substitutions or amino acid additions). In some embodiments, a signal sequence is a codon optimized signal sequence.

[0249] In some embodiments, a utilized signal sequence is a heterologous signal sequence. In some embodiments, a heterologous signal sequence comprises or consists of a non-human signal sequence. In some embodiments, a heterologous signal sequence comprises or consists of a viral signal sequence. In some embodiments, a viral signal sequence comprises or consists of an HSV signal sequence (e.g., an HSV-1 or HSV-2 signal sequence). In some embodiments, a signal sequence comprises or consists of an HSV-1 signal sequence. In some embodiments, a signal sequence comprises or consists of an HSV-2 signal sequence. In some embodiments, a signal sequence is characterized by a length of about 15 to 30 amino acids. In some embodiments, a signal sequence encodes a signal peptide that preferably allows transport of an HSV-1 glycoprotein, an HSV-2 glycoprotein, an HSV-1 and HSV-2 glycoprotein, or an immunogenic fragment of an HSV-1 and / or HSV-2 glycoprotein, with which it is associated into a defined cellular compartment, preferably a cell surface, endoplasmic reticulum (ER) or endosomal- lysosomal compartment.

[0250] In some embodiments, a signal sequence is the native signal sequence of the encoded glycoprotein. In some embodiments, a signal sequence is or comprises an HSV glycoprotein D (gD) signal sequence (e.g., an HSV-1 or HSV-2 gD signal sequence). In some embodiments, a signal peptide encoded by a signal sequence is or comprises an HSV-2 gD signal peptide (SEQ ID NO: 29). In another embodiment, an HSV-2 gD signal peptide comprises KY (SEQ ID NO: 30), KYA (SEQ ID NO: 31, KYAL (SEQ ID NO: 32), or KYALA (SEQ ID NO: 33) at the C terminus of the signal peptide. In some embodiments, a signal peptide is or comprises an HSV-1 gD signal 130 11979815v1P-627574-PC peptide (SEQ ID NO: 34). In some embodiments, an HSV-1 gD signal peptide comprises KY at the C terminus of the signal sequence (SEQ ID NO: 35).

[0251] In some embodiments, a signal sequence is or comprises an HSV glycoprotein C (gC) signal sequence (e.g., an HSV-1 or HSV-2 gC signal sequence). In another embodiment, a signal peptide encoded by a signal sequence is or comprises an HSV-2 gC signal peptide (SEQ ID NO: 36). In another embodiment, a signal peptide is or comprises an HSV-1 gC signal peptide (SEQ ID NO: 37).

[0252] In some embodiments, a signal sequence is or comprises an HSV glycoprotein E (gE) signal sequence (e.g., an HSV-1 or HSV-2 gE signal sequence). In some embodiments, a signal peptide encoded by a signal sequence is or comprises an HSV-2 gE signal sequence (SEQ ID NO: 38). In some embodiments, a signal peptide is or comprises an HSV-1 gE signal peptide (SEQ ID NO: 39). In some embodiments, an HSV-2 gE signal peptide comprises RTS at the C terminus of the signal peptide (SEQ ID NO: 40). In some embodiments, an HSV-2 gE signal peptide comprises A20V, A21V, and A22V substitutions (SEQ ID NO: 41).

[0253] In some embodiments, a signal sequence is or comprises an HSV gB signal sequence (e.g., an HSV-1 or HSV-2 gB signal sequence). In some embodiments, a signal peptide encoded by a signal sequence is or comprises an HSV-1 gB signal peptide (SEQ ID NO: 42). In some embodiments, a signal peptide encoded by a signal sequence is or comprises an HSV-2 gB signal peptide (SEQ ID NO: 43). In some embodiments, an HSV-1 gB signal peptide comprises AP at the C terminus of the signal peptide (SEQ ID NO: 44).

[0254] In some embodiments, a signal sequence is or comprises an HSV gI signal sequence (e.g., an HSV-1 or HSV-2 gI signal sequence). In some embodiments, a signal peptide encoded by a signal sequence is or comprises an HSV-1 gI signal peptide (SEQ ID NO: 45). In some embodiments, an HSV-2 gI signal sequence is or comprises an HSV-2 gI signal peptide (SEQ ID NO: 249).In some embodiments, a signal peptide encoded by a signal sequence is or comprises amino acid residues 1-18 of the wild-type sequence (SEQ ID NO: 46). In some embodiments, an HSV-2 gI signal peptide comprises an additional leucine residue at the C terminus of the signal peptide (SEQ ID NO: 47).

[0255] In other embodiments, a signal sequence is a heterologous signal sequence. In some embodiments, a heterologous signal peptide encoded by a heterologous signal sequence comprises an IL-2 signal peptide (SEQ ID NO: 220). In some embodiments, a heterologous signal peptide encoded by a heterologous signal sequence comprises or consists of an azurocidin signal peptide 131 11979815v1P-627574-PC (SEQ ID NO: 221). In some embodiments, a heterologous signal peptide encoded by a heterologous signal sequence comprises or consists of an MHC Class II signal peptide (SEQ ID NO: 222). In some embodiments, a signal sequence comprises or consists of an Ebola virus signal sequence. In some embodiments, an Ebola virus signal peptide comprises or consists of an Ebola virus spike glycoprotein (SGP) signal peptide (SEQ ID NO: 48). In other embodiments, an RNA encoding a glycoprotein as described herein does not comprise a signal sequence. In some embodiments, an RNA as described herein comprises only an ectodomain.

[0256] In some embodiments, a signal sequence encodes an exemplary signal peptide listed in Table 3, or a signal peptide having 1, 2, 3, 4, or 5 amino acid differences relative thereto. In some embodiments, a signal peptide is an exemplary signal peptide selected from those listed in Table 3 and functionally connected to the N-terminus of an exemplary HSV immunogen selected from those listed in Table 1. Table 3: Exemplary signal peptides Sequence Name Amino Acid Sequence SEQ ID NO:11979815v1P-627574-PC Sequence Name Amino Acid Sequence SEQ ID NO: HSV-2 gE Signal Sequence MARGAGLVFFVGVWVVSCLVVVP 41 [ ed in Table 4, or a signal sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to a sequence listed in Table 4. In some embodiments, an exemplary signal sequence is selected from those listed in Table 4 and functionally connected (i.e., in frame) to the 5' end of an exemplary HSV immunogen nucleic acid sequence selected from those listed in Table 2. 133 11979815v1P-627574-PC Table 4: Exemplary signal sequences Sequence Name Version Amino Acid Sequence SEQ ID NO: HSV-2 gD WT AUGGGCCGCCUGACCUCCGGCGUGGGC 5311979815v1P-627574-PC Sequence Name Version Amino Acid Sequence SEQ ID NO: UUGGUCUGAGAGUUGUGUGUGCCAAA11979815v1P-627574-PC Sequence Name Version Amino Acid Sequence SEQ ID NO: HSV-1 gD Version 4 AUGGGCGGCGCAGCCGCUAGACUGGG 255136 11979815v1P-627574-PC Sequence Name Version Amino Acid Sequence SEQ ID NO: HSV-2 gC Version 2 AUGGCCUUGGGGAGAGUGGGCCUUGC 7111979815v1P-627574-PC Sequence Name Version Amino Acid Sequence SEQ ID NO: HSV-2 gE RTS Version 2 AUGGCGAGAGGAGCCGGGCUCGUGUU 80138 11979815v1P-627574-PC Sequence Name Version Amino Acid Sequence SEQ ID NO: UGCUGGGACUGACACUGGGAGUUCUG139 11979815v1P-627574-PC Sequence Name Version Amino Acid Sequence SEQ ID NO: HSV-2 gI L Version 2 AUGCCCGGCAGAAGCCUCCAGGGACU 89140 11979815v1P-627574-PC Sequence Name Version Amino Acid Sequence SEQ ID NO: IL2 Version 3 AUGAGAAUGCAGCUGCUGCUGCUGAU 52

[0258] The present invention also provides RNA comprising a nucleotide sequence encoding a protein, wherein the protein comprises an HSV (e.g., HSV-1, HSV-2, or both) glycoprotein antigen or immunogenic fragment thereof and a signal peptide. In some embodiments, a nucleotide sequence encodes a protein, wherein the protein comprises an HSV-2 glycoprotein antigen, or immunogenic fragment thereof, and a signal peptide. 141 11979815v1P-627574-PC

[0259] Exemplary proteins comprising signal peptides and HSV-2 immunogens are shown in Table 5. In some embodiments, a protein of the present disclosure comprises an amino acid sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 5. Table 5. Exemplary signal peptide / HSV-2 immunogen combinations HSV SEQ Signal Glycoprotei Amino Acid Sequence S P R N R R T P S E N A P S Y S D S142 11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence T K G S E Q A C H S S L G I T G H143 11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence R A W M F G P T R A Y P C H S E G L11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence I I G H T T A I P P E I G H T T A I T R A Y11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence P C H S E R A W M F G P T K G S E Q11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence A C H TI T Y E Y E Q A C H P H D I147 11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence P R T D T G N A S T T E S V TI G T11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence I G K T R G T V S S L G I T G H T K G S E11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence Q A C H S P P E I G H T T A I A Q D A H P E11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence G H V P Y E N P A S P P A P A P H K N11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence A S S I Y F A F T IP K E E S I T IP L A L E S11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence D P L G Y V A C N D P M L153 11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence S E I A V M L G R P S L R V G R P11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence S L R V M P A S R S T R C A L T V A C11979815v1P-627574-PC HSV SEQ Signal Glycoprotei Amino Acid Sequence N

[0260] The present disclosure also provides RNAs comprising nucleotide sequences as provided herein. In some embodiments, an RNA provided herein comprises a nucleotide sequence that encodes an HSV-2 gC protein or immunogenic fragment thereof. In some embodiments, an RNA provided herein comprises a nucleotide sequence that encodes an HSV-2 gD protein or immunogenic fragment thereof. In some embodiments, an RNA provided herein comprises a nucleotide sequence that encodes an HSV-2 gE protein or immunogenic fragment thereof.

[0261] Exemplary RNA comprising a signal sequence (i.e., encoding a signal peptide) and a sequence encoding an HSV-2 glycoprotein are shown in Table 6 below. In some embodiments, an RNA of the present disclosure comprises a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 6. Table 6: Exemplary signal sequence / HSV-2 immunogen nucleotide sequence combinations SEQ Signal Immunoge Versio Nucleotide Sequence C C G A156 11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C U U A A C A G C C G C G C G G C G C C G C C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C C A C U U C A G A A C C C U G G G U C C C U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C C A G U U G A A A C A G A G A A C A A A A C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G A U A G G A C C A G A C U C A C G C C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G G C C C C C A C C C C A G C A C C A C G G G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G G G C C C C C G C C C C C G C C C G C C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C G C G G C C G G C G G C C C C G C G C G C C G G C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C U C G A G C A A C A G A G U A C C U C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C A G U A G A C A C A G A U C G A G C A A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C A G A G U A C C U C C C A G U A G A C A C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G A U C G A G C A A C A G A G U A C C U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C C A G U A G A C A C A G A C U C A C U C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C G C G A A U G C U G G A A G A G A A U C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C C A U C U A A A C G U C G A G C C G C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U G G A A G A G A A U A C A C A U C U A A A C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U C G A G A G G C U G G A A G A G A A U A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C A C A C G C C C A C C C C A G C A C C A C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G G G G G C C C C C G C C C C C G C C G A C A U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A U C A C C C C G U A U G U C U G A U G G G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U A A A U G A C A U A U C A C C C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U A U G U C U G A U G G G U A A A G A C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U A U C A C C C C G U A U G U C U G A U G G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U A A A G C C C C C G A U A C C C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U A U G U C U G A U G G G U A A A C U A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C U A C G C A A C G U U U G C A C A G A C G G C U C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A A A G G U C G C C A C A C A G C C A C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C G G U A G G A G C U C C U G U C C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C C C A G U U G G A U U C U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U A U G A A U G C C A C G A A U C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G C G G U A G A U G A C G U C A C U A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C U G C A G A G C U G U C G C C G G G C U A A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C U C G G G C G A C U C C C G G A C G G C C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C C U C C A C U G U U G A G G C C U U G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A C A C C U C U U C C C U U C A U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U C G C A U A C U G C C C A C G U G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C G C G G A G G C A A G C A C G U G U G U192 11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C G C C G C C G G C A C A G A A U G C U G G A A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G A G A A U C C C C C A U U G U A G A C C G U C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G C C G C U G G A A G A G A A U A C A C A195 11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G C C G C C G C G C G U C U A G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A C A G A G U A G C C G C C G G C G G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A U C U G C U U A U C U C A G C C C U U198 11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G A A A C U C A A G G G U C G U G U U C A G A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C U A C G G C G A C A A A G C G U U C G G C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C C G A G C A C U G A G C G C C C G C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U A A A A U C A C C C A G A C A G A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C U U A C A C A U A G A C C G G C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C C G A G C A C U G U A G C G C C A U G204 11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U C C C U C A C G C C U C G U A U A G C A C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U C A U C G A C G C C U C U C U G C G A C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G A C C A U C G U A U A U C A C C A A G C G A G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C U A A U U A A A G A A A C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C U G C A A C C U C U A C C C A C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C G U A C C C C U A C U U C A C C U C U U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U A C G C C G G G C C C G C C C G C C G G C G C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C G G C C C C C U G G C G A U C C G G A G U U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C A C A G C C C U A G C G U U A C U C C A U C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U G C A U U C C G U U C U U A C U C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A U C A U G C A U U C C G U U C U C G C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G A A U C C G C C C G C C G C U C A C C A A A C A216 11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A C C G C G C G G G G G G C G C C C C C C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A C G C C G G U U C U C A G U G U G U G C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U U U U U G A C G U U U G C G G C A U C C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G U U C A U A U G A C A C C G A C A U A C U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U G A C C A A C A A C G C G G A A U C A U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A C C C C U G A C G C C U A G A G C G C G C C C G C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C G C G G G C G A C A G G A C C C C C G G C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C G C G U G U G U G C G G U U U U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U G A C G U U U G C G G C A U U G C C G U G C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C G C G A C C U U C U A C U U G A C C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A U G C C G U G C C C G C G A C C U U C U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A C U U G A C C A A C G C C U G G U C U G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C C U U C U A A C C C A G G U C G C G229 11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G G C A C A G C G U G C U C A A A G G G C G U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C G U U G C C G G C A C A G C G U G C U C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A A A G G G C G U G C G U U G C C G G C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C A G C G U G C U C A A A G G G C G U G C G U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n U G C C G G C A C A G C G U G C U C A A A G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G G C G U G C G U U G C C G G C A C A G C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U G C U C A A A G G G C G U G C G U U G C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G C C C U C G A C C G C A U U C U A A U A G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G G C U C C C C C G A U A C U C A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C C A A C C C A C G A U G C G G C C G U C U11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G G U C C G C G A A A C C G A C U C C11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A G A C C U A U C C G U G C C G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n A C U G U U C A G A C C U A G11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n G U C C G C G A A A C C G A C U C C A G A11979815v1P-627574-PC SEQ Signal Immunoge Versio Nucleotide Sequence ID Sequenc n n C C U A U

[0262] In some embodiments, an RNA provided herein comprises a nucleotide sequence that encodes an HSV-2 gC protein or immunogenic fragment thereof and a signal sequence. In some embodiments, an RNA provided herein comprises a nucleotide sequence that encodes an HSV-2 gD protein or immunogenic fragment thereof and a signal sequence. In some embodiments, an RNA provided herein comprises a nucleotide sequence that encodes an HSV-2 gE protein or immunogenic fragment thereof and a signal sequence.

[0263] In some embodiments, nucleotide sequences described herein can comprise a nucleotide sequence that encodes a 5’UTR and / or a 3’ UTR. In some embodiments, polynucleotides described herein can comprise a nucleotide sequence that encodes a polyA tail. In some embodiments, nucleotide sequences described herein may comprise a 5’ cap, which may be incorporated during transcription, or joined to a nucleotide sequence post-transcription.

[0264] In some embodiments, a nucleotide sequence provided herein encodes one or more glycoproteins (e.g., glycoprotein C (gC), glycoprotein D (gD), glycoprotein E (gE), or a combination thereof), or an immunogenic fragment thereof. In some embodiments, an RNA comprises a 5’ cap, a 5’UTR, a nucleotide sequence that encodes one or more glycoproteins (e.g., glycoprotein C (gC), glycoprotein D (gD), glycoprotein E (gE), or a combination thereof), or an immunogenic fragment thereof, a 3’ UTR, and a polyA tail. 1. 5' Cap

[0265] A structural feature of messenger RNA (mRNA) is a cap structure at the five-prime end (5'). Natural eukaryotic mRNA comprise a 7-methylguanosine cap linked to the mRNA via a 5´ to 5´-triphosphate bridge resulting in a cap0 structure (m7GpppN). In most eukaryotic mRNA and 244 11979815v1P-627574-PC some viral mRNA, further modifications can occur at the 2'-hydroxyl-group (2’-OH) (e.g., the 2'- hydroxyl group may be methylated to form 2'-O-Me) of the first and subsequent nucleotides producing “cap1” and “cap2” five-prime ends, respectively). Diamond, et al., (2014) Cytokine & growth Factor Reviews, 25:543–550, which is incorporated herein by reference in its entirety, reported that cap0-mRNA cannot be translated as efficiently as cap1-mRNA in which the role of 2'-O-Me in the penultimate position at the mRNA 5’ end is determinant. Lack of the 2'-O-met has been shown to trigger innate immunity and activate an interferon (IFN) response. Daffis, et al. (2010) Nature, 468:452-456; and Züst et al. (2011) Nature Immunology, 12:137-143, each of which is incorporated herein by reference in its entirety.

[0266] RNA capping is well researched and is described, e.g., in Decroly E et al. (2012) Nature Reviews 10: 51-65; and in Ramanathan A. et al., (2016) Nucleic Acids Res; 44(16): 7511–7526, the entire contents of each of which are hereby incorporated by reference. For example, in some embodiments, a 5’-cap structure which may be suitable in the context of the present invention is a cap0 (methylation of the first nucleobase, e.g., m7GpppN), cap1 (additional methylation of the ribose of the adjacent nucleotide of m7GpppN), cap2 (additional methylation of the ribose of the 2nd nucleotide downstream of the m7GpppN), cap3 (additional methylation of the ribose of the 3rd nucleotide downstream of the m7GpppN), cap4 (additional methylation of the ribose of the 4th nucleotide downstream of the m7GpppN), ARCA (“anti-reverse cap analogue”), modified ARCA (e.g. phosphothioate modified ARCA), inosine, N1 -methyl-guanosine, 2’-fluoro- guanosine, 7-deaza-guanosine, 8-oxo-guanosine, 2-amino-guanosine, LNA-guanosine, and 2- azido-guanosine.

[0267] The term “5'-cap” as used herein refers to a structure found on the 5'-end of an RNA, e.g., mRNA, and generally includes a guanosine nucleotide connected to an RNA, e.g., mRNA, via a 5'- to 5'-triphosphate linkage (also referred to as Gppp or G(5')ppp(5')). In some embodiments, a guanosine nucleoside included in a 5’ cap may be modified, for example, by methylation at one or more positions (e.g., at the 7-position) on a base (guanine), and / or by methylation at one or more positions of a ribose. In some embodiments, a guanosine nucleoside included in a 5’ cap comprises a 3’O methylation at a ribose (3’OMeG). In some embodiments, a guanosine nucleoside included in a 5' cap comprises methylation at the 7-position of guanine (m7G). In some embodiments, a guanosine nucleoside included in a 5' cap comprises methylation at the 7'-position of guanine and a 3' O methylation at a ribose (m7(3'OMeG)). It will be understood that the notation used in the 245 11979815v1P-627574-PC above paragraph, e.g., “(m27,3'-O)G” or “m7(3'OMeG)”, applies to other structures described herein.

[0268] In some embodiments, providing an RNA with a 5'-cap disclosed herein may be achieved by in vitro transcription, in which a 5'-cap is co-transcriptionally incorporated into an RNA strand, or may be attached to an RNA post-transcriptionally using capping enzymes. In some embodiments, co-transcriptional capping with a cap disclosed herein improves the capping efficiency of an RNA compared to co-transcriptional capping with an appropriate reference comparator. In some embodiments, improving capping efficiency can increase a translation efficiency and / or translation rate of an RNA, and / or increase expression of an encoded protein. In some embodiments, alterations to polynucleotides generate a non-hydrolyzable cap structure which can, for example, prevent decapping and increase RNA half-life.

[0269] In some embodiments, a utilized 5' cap is a cap0, a cap1, or cap2 structure. See, e.g., Fig. 1 of Ramanathan A et al., and Fig. 1 of Decroly E et al., each of which is incorporated herein by reference in its entirety. In some embodiments, an RNA described herein comprises a cap1 structure. In some embodiments, an RNA described herein comprises a cap2 structure.

[0270] In some embodiments, an RNA described herein comprises a cap0 structure. In some embodiments, a cap0 structure comprises a guanosine nucleoside methylated at the 7-position of guanine ((m7)G). In some embodiments, such a cap0 structure is connected to an RNA via a 5'- to 5'-triphosphate linkage and is also referred to herein as (m7)Gppp. In some embodiments, a cap0 structure comprises a guanosine nucleoside methylated at the 2'-position of the ribose of guanosine. In some embodiments, a cap0 structure comprises a guanosine nucleoside methylated at the 3'-position of the ribose of guanosine. In some embodiments, a guanosine nucleoside included in a 5' cap comprises methylation at the 7-position of guanine and at the 2'-position of the ribose ((m27,2'-O)G). In some embodiments, a guanosine nucleoside included in a 5' cap comprises methylation at the 7-position of guanine and at the 2'-position of the ribose ((m27,3'-O)G).

[0271] In some embodiments, a cap1 structure comprises a guanosine nucleoside methylated at the 7-position of guanine ((m7)G) and optionally methylated at the 2' or 3' position of the ribose, and a 2'O methylated first nucleotide in an RNA ((m2'-O)N1). In some embodiments, a cap1 structure comprises a guanosine nucleoside methylated at the 7-position of guanine ((m7)G) and the 3' position of the ribose, and a 2'O methylated first nucleotide in an RNA ((m2'-O)N1). In some embodiments, a cap1 structure is connected to an RNA via a 5'- to 5'-triphosphate linkage and is 246 11979815v1P-627574-PC also referred to herein as, e.g., ((m7)Gppp(2'-O)N1) or (m27,3’-O)Gppp(2'-O)N1), wherein N1 is as defined and described herein. In some embodiments, a cap1 structure comprises a second nucleotide, N2, which is at position 2 and is chosen from A, G, C, or U, e.g., (m7)Gppp(2'- O)N1pN2 or (m27,3’-O)Gppp(2'-O)N1pN2 , wherein each of N1 and N2 is as defined and described herein.

[0272] In some embodiments, a cap2 structure comprises a guanosine nucleoside methylated at the 7-position of guanine ((m7)G) and optionally methylated at the 2' or 3' position of the ribose, and 2'O methylated first and second nucleotides in an RNA ((m2’-O)N1p(m2’-O)N2). In some embodiments, a cap2 structure comprises a guanosine nucleoside methylated at the 7-position of guanine ((m7)G) and the 3' position of the ribose, and 2'O methylated first and second nucleotides in an RNA. In some embodiments, a cap2 structure is connected to an RNA via a 5'- to 5'- triphosphate linkage and is also referred to herein as, e.g., ((m7)Gppp(2'-O)N1p(2'-O)N2) or (m27,3’-O)Gppp(2'-O)N1p(2'-O)N2), wherein each of N1 and N2 is as defined and described herein.

[0273] In some embodiments, the 5' cap is a dinucleotide cap structure. In some embodiments, the 5' cap is a dinucleotide cap structure comprising N1, wherein N1 is as defined and described herein. In some embodiments, the 5' cap is a dinucleotide cap G*N1, wherein N1 is as defined above and herein, and G* comprises a structure of formula (I):wherein each R2and R3is -OH or -OCH3; and X is O or S.

[0274] In some embodiments, R2is -OH. In some embodiments, R2is -OCH3. In some embodiments, R3 is -OH. In some embodiments, R3 is -OCH3. In some embodiments, R2 is -OH and R3 is -OH. In some embodiments, R2 is -OH and R3 is -CH3. In some embodiments, R2 is - CH3 and R3 is -OH. In some embodiments, R2 is -CH3 and R3 is -CH3.

[0275] In some embodiments, X is O. In some embodiments, X is S. 247 11979815v1P-627574-PC

[0276] In some embodiments, the 5' cap is a dinucleotide cap0 structure (e.g., (m7)GpppN1, (m27,2’-O)GpppN1, (m27,3’-O)GpppN1, (m7)GppSpN1, (m27,2’-O)GppSpN1, or (m27,3’- O)GppSpN1), wherein N1 is as defined and described herein. In some embodiments, the 5' cap is a dinucleotide cap0 structure (e.g., (m7)GpppN1, (m27,2’-O)GpppN1, (m27,3’-O)GpppN1, (m7)GppSpN1, (m27,2’-O)GppSpN1, or (m27,3’-O)GppSpN1), wherein N1 is G. In some embodiments, the 5' cap is a dinucleotide cap0 structure (e.g., (m7)GpppN1, (m27,2’-O)GpppN1, (m27,3’-O)GpppN1, (m7)GppSpN1, (m27,2’-O)GppSpN1, or (m27,3’-O)GppSpN1), wherein N1 is A, U, or C. In some embodiments, the 5' cap is a dinucleotide cap1 structure (e.g., (m7)Gppp(m2’-O)N1, (m27,2’-O)Gppp(m2’-O)N1, (m27,3’-O)Gppp(m2’-O)N1, (m7)GppSp(m2’-O)N1, (m27,2’-O)GppSp(m2’-O)N1, or (m27,3’-O)GppSp(m2’-O)N1), wherein N1is as defined and described herein. In some embodiments, the 5' cap is selected from the group consisting of (m7)GpppG (“Ecap0”), (m7)Gppp(m2’-O)G (“Ecap1”), (m27,3’-O)GpppG (“ARCA” or “D1”), and (m27,2’-O)GppSpG (“beta-S-ARCA”). In some embodiments, the 5' cap is (m7)GpppG (“Ecap0”), having a structure of formula (II):

[0277] In some embodiments, the 5' cap is (m7)Gppp(m2’-O)G (“Ecap1”), having a structure of formula (III):P-627574-PC

[0278] In some embodiments, the 5' cap is (m27,3’-O)GpppG (“ARCA” or “D1”), having a structure of formula (IV): OH O Osome cap ARCA”), having a structure of formula (V): O OH O

[0280] In some embodiments, the 5' cap is a trinucleotide cap structure. In some embodiments, the 5' cap is a trinucleotide cap structure comprising N1pN2, wherein N1and N2are as defined and described herein. In some embodiments, the 5' cap is a dinucleotide cap G*N1pN2, wherein N1 and N2are as defined above and herein, and G* comprises a structure of formula (VI):defined and described herein. 249 11979815v1P-627574-PC

[0281] In some embodiments, the 5' cap is a trinucleotide cap0 structure (e.g., (m7)GpppN1pN2, (m27,2’-O)GpppN1pN2, or (m27,3’-O)GpppN1pN2), wherein N1and N2are as defined and described herein). In some embodiments, the 5' cap is a trinucleotide cap1 structure (e.g., (m7)Gppp(m2’-O)N1pN2, (m27,2’-O)Gppp(m2’-O)N1pN2, (m27,3’-O)Gppp(m2’-O)N1pN2), wherein N1and N2are as defined and described herein. In some embodiments, the 5' cap is a trinucleotide cap2 structure (e.g., (m7)Gppp(m2’-O)N1p(m2’-O)N2, (m27,2’-O)Gppp(m2’-O)N1p(m2’-O)N2, (m27,3’-O)Gppp(m2’-O)N1p(m2’-O)N2), wherein N1and N2are as defined and described herein. In some embodiments, the 5' cap is selected from the group consisting of (m27,3’-O)Gppp(m2’-O)ApG (“CleanCap AG”, “CC413”), (m27,3’-O)Gppp(m2’-O)GpG (“CleanCap GG”), (m7)Gppp(m2’-O)ApG, (m7)Gppp(m2’-O)GpG, (m27,3’-O)Gppp(m26,2’-O)ApG, and (m7)Gppp(m2’-O)ApU.

[0282] In some embodiments, the 5' cap is (m27,3’-O)Gppp(m2’-O)ApG (“CleanCap AG”, “CC413”), having a structure of formula (VII):

[0283] In some embodiments, the 5' cap is (m27,3’-O)Gppp(m2’-O)GpG (“CleanCap GG”), having a structure of formula (VIII): 250 11979815v1P-627574-PCsome cap a structure of formula (IX): OH OH NH2

[0285] In some embodiments, the 5' cap is (m7)Gppp(m2’-O)GpG, having a structure of formula (X): 251 11979815v1P-627574-PCor a

[0286] In some embodiments, the 5' cap is (m27,3’-O)Gppp(m26,2’-O)ApG, having a structure of formula (XI):

[0287] In some embodiments, the 5' cap is (m7)Gppp(m2’-O)ApU, having a structure of formula (XII): 252 11979815v1P-627574-PCor a

[0288] In some embodiments, the 5' cap is a tetranucleotide cap structure. In some embodiments, the 5' cap is a tetranucleotide cap structure comprising N1pN2pN3, wherein N1, N2, and N3are as defined and described herein. In some embodiments, the 5' cap is a tetranucleotide cap G*N1pN2pN3, wherein N1, N2, and N3are as defined above and herein, and G* comprises a structure of formula (XIII):or a salt thereof, wherein R2, R3, and X are as defined and described herein.

[0289] In some embodiments, the 5' cap is a tetranucleotide cap0 structure (e.g. (m7)GpppN1pN2pN3, (m27,2’-O)GpppN1pN2pN3, or (m27,3’-O)GpppN1N2pN3), wherein N1, N2, and N3are as defined and described herein). In some embodiments, the 5’ cap is a tetranucleotide Cap1 structure (e.g., (m7)Gppp(m2’-O)N1pN2pN3, (m27,2’-O)Gppp(m2’-O)N1pN2pN3, (m27,3’-O)Gppp(m2’-O)N1pN2N3), wherein N1, N2, and N3are as defined and described herein. In some embodiments, the 5' cap is a tetranucleotide Cap2 structure (e.g., (m7)Gppp(m2’-O)N1p(m2’-O)N2pN3, (m27,2’-O)Gppp(m2’-O)N1p(m2’-O)N2pN3, (m27,3’-O)Gppp(m2’-O)N1p(m2’-O)N2pN3), wherein N1, N2, and N3are as defined and described herein. In some embodiments, the 5' cap is selected from the group 253 11979815v1P-627574-PC consisting of (m27,3’-O)Gppp(m2’-O)Ap(m2’-O)GpG, (m27,3’-O)Gppp(m2’-O)Gp(m2’-O)GpC, (m7)Gppp(m2’-O)Ap(m2’-O)UpA, and (m7)Gppp(m2’-O)Ap(m2’-O)GpG.

[0290] In some embodiments, the 5' cap is (m27,3’-O)Gppp(m2’-O)Ap(m2’-O)GpG, having a structure of formula (XIV):

[0291] In some embodiments, the 5' cap is (m27,3’-O)Gppp(m2’-O)Gp(m2’-O)GpC, having a structure of formula (XV): 254 11979815v1P-627574-PCsome cap having a structure of formula (XVI):P-627574-PC

[0293] In some embodiments, the 5' cap is (m7)Gppp(m2’-O)Ap(m2’-O)GpG, having a structure of formula (XVII):or a salt thereof. 2. Cap Proximal Sequences

[0294] In some embodiments, a 5' UTR utilized in accordance with the present disclosure comprises a cap proximal sequence, e.g., as disclosed herein. In some embodiments, a cap proximal sequence comprises a sequence adjacent to a 5' cap. In some embodiments, a cap proximal sequence comprises nucleotides in positions +1, +2, +3, +4, and / or +5 of an RNA polynucleotide.

[0295] In some embodiments, a cap structure comprises one or more polynucleotides of a cap proximal sequence. In some embodiments, a cap structure comprises an m7 guanosine cap and nucleotide +1 (N1) of an RNA polynucleotide. In some embodiments, a cap structure comprises an m7 guanosine cap and nucleotide +2 (N2) of an RNA polynucleotide. In some embodiments, a cap structure comprises an m7 guanosine cap and nucleotides +1 and +2 (N1 and N2) of an RNA polynucleotide. In some embodiments, a cap structure comprises an m7 guanosine cap and nucleotides +1, +2, and +3 (N1, N2, and N3) of an RNA polynucleotide.

[0296] Those skilled in the art, reading the present disclosure, will appreciate that, in some embodiments, one or more residues of a cap proximal sequence (e.g., one or more of residues +1, 256 11979815v1P-627574-PC +2, +3, +4, and / or +5) may be included in an RNA by virtue of having been included in a cap entity (e.g., a cap1 or cap2 structure, etc.); alternatively, in some embodiments, at least some of the residues in a cap proximal sequence may be enzymatically added (e.g., by a polymerase such as a T7 polymerase). For example, in certain exemplified embodiments where a m27,3’- OGppp(m12’-O)ApG cap is utilized, +1 (i.e., N1) and +2 (i.e. N2) are the (m12’-O)A and G residues of the cap, and +3, +4, and +5 are added by a polymerase (e.g., T7 polymerase).

[0297] In some embodiments, the 5'’ cap is a dinucleotide cap structure, wherein the cap proximal sequence comprises N1 of the 5’ cap, where N1 is any nucleotide, e.g., A, C, G or U. In some embodiments, the 5' cap is a trinucleotide cap structure (e.g., the trinucleotide cap structures described above and herein), wherein the cap proximal sequence comprises N1 and N2 of the 5' cap, wherein N1 and N2 are independently any nucleotide, e.g., A, C, G or U. In some embodiments, the 5' cap is a tetranucleotide cap structure (e.g., the trinucleotide cap structures described above and herein), wherein the cap proximal sequence comprises N1, N2, and N3 of the 5' cap, wherein N1, N2, and N3 are any nucleotide, e.g., A, C, G or U.

[0298] In some embodiments, e.g., where the 5' cap is a dinucleotide cap structure, a cap proximal sequence comprises N1 of a the 5' cap, and N2, N3, N4 and N5, wherein N1 to N5 correspond to positions +1, +2, +3, +4, and / or +5 of an RNA polynucleotide. In some embodiments, e.g., where the 5' cap is a trinucleotide cap structure, a cap proximal sequence comprises N1 and N2 of a the 5' cap, and N3, N4 and N5, wherein N1 to N5 correspond to positions +1, +2, +3, +4, and / or +5 of an RNA polynucleotide. In some embodiments, e.g., where the 5' cap is a tetranucleotide cap structure, a cap proximal sequence comprises N1, N2, and N3 of a the 5’ cap, and N4 and N5, wherein N1 to N5 correspond to positions +1, +2, +3, +4, and / or +5 of an RNA polynucleotide.

[0299] In some embodiments, N1 is A. In some embodiments, N1 is C. In some embodiments, N1 is G. In some embodiments, N1 is U. In some embodiments, N2 is A. In some embodiments, N2 is C. In some embodiments, N2 is G. In some embodiments, N2 is U. In some embodiments, N3 is A. In some embodiments, N3 is C. In some embodiments, N3 is G. In some embodiments, N3 is U. In some embodiments, N4 is A. In some embodiments, N4 is C. In some embodiments, N4 is G. In some embodiments, N4 is U. In some embodiments, N5 is A. In some embodiments, N5 is C. In some embodiments, N5 is G. In some embodiments, N5 is U. It will be understood that, each of the embodiments described above and herein (e.g., for N1 through N5) may be taken singly or in combination and / or may be combined with other embodiments of variables described above and herein (e.g., 5' caps). 257 11979815v1P-627574-PC

[0300] In some embodiments, a cap proximal sequence comprises A1 and G2 of the Cap1 structure, and a sequence comprising: A3A4U5at positions +3, +4 and +5 respectively of the nucleotide sequence. 3. 5’ UTR

[0301] In some embodiments, an RNA utilized in accordance with the present disclosure comprises a 5'-UTR. In some embodiments, a 5’-UTR may comprise a plurality of distinct sequence elements; in some embodiments, such plurality may be or comprise multiple copies of one or more particular sequence elements (e.g., as may be from a particular source or otherwise known as a functional or characteristic sequence element). In some embodiments, a 5’ UTR comprises multiple different sequence elements.

[0302] The term “untranslated region” or “UTR” is commonly used in the art to refer to a region in a DNA molecule which is transcribed but is not translated into an amino acid sequence, or to the corresponding region in an RNA polynucleotide, such as an mRNA molecule. An untranslated region (UTR) can be present 5' (upstream) of an open reading frame (5'-UTR) and / or 3' (downstream) of an open reading frame (3'-UTR). As used herein, the terms “five prime untranslated region” or “5' UTR” refer to a sequence of a nucleotide sequence between the 5' end of the nucleotide sequence (e.g., a transcription start site) and a start codon of a coding region of the nucleotide sequence. In some embodiments, “5' UTR” refers to a sequence of a nucleotide sequence that begins at the 5' end of the nucleotide sequence (e.g., a transcription start site) and ends one nucleotide (nt) before a start codon (usually AUG) of a coding region of the nucleotide sequence, e.g., in its natural context. In some embodiments, a 5' UTR comprises a Kozak sequence. A 5'-UTR is downstream of the 5'-cap (if present), e.g., directly adjacent to the 5'-cap. In some embodiments, a 5' UTR disclosed herein comprises a cap proximal sequence, e.g., as defined and described herein. In some embodiments, a cap proximal sequence comprises a sequence adjacent to a 5' cap.

[0303] Exemplary 5' UTRs include a human alpha globin (hAg) 5'UTR or a fragment thereof, a TEV 5' UTR or a fragment thereof, a HSP705' UTR or a fragment thereof, or a c-Jun 5' UTR or a fragment thereof.

[0304] In some embodiments, an RNA disclosed herein comprises a hAg 5' UTR or a fragment thereof.

[0305] In some embodiments, an RNA disclosed herein comprises a 5' UTR having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% 258 11979815v1P-627574-PC identity to a 5' UTR with the sequence AGAATAAACTAGTATTCTTCTGGTCCCCACAGACTCAGAGAGAACCCGCCACC (SEQ ID NO: 210). In some embodiments, an RNA disclosed herein comprises a 5' UTR having the sequence as set forth in SEQ ID NO: 210.

[0306] In some embodiments, an RNA disclosed herein comprises a 5' UTR having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a 5’ UTR with the sequence AACUAGUAUUCUUCUGGUCCCCACAGACUCAGAGAGAACCCGCCACC (SEQ ID NO: 211) (hAg-Kozak / 5'UTR). In some embodiments, an RNA disclosed herein comprises a 5' UTR having the sequence as set forth in SEQ ID NO 211. 4. PolyA Tail

[0307] In some embodiments, a polynucleotide (e.g., DNA, RNA) disclosed herein comprises a polyadenylate (polyA) sequence, e.g., as described herein. In some embodiments, a polyA sequence is situated downstream of a 3'-UTR, e.g., adjacent to a 3'-UTR.

[0308] As used herein, the term “poly(A) sequence” or “poly-A tail” refers to an uninterrupted or interrupted sequence of adenylate residues which is typically located at the 3'-end of an RNA polynucleotide. Poly(A) sequences are known to those of skill in the art and may follow the 3’- UTR in the RNAs described herein. An uninterrupted poly(A) sequence is characterized by consecutive adenylate residues. In nature, an uninterrupted poly(A) sequence is typical. In some embodiments, polynucleotides disclosed herein comprise an uninterrupted poly(A) sequence. In some embodiments, polynucleotides disclosed herein comprise interrupted poly(A) sequence. In some embodiments, RNAs disclosed herein can have a poly(A) sequence attached to the free 3'- end of the RNA by a template-independent RNA polymerase after transcription or a poly(A) sequence encoded by DNA and transcribed by a template-dependent RNA polymerase.

[0309] It has been demonstrated that a poly(A) sequence of about 120 A nucleotides has a beneficial influence on the levels of RNA in transfected eukaryotic cells, as well as on the levels of protein that are translated from an open reading frame that is present upstream (5') of the poly(A) sequence (Holtkamp et al., 2006, Blood, vol.108, pp.4009-4017, which is herein incorporated by reference).

[0310] In some embodiments, a poly(A) sequence in accordance with the present disclosure is not limited to a particular length; in some embodiments, a poly(A) sequence is any length. In some embodiments, a poly(A) sequence comprises, essentially consists of, or consists of at least 20, at 259 11979815v1P-627574-PC least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 A nucleotides, and, in particular, about 120 A nucleotides. In this context, "essentially consists of" means that most nucleotides in the poly(A) sequence, typically at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% by number of nucleotides in the poly(A) sequence are A nucleotides, but permits that remaining nucleotides are nucleotides other than A nucleotides, such as U nucleotides (uridylate), G nucleotides (guanylate), or C nucleotides (cytidylate). In this context, "consists of" means that all nucleotides in the poly(A) sequence, i.e., 100% by number of nucleotides in the poly(A) sequence, are A nucleotides. The term “A nucleotide” or “A” refers to adenylate.

[0311] In some embodiments, a poly(A) sequence is attached during RNA transcription, e.g., during preparation of in vitro transcribed RNA, based on a DNA template comprising repeated dT nucleotides (deoxythymidylate) in the strand complementary to the coding strand. The DNA sequence encoding a poly(A) sequence (coding strand) is referred to as a poly(A) cassette.

[0312] In some embodiments, the poly(A) cassette present in the coding strand of DNA essentially consists of dA nucleotides, but is interrupted by a random sequence of the four nucleotides (dA, dC, dG, and dT). Such a random sequence may be 5 to 50, 10 to 30, or 10 to 20 nucleotides in length. Such a cassette is disclosed in WO 2016 / 005324 A1, hereby incorporated by reference. Any poly(A) cassette disclosed in WO 2016 / 005324 A1, which is incorporated herein by reference in its entirety, may be used in accordance with the present disclosure. A poly(A) cassette that essentially consists of dA nucleotides, but is interrupted by a random sequence having an equal distribution of the four nucleotides (dA, dC, dG, dT) and having a length of e.g., 5 to 50 nucleotides shows, at the DNA level, constant propagation of plasmid DNA in E. coli and is still associated, at the RNA level, with the beneficial properties with respect to supporting RNA stability and translational efficiency is encompassed. In some embodiments, the poly(A) sequence contained in an RNA polynucleotide described herein essentially consists of A nucleotides, but is interrupted by a random sequence of the four nucleotides (A, C, G, U). Such a random sequence may be 5 to 50, 10 to 30, or 10 to 20 nucleotides in length.

[0313] In some embodiments, no nucleotides other than A nucleotides flank a poly(A) sequence at its 3'-end, i.e., the poly(A) sequence is not masked or followed at its 3'-end by a nucleotide other than A.

[0314] In some embodiments, the poly(A) sequence may comprise at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 260 11979815v1P-627574-PC nucleotides. In some embodiments, the poly(A) sequence may essentially consist of at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides. In some embodiments, the poly(A) sequence may consist of at least 20, at least 30, at least 40, at least 80, or at least 100 and up to 500, up to 400, up to 300, up to 200, or up to 150 nucleotides. In some embodiments, the poly(A) sequence comprises at least 100 nucleotides. In some embodiments, the poly(A) sequence comprises about 150 nucleotides. In some embodiments, the poly(A) sequence comprises about 120 nucleotides.

[0315] In some embodiments, a poly(A) sequence comprises a specific number of adenosines, such as about 50 or more, about 60 or more, about 70 or more, about 80 or more, about 90 or more, about 100 or more, about 120, or about 150 or about 200. In some embodiments a poly(A) sequence of an RNA may comprise 200 A residues or less. In some embodiments, a poly(A) sequence of an RNA may comprise about 200 A residues. In some embodiments, a poly(A) sequence of an RNA may comprise 180 A residues or less. In some embodiments, a poly(A) sequence of an RNA may comprise about 180 A residues. In some embodiments, a poly(A) sequence may comprise 150 residues or less.

[0316] In some embodiments, RNA comprises a poly(A) sequence comprising the nucleotide sequence of: AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCATATGACTAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAA (SEQ ID NO: 212), or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of: SEQ ID NO: 212. In some embodiments, a poly(A) sequence comprises a plurality of A residues interrupted by a linker. In some embodiments, a linker comprises the nucleotide sequence GCATATGAC.

[0317] In some embodiments, an RNA comprises a poly(A) sequence comprising the nucleotide sequence of: AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAGCAUAUGACUAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAA (SEQ ID NO: 214), or a nucleotide sequence having at least 99%, 98%, 97%, 96%, 95%, 90%, 85%, or 80% identity to the nucleotide sequence of SEQ ID NO: 214. In some embodiments, a poly(A) sequence comprises a plurality of A residues interrupted by a linker. In some embodiments, a linker comprises the nucleotide sequence GCAUAUGAC. 261 11979815v1P-627574-PC 5. 3' UTR

[0318] In some embodiments, an RNA utilized in accordance with the present disclosure comprises a 3'-UTR. As used herein, the terms “three prime untranslated region,” “3' untranslated region,” or “3' UTR” refer to a sequence of an mRNA molecule that begins following a stop codon of a coding region of an open reading frame sequence. In some embodiments, the 3' UTR begins immediately after a stop codon of a coding region of an open reading frame sequence, e.g., in its natural context. In other embodiments, the 3' UTR does not begin immediately after stop codon of the coding region of an open reading frame sequence, e.g., in its natural context. The term “3'- UTR” preferably does not include the poly(A) sequence. Thus, the 3'-UTR is upstream of the poly(A) sequence (if present), e.g. directly adjacent to the poly(A) sequence.

[0319] In some embodiments, an RNA disclosed herein comprises a 3'UTR comprising an F element and / or an I element. In some embodiments, a 3' UTR or a proximal sequence thereto comprises a restriction site. In some embodiments, a restriction site is a BamHI site. In some embodiments, a restriction site is an XhoI site.

[0320] In some embodiments, an RNA construct comprises an F element. In some embodiments, an F element sequence is a 3' UTR of amino-terminal enhancer of split (AES).

[0321] In some embodiments, an RNA disclosed herein comprises a 3' UTR having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a 3’ UTR with the sequence of CTGGTACTGCATGCACGCAATGCTAGCTGCCCCTTTCCCGTCCTGGGTACCCCGAGT CTCCCCCGACCTCGGGTCCCAGGTATGCTCCCACCTCCACCTGCCCCACTCACCACC TCTGCTAGTTCCAGACACCTCCCAAGCACGCAGCAATGCAGCTCAAAACGCTTAGCC TAGCCACACCCCCACGGGAAACAGCAGTGATTAACCTTTAGCAATAAACGAAAGTT TAACTAAGCTATACTAACCCCAGGGTTGGTCAATTTCGTGCCAGCCACACC (SEQ ID NO: 216). In some embodiments, an RNA disclosed herein comprises a 3' UTR with the sequence of SEQ ID NO: 216.

[0322] In some embodiments, an RNA disclosed herein comprises a 3' UTR having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% identity to a 3’ UTR with the sequence of CUGGUACUGCAUGCACGCAAUGCUAGCUGCCCCUUUCCCGUCCUGGGUACCCCGA GUCUCCCCCGACCUCGGGUCCCAGGUAUGCUCCCACCUCCACCUGCCCCACUCACC ACCUCUGCUAGUUCCAGACACCUCCCAAGCACGCAGCAAUGCAGCUCAAAACGCU 262 11979815v1P-627574-PC UAGCCUAGCCACACCCCCACGGGAAACAGCAGUGAUUAACCUUUAGCAAUAAACG AAAGUUUAACUAAGCUAUACUAACCCCAGGGUUGGUCAAUUUCGUGCCAGCCACA CC (SEQ ID NO: 217). In some embodiments, an RNA disclosed herein comprises a 3' UTR with the sequence of SEQ ID NO: 217.

[0323] In some embodiments, a 3' UTR is an FI element as described in WO2017 / 060314, which is herein incorporated by reference in its entirety. B. Modified RNAs

[0324] In some embodiments, the present disclosure provides compositions comprising modified RNAs and methods of use thereof. In some embodiments, the modified RNA comprises one or more modified nucleoside residues. For example, in some embodiments, an RNA comprising a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 2, Table 4, or Table 6, comprises one or more modified nucleoside residues.

[0325] In some embodiments, an RNA as described herein refers to a messenger RNA.

[0326] In some embodiments, all uridine residues are modified as described herein. In some embodiments, one or more of the RNAs as described herein are nucleoside modified RNAs. In other embodiments, two or more of the RNAs as described herein are nucleoside modified RNAs. In other embodiments, three or more of the RNAs as described herein are nucleoside modified RNAs.

[0327] In some embodiments, the modified nucleoside of the methods and compositions of the present disclosure is m5C (5-methylcytidine). In another embodiment, the modified nucleoside is m5U (5-methyluridine). In another embodiment, the modified nucleoside is m6A (N6- methyladenosine). In another embodiment, the modified nucleoside is s2U (2-thiouridine). In another embodiment, the modified nucleoside is Ψ (pseudouridine). In another embodiment, the modified nucleoside is Um (2'-O-methyluridine).

[0328] In some embodiments, a modified nucleoside is m1A (1-methyladenosine), m2A (2- methyladenosine), m6A (N6-methyladenosine), Am (2'-O-methyladenosine), ms2m6A (2- methylthio-N6-methyladenosine), i6A (N6-isopentenyladenosine), ms2i6A (2-methylthio-N6- isopentenyladenosine), io6A (N6-(cis-hydroxyisopentenyl)adenosine), ms2io6A (2-methylthio- N6-(cis-hydroxyisopentenyl) adenosine), g6A (N6-glycinylcarbamoyladenosine), t6A (N6- threonylcarbamoyladenosine), ms2t6A (2-methylthio-N6-threonyl carbamoyladenosine), m6t6A 263 11979815v1P-627574-PC (N6-methyl-N6-threonylcarbamoyladenosine), hn6A (N6-hydroxynorvalylcarbamoyladenosine), ms2hn6A (2-methylthio-N6-hydroxynorvalyl carbamoyladenosine), Ar(p) (2'-O-ribosyladenosine (phosphate)), I (inosine), m1I (1-methylinosine), m1Im (1,2'-O-dimethylinosine), m3C (3- methylcytidine), m5C (5-methylcytidine), Cm (2'-O-methylcytidine), s2C (2-thiocytidine), ac4C (N4-acetylcytidine), f5C (5-formylcytidine), m5Cm (5,2'-O-dimethylcytidine), ac4Cm (N4-acetyl- 2'-O-methylcytidine), k2C (lysidine), m1G (1-methylguanosine), m2G (N2-methylguanosine), m7G (7-methylguanosine), Gm (2'-O-methylguanosine), m22G (N2,N2-dimethylguanosine), m2Gm (N2,2'-O-dimethylguanosine), m22Gm (N2,N2,2'-O-trimethylguanosine), Gr(p) (2'-O- ribosylguanosine (phosphate)), yW (wybutosine), o2yW (peroxywybutosine), OHyW (hydroxywybutosine), OHyW* (undermodified hydroxywybutosine), imG (wyosine), mimG (methylwyosine), Q (queuosine), oQ (epoxyqueuosine), galQ (galactosyl-queuosine), manQ (mannosyl-queuosine), preQ0 (7-cyano-7-deazaguanosine), preQ1 (7-aminomethyl-7- deazaguanosine), G+(archaeosine), ^ (pseudouridine), D (dihydrouridine), m5U (5- methyluridine), Um (2'-O-methyluridine), m5Um (5,2'-O-dimethyluridine), m1^ (1- methylpseudouridine), ^m (2'-O-methylpseudouridine), s2U (2-thiouridine), s4U (4-thiouridine), m5s2U (5-methyl-2-thiouridine), s2Um (2-thio-2'-O-methyluridine), acp3U (3-(3-amino-3- carboxypropyl)uridine), ho5U (5-hydroxyuridine), mo5U (5-methoxyuridine), cmo5U (uridine 5- oxyacetic acid), mcmo5U (uridine 5-oxyacetic acid methyl ester), chm5U (5- (carboxyhydroxymethyl)uridine), mchm5U (5-(carboxyhydroxymethyl)uridine methyl ester), mcm5U (5-methoxycarbonylmethyluridine), mcm5Um (5-methoxycarbonylmethyl-2'-O- methyluridine), mcm5s2U (5-methoxycarbonylmethyl-2-thiouridine), nm5s2U (5-aminomethyl-2- thiouridine), mnm5U (5-methylaminomethyluridine), mnm5s2U (5-methylaminomethyl-2- thiouridine), mnm5se2U (5-methylaminomethyl-2-selenouridine), ncm5U (5- carbamoylmethyluridine), ncm5Um (5-carbamoylmethyl-2'-O-methyluridine), cmnm5U (5- carboxymethylaminomethyluridine), cmnm5Um (5-carboxymethylaminomethyl- 2'-O- methyluridine), cmnm5s2U (5-carboxymethylaminomethyl-2-thiouridine), m62A (N6,N6- dimethyladenosine), Im (2'-O-methylinosine), m4C (N4-methylcytidine), m4Cm (N4,2'-O- dimethylcytidine), hm5C (5-hydroxymethylcytidine), m3U (3-methyluridine), m1acp3^ (1-methyl- 3-(3-amino-3-carboxypropyl) pseudouridine), cm5U (5-carboxymethyluridine), m6Am (N6,2'-O- dimethyladenosine), m62Am (N6,N6,2'-O-trimethyladenosine), m2,7G (N2,7-dimethylguanosine), m2,2,7G (N2,N2,7-trimethylguanosine), m3Um (3,2'-O-dimethyluridine), m5D (5- methyldihydrouridine), m3^ (3-methylpseudouridine), f5Cm (5-formyl-2'-O-methylcytidine), 264 11979815v1P-627574-PC m1Gm (1,2'-O-dimethylguanosine), m1Am (1,2'-O-dimethyladenosine), ^m5U (5- taurinomethyluridine), ^m5s2U (5-taurinomethyl-2-thiouridine), imG-14 (4-demethylwyosine), imG2 (isowyosine), ac6A (N6-acetyladenosine), inm5U (5-(isopentenylaminomethyl)uridine), inm5s2U (5-(isopentenylaminomethyl)- 2-thiouridine), inm5Um (5-(isopentenylaminomethyl)- 2'- O-methyluridine), m2,7Gm (N2,7,2'-O-trimethylguanosine), m42Cm (N4,N4,2'-O- trimethylcytidine), C+(agmatidine), m8A (8-methyladenosine), gmnm5s2U (geranylated 5- methylaminomethyl-2-thiouridine), gcmnm5s2U (geranylated 5-carboxymethylaminomethyl-2- thiouridine), or cnm5U (5-cyanomethyl-uridine).

[0329] In some embodiments, modified nucleoside residues are pseudouridine or pseudouridine family residues.

[0330] In some embodiments, the modified RNA comprises pseudouridine residues. In some embodiments, pseudouridine refers to the C-glycoside isomer of the nucleoside uridine. In some embodiments, pseudouridine residues comprise m1acp3Ψ (1-methyl-3-(3-amino-5- carboxypropyl)pseudouridine, m1Ψ (1-methylpseudouridine), Ψm (2′-O-methylpseudouridine, m5D (5-methyldihydrouridine), m3Ψ (3-methylpseudouridine), or a combination thereof. In some embodiments, said pseudouridine residues comprise 1-methylpseudouridine residues instead of uridine.

[0331] In some embodiments, modified nucleoside residues are pseudouridine analogues. In some embodiments, a "pseudouridine analog" is any modification, variant, isoform or derivative of pseudouridine. For example, pseudouridine analogs include but are not limited to 1- carboxymethyl-pseudouridine, 1-propynyl-pseudouridine, 1-taurinomethyl-pseudouridine, 1- taurinomethyl-4-thio-pseudouridine, 1-methylpseudouridine (m1^), 1-methyl-4-thio- pseudouridine (m1s4^), 4-thio-1-methyl-pseudouridine, 3-methyl-pseudouridine (m3^), 2-thio-1- methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydropseudouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio- uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3^), and 2'-O-methyl-pseudouridine ( ^m).

[0332] In some embodiments, a modified nucleobase is a modified uracil. Exemplary nucleobases and nucleosides having a modified uracil include pseudouridine ( ^), pyridin-4-one ribonucleoside, 5-aza-uridine, 6-aza-uridine, 2-thio-5-aza-uridine, 2-thio-uridine (s2U), 4-thio- uridine (s4U), 4-thio-pseudouridine, 2-thio-pseudouridine, 5-hydroxy-uridine (ho5U), 5- 265 11979815v1P-627574-PC aminoallyl-uridine, 5-halo-uridine (e.g., 5-iodo-uridine or 5-bromo-uridine), 3-methyl-uridine (m3U), 5-methoxy-uridine (mo5U), uridine 5-oxyacetic acid (cmo5U), uridine 5-oxyacetic acid methyl ester (mcmo5U), 5-carboxymethyl-uridine (cm5U), 1-carboxymethyl-pseudouridine, 5- carboxyhydroxymethyl-uridine (chm5U), 5-carboxyhydroxymethyl-uridine methyl ester (mchm5U), 5-methoxycarbonylmethyl-uridine (mcm5U), 5-methoxycarbonylmethyl-2-thio- uridine (mcm5s2U), 5-aminomethyl-2-thio-uridine (nm5s2U), 5-methylaminomethyl-uridine (mnm5U), 5-methylaminomethyl-2-thio-uridine (mnm5s2U), 5-methylaminomethyl-2-seleno- uridine (mnm5se2U), 5-carbamoylmethyl-uridine (ncm5U), 5-carboxymethylaminomethyl-uridine (cmnm5U), 5-carboxymethylaminomethyl-2-thio-uridine (cmnm5s2U), 5-propynyl-uridine, 1- propynyl-pseudouridine, 5-taurinomethyl-uridine ( ^cm5U), 1-taurinomethyl-pseudouridine, 5- taurinomethyl-2-thio-uridine ( ^rm5s2U), 1-taurinomethyl-4-thio-pseudouridine, 5-methyl-uridine (m5U, i.e., having the nucleobase deoxythymine), 1-methylpseudouridine (m1^), 5-methyl-2-thio- uridine (m5s2U), 1-methyl-4-thio-pseudouridine (m1s4^), 4-thio-1-methyl-pseudouridine, 3- methyl-pseudouridine (m3^), 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydrouridine (D), dihydropseudouridine, 5,6- dihydrouridine, 5-methyl-dihydrouridine (m5D), 2-thio-dihydrouridine, 2-thio- dihydropseudouridine, 2-methoxy-uridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, N1-methyl-pseudouridine (also known as 1- methylpseudouridine (m1^), 3-(3-amino-3-carboxypropyl)uridine (acp3U), 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine (acp3^), 5-(isopentenylaminomethyl)uridine (inm5U), 5-(isopentenylaminomethyl)-2-thio-uridine (inm5s2U), α-thio-uridine, 2'-O-methyl-uridine (Um), 5,2'-O-dimethyl-uridine (m5Um), 2'-O-methyl-pseudouridine ( ^m), 2-thio-2'-O-methyl-uridine (s2Um), 5-methoxycarbonylmethyl-2'-O-methyl-uridine (mcm5Um), 5-carbamoylmethyl-2'-β- methyl-uridine (ncm5Um), 5-carboxymethylaminomethyl-2'-O-methyl-uridine (cmnm5Um), 3,2'-O-dimethyl-uridine (m3Um), 5-(isopentenylaminomethyl)-2'-β-methyl-uridine (inm5Um), 1-thio-uridine, deoxythymidine, 2'-F-ara-uridine, 2'-F-uridine, 2'-OH-ara-uridine, 5-(2- carbomethoxyvinyl)uridine, and 5-[3-(1-E-propenylamino)uridine.

[0333] In some embodiments, a modified nucleobase is a modified cytosine. Exemplary nucleobases and nucleosides having a modified cytosine include 5-aza-cytidine, 6-aza-cytidine, pseudoisocytidine, 3-methyl-cytidine (m3C), N4-acetyl-cytidine (ac4C), 5-formyl-cytidine (f5C), N4-methyl-cytidine (m4C), 5-methyl-cytidine (m5C), 5-halo-cytidine (e.g., 5-iodo-cytidine), 5- hydroxymethyl-cytidine (hm5C), 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo- 266 11979815v1P-627574-PC pseudoisocytidine, 2-thio-cytidine (s2C), 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4- thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza- pseudoisocytidine, zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2- thio-zebularine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy- pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, lysidine (k2C), α-thio-cytidine, 2'-O- methyl-cytidine (Cm), 5,2'-O-dimethyl-cytidine (m5Cm), N4-acetyl-2'-O-methyl-cytidine (ac4Cm), N4,2'-O-dimethyl-cytidine (m4Cm), 5-formyl-2'-O-methyl-cytidine (f5Cm), N4,N4,2'-O- trimethyl-cytidine (m42Cm), 1-thio-cytidine, 2'-F-ara-cytidine, 2'-F-cytidine, and 2'-OH-ara- cytidine.

[0334] In some embodiments, a modified nucleobase is a modified adenine. Exemplary nucleobases and nucleosides having a modified adenine include 2-amino-purine, 2,6- diaminopurine, 2-amino-6-halo-purine (e.g., 2-amino-6-chloro-purine), 6-halo-purine (e.g., 6- chloro-purine), 2-amino-6-methyl-purine, 8-azido-adenosine, 7-deaza-adenine, 7-deaza-8-aza- adenine, 7-deaza-2-amino-purine, 7-deaza-8-aza-2-amino-purine, 7-deaza-2,6-diaminopurine, 7- deaza-8-aza-2,6-diaminopurine, 1-methyl-adenosine (m1A), 2-methyl-adenine (m2A), N6-methyl- adenosine (m6A), 2-methylthio-N6-methyl-adenosine (ms2m6A), N6-isopentenyl-adenosine (i6A), 2-methylthio-N6-isopentenyl-adenosine (ms2i6A), N6-(cis-hydroxyisopentenyl)adenosine (io6A), 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine (ms2io6A), N6-glycinylcarbamoyl- adenosine (g6A), N6-threonylcarbamoyl-adenosine (t6A), N6-methyl-N6-threonylcarbamoyl- adenosine (m6t6A), 2-methylthio-N6-threonylcarbamoyl-adenosine (ms2g6A), N6,N6-dimethyl- adenosine (m62A), N6-hydroxynorvalylcarbamoyl-adenosine (hn6A), 2-methylthio-N6- hydroxynorvalylcarbamoyl-adenosine (ms2hn6A), N6-acetyl-adenosine (ac6A), 7-methyl-adenine, 2-methylthio-adenine, 2-methoxy-adenine, α-thio-adenosine, 2'-O-methyl-adenosine (Am), N6,2'- O-dimethyl-adenosine (m6Am), N6,N6,2'-O-trimethyl-adenosine (m62Am), 1,2'-O-dimethyl- adenosine (m1Am), 2'-β-ribosyladenosine (phosphate) (Ar(p)), 2-amino-N6-methyl-purine, 1- thio-adenosine, 8-azido-adenosine, 2'-F-ara-adenosine, 2'-F-adenosine, 2'-OH-ara-adenosine, and N6-(19-amino-pentaoxanonadecyl)-adenosine.

[0335] In some embodiments, a modified nucleobase is a modified guanine. Exemplary nucleobases and nucleosides having a modified guanine include inosine (I), 1-methyl-inosine (m1I), wyosine (imG), methylwyosine (mimG), 4-demethyl-wyosine (imG-14), isowyosine (imG2), wybutosine (yW), peroxywybutosine (o2yW), hydroxywybutosine (OHyW), undermodified hydroxywybutosine (OHyW*), 7-deaza-guanosine, queuosine (Q), 267 11979815v1P-627574-PC epoxyqueuosine (oQ), galactosyl-queuosine (galQ), mannosyl-queuosine (manQ), 7-cyano-7- deaza-guanosine (preQ0), 7-aminomethyl-7-deaza-guanosine (preQ1), archaeosine (G+), 7-deaza- 8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7- methyl-guanosine (m7G), 6-thio-7-methyl-guanosine, 7-methyl-inosine, 6-methoxy-guanosine, 1- methyl-guanosine (m1G), N2-methyl-guanosine (m2G), N2,N2-dimethyl-guanosine (m22G), N2,7- dimethyl-guanosine (m2,7G), N2,N2,7-dimethyl-guanosine (m2,2,7G), 8-oxo-guanosine, 7- methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine, N2,N2- dimethyl-6-thio-guanosine, α-thio-guanosine, 2'-O-methyl-guanosine (Gm), N2-methyl-2'-O- methyl-guanosine (m2Gm), N2,N2-dimethyl-2'-O-methyl-guanosine (m22Gm), 1-methyl-2'-O- methyl-guanosine (m1Gm), N2,7-dimethyl-2'-O-methyl-guanosine (m2'7Gm), 2'-O-methyl-inosine (Im), 1,2'-O-dimethyl-inosine (m1Im), and 2'-O-ribosylguanosine (phosphate) (Gr(p)).

[0336] The nucleobase of the nucleotide can be independently selected from a purine, a pyrimidine, a purine or pyrimidine analog. For example, the nucleobase can each be independently selected from adenine, cytosine, guanine, uracil, or hypoxanthine. In another embodiment, the nucleobase can also include, for example, naturally-occurring and synthetic derivatives of a base, including pyrazolo[3,4-d]pyrimidines, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo (e.g., 8-bromo), 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, deazaguanine, 7-deazaguanine, 3-deazaguanine, deazaadenine, 7-deazaadenine, 3- deazaadenine, pyrazolo[3,4-d]pyrimidine, imidazo[1,5-a]1,3,5 triazinones, 9-deazapurines, imidazo[4,5-d]pyrazines, thiazolo[4,5-d]pyrimidines, pyrazin-2-ones, 1,2,4-triazine, pyridazine; and 1,3,5 triazine. When the nucleotides are depicted using the shorthand A, G, C, T or U, each letter refers to the representative base and / or derivatives thereof, e.g., A includes adenine or adenine analogs, e.g., 7-deaza adenine). Modifications on the Internucleoside Linkage

[0337] The modified nucleotides, which may be incorporated into a polynucleotide, primary construct, or RNA molecule, can be modified on the internucleoside linkage (e.g., phosphate backbone). Herein, in the context of the polynucleotide backbone, the phrases "phosphate" and 268 11979815v1P-627574-PC "phosphodiester" are used interchangeably. Backbone phosphate groups can be modified by replacing one or more of the oxygen atoms with a different substituent. Further, the modified nucleosides and nucleotides can include the wholesale replacement of an unmodified phosphate moiety with another internucleoside linkage as described herein. Examples of modified phosphate groups include, but are not limited to, phosphorothioate, phosphoroselenates, boranophosphates, boranophosphate esters, hydrogen phosphonates, phosphoramidates, phosphorodiamidates, alkyl or aryl phosphonates, and phosphotriesters. Phosphorodithioates have both non-linking oxygens replaced by sulfur. The phosphate linker can also be modified by the replacement of a linking oxygen with nitrogen (bridged phosphoramidates), sulfur (bridged phosphorothioates), and carbon (bridged methylene-phosphonates).

[0338] The α-thio substituted phosphate moiety is provided to confer stability to RNA and DNA polymers through the unnatural phosphorothioate backbone linkages. Phosphorothioate DNA and RNA have increased nuclease resistance and subsequently a longer half-life in a cellular environment. Phosphorothioate linked polynucleotides, primary constructs, or modified RNA molecules are expected to also reduce the innate immune response through weaker binding / activation of cellular innate immune molecules.

[0339] In specific embodiments, a modified nucleoside includes an alpha-thio-nucleoside (e.g., 5'- O-(1-thiophosphate)-adenosine, 5'-O-(1-thiophosphate)-cytidine (α-thio-cytidine), 5'-O-(1- thiophosphate)-guanosine, 5'-O-(1-thiophosphate)-uridine, or 5'-O-(1-thiophosphate)- pseudouridine).

[0340] Other internucleoside linkages that may be employed according to the present disclosure, including internucleoside linkages which do not contain a phosphorous atom, are described herein below. Combinations of Modified Sugars, Nucleobases, and Internucleoside Linkages

[0341] The polynucleotides, primary constructs, and modified RNA of the disclosure can include a combination of modifications to the sugar, the nucleobase, and / or the internucleoside linkage.

[0342] In another embodiment, the purified preparation of RNA, oligoribonucleotide, or polyribonucleotide of the methods and compositions of the present disclosure comprises a combination of two or more of the above-described modifications. In another embodiment, the purified preparation of the RNA or oligoribonucleotide comprises a combination of three or more of the above-described modifications. In another embodiment, the purified preparation of the RNA 269 11979815v1P-627574-PC or oligoribonucleotide comprises a combination of more than three of the above-described modifications.

[0343] In some embodiments, the modified RNAs comprise in vitro-synthesized modified RNAs.

[0344] In some embodiments, the present disclosure comprises one or more modified RNAs encoding an HSV glycoprotein. In some embodiments, the modified RNA comprises pseudouridine or pseudouridine family residues. In another embodiment, the modified RNAs of the present disclosure are capable of directing protein expression of HSV glycoproteins encoded thereon.

[0345] In another embodiment, the present disclosure provides an in vitro-transcribed mRNA molecule encoding an HSV glycoprotein, comprising a pseudouridine. In another embodiment, the present disclosure provides a synthetic RNA molecule encoding an HSV glycoprotein, comprising a pseudouridine.

[0346] In another embodiment, an in vitro-transcribed RNA molecule of the methods and compositions of the present disclosure is synthesized by T7 phage RNA polymerase. In another embodiment, the molecule is synthesized by SP6 phage RNA polymerase. In another embodiment, the molecule is synthesized by T3 phage RNA polymerase. In another embodiment, the molecule is synthesized by a polymerase selected from the above polymerases. In another embodiment, the RNA is synthesized chemically on a column similar to DNA.

[0347] In another embodiment, the nucleoside that is modified in an RNA, oligoribonucleotide, or polyribonucleotide of the methods and compositions of the present disclosure is uridine (U). In another embodiment, the modified nucleoside is cytidine (C). In another embodiment, the modified nucleoside is adenine (A). In another embodiment the modified nucleoside is guanine (G).

[0348] In another embodiment, the RNA of the methods and compositions of the present disclosure further comprises a poly-A tail. In another embodiment, the RNA of the methods and compositions of the present disclosure does not comprise a poly-A tail. Each possibility represents a separate embodiment of the present disclosure.

[0349] In another embodiment, the RNA of the methods and compositions of the present disclosure comprises an m7GpppG cap. In another embodiment, the RNA of the methods and compositions of the present disclosure does not comprise an m7GpppG cap. In another embodiment, the RNA of the methods and compositions of the present disclosure comprises a 3′- O-methyl-m7GpppG. In another embodiment, the RNA of methods and composition of the present 270 11979815v1P-627574-PC disclosure comprise a non-reversible cap analog, which, in some embodiments, is added during transcription of the RNA. In another embodiment, the RNA of methods and composition of the present disclosure comprise an anti-reverse cap analog. Each possibility represents a separate embodiment of the present disclosure.

[0350] In another embodiment, the RNA of the methods and compositions of the present disclosure further comprises a cap-independent translational enhancer. In another embodiment, the RNA of the methods and compositions of the present disclosure does not comprise a cap- independent translational enhancer. In another embodiment, the cap-independent translational enhancer is a tobacco etch virus (TEV) cap-independent translational enhancer. In another embodiment, the cap-independent translational enhancer is any other cap-independent translational enhancer known in the art. Each possibility represents a separate embodiment of the present disclosure.

[0351] In some embodiments, “pseudouridine” refers to m1acp3Ψ (1-methyl-3-(3-amino-5- carboxypropyl)pseudouridine. In another embodiment, the term refers to m1Ψ (1- methylpseudouridine). In another embodiment, the term refers to Ψm (2′-O-methylpseudouridine. In another embodiment, the term refers to m5D (5-methyldihydrouridine). In another embodiment, the term refers to m3Ψ (3-methylpseudouridine). In another embodiment, the modified nucleoside is 4' (pseudouridine). In another embodiment, the term refers to a pseudouridine moiety that is not further modified. In another embodiment, the term refers to a monophosphate, diphosphate, or triphosphate of any of the above pseudouridines. In another embodiment, the term refers to any other pseudouridine known in the art. Each possibility represents a separate embodiment of the present disclosure.

[0352] In another embodiment, a modified RNA comprises a modified nucleoside, which in some embodiments, comprises m5C, m5U, m6A, s2U, ^ ^, 2'-O-methyl-U, 2’-O-methylpseudouridine, or a combination thereof.

[0353] In another embodiment, the present disclosure provides a method for delivering a recombinant protein to a subject, the method comprising the step of contacting the subject with an RNA of the methods and compositions of the present disclosure, thereby delivering a recombinant protein to a subject.

[0354] In another embodiment, a method of the present disclosure comprises increasing the number, percentage, or frequency of modified uridine nucleosides in the RNA molecule to decrease immunogenicity or increase efficiency of translation. In some embodiments, the number 271 11979815v1P-627574-PC of modified uridine residues in an RNA, oligoribonucleotide, or polyribonucleotide molecule determines the magnitude of the effects observed in the present disclosure.

[0355] In another embodiment, between 0.1% and 100% of the uridine residues in the modified RNAs of the methods and compositions of the present disclosure are modified (e.g. by the presence of pseudouridine). In another embodiment, 0.1% of the residues are modified. In another embodiment, 0.2%. In another embodiment, the fraction is 0.3%. In another embodiment, the fraction is 0.4%. In another embodiment, the fraction is 0.5%. In another embodiment, the fraction is 0.6%. In another embodiment, the fraction is 0.8%. In another embodiment, the fraction is 1%. In another embodiment, the fraction is 1.5%. In another embodiment, the fraction is 2%. In another embodiment, the fraction is 2.5%. In another embodiment, the fraction is 3%. In another embodiment, the fraction is 4%. In another embodiment, the fraction is 5%. In another embodiment, the fraction is 6%. In another embodiment, the fraction is 8%. In another embodiment, the fraction is 10%. In another embodiment, the fraction is 12%. In another embodiment, the fraction is 14%. In another embodiment, the fraction is 16%. In another embodiment, the fraction is 18%. In another embodiment, the fraction is 20%. In another embodiment, the fraction is 25%. In another embodiment, the fraction is 30%. In another embodiment, the fraction is 35%. In another embodiment, the fraction is 40%. In another embodiment, the fraction is 45%. In another embodiment, the fraction is 50%. In another embodiment, the fraction is 60%. In another embodiment, the fraction is 70%. In another embodiment, the fraction is 80%. In another embodiment, the fraction is 90%. In another embodiment, the fraction is 100%.

[0356] In another embodiment, the fraction is less than 5%. In another embodiment, the fraction is less than 3%. In another embodiment, the fraction is less than 1%. In another embodiment, the fraction is less than 2%. In another embodiment, the fraction is less than 4%. In another embodiment, the fraction is less than 6%. In another embodiment, the fraction is less than 8%. In another embodiment, the fraction is less than 10%. In another embodiment, the fraction is less than 12%. In another embodiment, the fraction is less than 15%. In another embodiment, the fraction is less than 20%. In another embodiment, the fraction is less than 30%. In another embodiment, the fraction is less than 40%. In another embodiment, the fraction is less than 50%. In another embodiment, the fraction is less than 60%. In another embodiment, the fraction is less than 70%

[0357] In another embodiment, 0.1% of the residues of a given uridine nucleotide are modified. In another embodiment, the fraction of the nucleotide is 0.2%. In another embodiment, the fraction 272 11979815v1P-627574-PC is 0.3%. In another embodiment, the fraction is 0.4%. In another embodiment, the fraction is 0.5%. In another embodiment, the fraction is 0.6%. In another embodiment, the fraction is 0.8%. In another embodiment, the fraction is 1%. In another embodiment, the fraction is 1.5%. In another embodiment, the fraction is 2%. In another embodiment, the fraction is 2.5%. In another embodiment, the fraction is 3%. In another embodiment, the fraction is 4%. In another embodiment, the fraction is 5%. In another embodiment, the fraction is 6%. In another embodiment, the fraction is 8%. In another embodiment, the fraction is 10%. In another embodiment, the fraction is 12%. In another embodiment, the fraction is 14%. In another embodiment, the fraction is 16%. In another embodiment, the fraction is 18%. In another embodiment, the fraction is 20%. In another embodiment, the fraction is 25%. In another embodiment, the fraction is 30%. In another embodiment, the fraction is 35%. In another embodiment, the fraction is 40%. In another embodiment, the fraction is 45%. In another embodiment, the fraction is 50%. In another embodiment, the fraction is 60%. In another embodiment, the fraction is 70%. In another embodiment, the fraction is 80%. In another embodiment, the fraction is 90%. In another embodiment, the fraction is 100%.

[0358] In another embodiment, the fraction of the given uridine nucleotide is less than 8%. In another embodiment, the fraction is less than 10%. In another embodiment, the fraction is less than 5%. In another embodiment, the fraction is less than 3%. In another embodiment, the fraction is less than 1%. In another embodiment, the fraction is less than 2%. In another embodiment, the fraction is less than 4%. In another embodiment, the fraction is less than 6%. In another embodiment, the fraction is less than 12%. In another embodiment, the fraction is less than 15%. In another embodiment, the fraction is less than 20%. In another embodiment, the fraction is less than 30%. In another embodiment, the fraction is less than 40%. In another embodiment, the fraction is less than 50%. In another embodiment, the fraction is less than 60%. In another embodiment, the fraction is less than 70%.

[0359] In another embodiment, the terms “ribonucleotide,” “oligoribonucleotide,” and polyribonucleotide refers to, in some embodiments, compounds comprising nucleotides in which the sugar moiety is ribose. In another embodiment, the term includes both RNA and RNA derivates in which the backbone is modified. Numerous RNA backbone modifications are known in the art and contemplated in the present disclosure. In some embodiments, modified RNA is a PNA (peptide nucleic acid). PNA contain peptide backbones and nucleotide bases and are able to bind, in another embodiment, to both DNA and RNA molecules. In another embodiment, the nucleotide 273 11979815v1P-627574-PC is modified by replacement of one or more phosphodiester bonds with a phosphorothioate bond. In another embodiment, the artificial nucleic acid contains any other variant of the phosphate backbone of native nucleic acids known in the art. Each nucleic acid derivative represents a separate embodiment of the present disclosure.

[0360] Methods for production of nucleic acids having modified backbones are well known in the art, and are described, for example in U.S. Pat. Nos.5,723,335 and 5,663,153 issued to Hutcherson et al. and related PCT publication WO95 / 26204. Each method represents a separate embodiment of the present disclosure.

[0361] The nucleic acid of interest can be purified by any method known in the art, or any method to be developed, so long as the method of purification removes contaminants from the nucleic acid preparation and thereby substantially reduces the immunogenicity potential of the nucleic acid preparation. In some embodiments, the nucleic acid of interest is purified using high-performance liquid chromatography (HPLC). In another embodiment, the nucleic acid of interest is purified by contacting the nucleic acid of interest with the bacterial enzyme RNase III. In other various embodiments, any method of nucleic acid purification that substantially reduces the immunogenicity of the nucleic acid preparation can be used. Non-limiting examples of purification methods that can be used with the compositions and methods of the disclosure include liquid chromatography separation and enzyme digestion, each used alone or in any combination, simultaneously or in any order. Non-limiting examples of liquid chromatography separation include HPLC and fast protein liquid chromatography (FPLC). Materials useful in the HPLC and FPLC methods of the disclosure include, but are not limited to, cross-linked polystyrene / divinylbenzene (PS / DVB), PS / DVB-C18, PS / DVB-alkylated, Helix DNA columns (Varian), Eclipse dsDNA Analysis Columns (Agilent Technologies), Reverse-phase 5 (RPC-5) exchange material, DNAPac, ProSwift, and bio-inert UltiMate.RTM. 3000 Titanium columns (Dionex). Enzymes useful in the enzyme digestion methods of the disclosure include any enzyme able to digest any contaminant in a nucleic acid preparation of the disclosure, such as, for example a dsRNA contaminant, and include but are not limited to, RNase III, RNase V1, Dicer, and Chipper (see Fruscoloni et al., 2002, PNAS 100:1639) Non-limiting examples of assays for assessing the purity of the nucleic acid of interest include a dot-blot assay, a Northern blot assay, and a dendritic cell activation assay, as described elsewhere herein.

[0362] In another embodiment, the modified RNA of the methods and compositions of the present disclosure is significantly less immunogenic than an unmodified in vitro-synthesized RNA 274 11979815v1P-627574-PC molecule with the same sequence. In another embodiment, the modified RNA molecule is 2-fold less immunogenic than its unmodified counterpart. In another embodiment, immunogenicity is reduced by a 3-fold factor. In another embodiment, immunogenicity is reduced by a 5-fold factor. In another embodiment, immunogenicity is reduced by a 7-fold factor. In another embodiment, immunogenicity is reduced by a 10-fold factor. In another embodiment, immunogenicity is reduced by a 15-fold factor. In another embodiment, immunogenicity is reduced by a fold factor. In another embodiment, immunogenicity is reduced by a 50-fold factor. In another embodiment, immunogenicity is reduced by a 100-fold factor. In another embodiment, immunogenicity is reduced by a 200-fold factor. In another embodiment, immunogenicity is reduced by a 500-fold factor. In another embodiment, immunogenicity is reduced by a 1000-fold factor. In another embodiment, immunogenicity is reduced by a 2000-fold factor. In another embodiment, immunogenicity is reduced by another fold difference.

[0363] In another embodiment, “significantly less immunogenic” refers to a detectable decrease in immunogenicity. In another embodiment, the term refers to a fold decrease in immunogenicity (e.g. 1 of the fold decreases enumerated above). In another embodiment, the term refers to a decrease such that an effective amount of the modified RNA can be administered without triggering a detectable immune response. In another embodiment, the term refers to a decrease such that the modified RNA can be repeatedly administered without eliciting an immune response sufficient to detectably reduce expression of the recombinant protein. In another embodiment, the decrease is such that the modified RNA can be repeatedly administered without eliciting an immune response sufficient to eliminate detectable expression of the recombinant protein.

[0364] Methods of determining immunogenicity are well known in the art, and described in detail in U. S. Patent 8,278,036 which is hereby incorporated by reference herein.

[0365] In another embodiment, the modified RNA of the methods and compositions of the present disclosure is translated in the cell more efficiently than an unmodified RNA molecule with the same sequence. In another embodiment, the modified RNA exhibits enhanced ability to be translated by a target cell. In another embodiment, translation is enhanced by a factor of 2-fold relative to its unmodified counterpart. In another embodiment, translation is enhanced by a 3-fold factor. In another embodiment, translation is enhanced by a 5-fold factor. In another embodiment, translation is enhanced by a 7-fold factor. In another embodiment, translation is enhanced by a 10- fold factor. In another embodiment, translation is enhanced by a 15-fold factor. In another embodiment, translation is enhanced by a 20-fold factor. In another embodiment, translation is 275 11979815v1P-627574-PC enhanced by a 50-fold factor. In another embodiment, translation is enhanced by a 100-fold factor. In another embodiment, translation is enhanced by a 200-fold factor. In another embodiment, translation is enhanced by a 500-fold factor. In another embodiment, translation is enhanced by a 1000-fold factor. In another embodiment, translation is enhanced by a 2000-fold factor. In another embodiment, the factor is 10-1000-fold. In another embodiment, the factor is 10-100-fold. In another embodiment, the factor is 10-200-fold. In another embodiment, the factor is 10-300-fold. In another embodiment, the factor is 10-500-fold. In another embodiment, the factor is 20-1000- fold. In another embodiment, the factor is 30-1000-fold. In another embodiment, the factor is 50- 1000-fold. In another embodiment, the factor is 100-1000-fold. In another embodiment, the factor is 200-1000-fold. In another embodiment, translation is enhanced by any other significant amount or range of amounts. Each possibility represents a separate embodiment of the present disclosure.

[0366] Methods of determining translation efficiency are well known in the art, and include, e.g. measuring the activity of an encoded reporter protein (e.g., luciferase or renilla or green fluorescent protein [Wall A A, Phillips A M et al, Effective translation of the second cistron in two Drosophila dicistronic transcripts is determined by the absence of in-frame AUG codons in the first cistron. J Biol Chem 2005; 280(30): 27670-8]), or measuring radioactive label incorporated into the translated protein (Ngosuwan J, Wang N M et al., Roles of cytosolic Hsp70 and Hsp40 molecular chaperones in post-translational translocation of pre-secretory proteins into the endoplasmic reticulum. J Biol Chem 2003; 278(9): 7034-42). Each method represents a separate embodiment of the present disclosure.

[0367] In another embodiment, the target cell of the method of the present disclosure is a dendritic cell. In another embodiment, the target cell of the method of the present disclosure is a macrophage. In another embodiment, the target cell of the method of the present disclosure is a B cell. In another embodiment, the target cell of the method of the present disclosure is another antigen presenting cell. In another embodiment, the target cell of methods of the present disclosure is a mucosal cell. In another embodiment, the target cell of methods of the present disclosure is an epithelial cell. In another embodiment, the cell is a skin cell. In another embodiment, the cell is an epidermal cell. In another embodiment, the cell is a keratinocyte. In another embodiment, the cell is a Merkel cell, melanocyte or Langerhans cell. Each possibility represents a separate embodiment of the present disclosure. C. Codon Optimization and GC Enrichment

[0368] The present disclosure also provides codon optimized nucleotide sequences. 276 11979815v1P-627574-PC

[0369] As used herein, the term “codon-optimized” refers to alteration of codons in a coding region of a nucleic acid molecule (e.g., a nucleotide sequence) to reflect the typical codon usage of a host organism (e.g., a subject receiving a nucleic acid molecule (e.g., a nucleotide sequence)) preferably without altering the amino acid sequence encoded by the nucleic acid molecule. Within the context of the present disclosure, in some embodiments, coding regions are codon-optimized for optimal expression in a subject to be treated using the RNA molecules described herein. In some embodiments, codon-optimization may be performed such that codons for which frequently occurring tRNAs are available are inserted in place of “rare codons.” In some embodiments, codon-optimization may include increasing guanosine / cytosine (G / C) content of a coding region of RNA described herein as compared to the G / C content of the corresponding coding sequence of a wild type RNA, wherein the amino acid sequence encoded by the RNA is preferably not modified compared to the amino acid sequence.

[0370] In some embodiments, a coding sequence (also referred to as a “coding region”) is codon optimized for expression in the subject to whom a composition (e.g., a pharmaceutical composition) is to be administered (e.g., a human). Thus, in some embodiments, sequences in such a polynucleotide (e.g., a nucleotide sequence) may differ from wild type sequences encoding the relevant antigen, fragment or epitope thereof, even when the amino acid sequence of the antigen, fragment or epitope thereof is wild type.

[0371] In some embodiments, strategies for codon optimization for expression in a relevant subject (e.g., a human), and even, in some cases, for expression in a particular cell or tissue.

[0372] Various species exhibit particular bias for certain codons of a particular amino acid. Without wishing to be bound by any one theory, codon bias (differences in codon usage between organisms) often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, among other things, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. The predominance of selected tRNAs in a cell may generally be a reflection of the codons used most frequently in peptide synthesis. Accordingly, genes may be tailored for optimal gene expression in a given organism based on codon optimization. Codon usage tables are available, for example, at the "Codon Usage Database" available at www.kazusa.orjp / codon / and these tables may be adapted in a number of ways. Computer algorithms for codon optimizing a particular sequence for expression in a particular subject or its cells are also available, such as Gene Forge (Aptagen; Jacobus, PA), are also available. 277 11979815v1P-627574-PC

[0373] In some embodiments, a polynucleotide (e.g., a polyribonucleotide or a nucleotide sequence) of the present disclosure is codon optimized, wherein the codons in the polynucleotide (e.g., the polyribonucleotide) are adapted to human codon usage (herein referred to as “human codon optimized polynucleotide”). In some embodiments, a portion of a nucleotide sequence is codon optimized (e.g., a portion of or the portion encoding a glycoprotein or a portion of or the portion encoding a signal sequence). In some embodiments, the entire nucleotide sequence is codon optimized. Codons encoding the same amino acid occur at different frequencies in a subject, e.g., a human. Accordingly, in some embodiments, the coding sequence of a polynucleotide of the present disclosure is modified such that the frequency of the codons encoding the same amino acid corresponds to the naturally occurring frequency of that codon according to the human codon usage, e.g., as shown in Table 7. For example, in the case of the amino acid Ala, the wild type coding sequence is preferably adapted in a way that the codon “GCC” is used with a frequency of 0.40, the codon “GCT” is used with a frequency of 0.28, the codon “GCA” is used with a frequency of 0.22 and the codon “GCG” is used with 30 a frequency of 0.10 etc. (see Table 7). Accordingly, in some embodiments, such a procedure (as exemplified for Ala) is applied for each amino acid encoded by the coding sequence of a polynucleotide to obtain sequences adapted to human codon usage. Table 7: Human codon usage with frequencies indicated for each amino acid. Amino Codon Frequency Amino Codon Frequency11979815v1P-627574-PC Amino Codon Frequency Amino Codon Frequency Acid Acid

[0374] Certain strategies for codon optimization and / or G / C enrichment for human expression are described in WO2002 / 098443, which is incorporated by reference herein in its entirety. In some embodiments, a coding sequence may be optimized using a multiparametric optimization strategy. In some embodiments, optimization parameters may include parameters that influence protein expression, which can be, for example, impacted on a transcription level, an RNA level, and / or a translational level. In some embodiments, exemplary optimization parameters include, but are not limited to transcription-level parameters (including, e.g., GC content, consensus splice sites, cryptic splice sites, SD sequences, TATA boxes, termination signals, artificial recombination sites, and combinations thereof); RNA-level parameters (including, e.g., RNA instability motifs, 279 11979815v1P-627574-PC ribosomal entry sites, repetitive sequences, and combinations thereof); translation-level parameters (including, e.g., codon usage, premature poly(A) sites, ribosomal entry sites, secondary structures, and combinations thereof); or combinations thereof. In some embodiments, a coding sequence may be optimized by a GeneOptimizer algorithm as described in Fath et al. “Multiparameter RNA and Codon Optimization: A Standardized Tool to Assess and Enhance Autologous Mammalian Gene Expression” PLoS ONE 6(3): e17596; Rabb et al., which is incorporated herein by reference in its entirety, “The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization” Systems and Synthetic Biology (2010) 4:215-225; and Graft et al. “Codon- optimized genes that enable increased heterologous expression in mammalian cells and elicit efficient immune responses in mice after vaccination of naked DNA” Methods Mol Med (2004) 94:197-210, the entire content of each of which is incorporated herein for the purposes described herein. In some embodiments, a coding sequence may be optimized by Eurofins’ adaption and optimization algorithm “GENEius” as described in Eurofins’ Application Notes: Eurofins’ adaption and optimization software “GENEius” in comparison to other optimization algorithms, the entire content of which is incorporated by reference for the purposes described herein.

[0375] In some embodiments, a coding sequence utilized in accordance with the present disclosure has G / C content that is increased compared to a coding sequence for an HSV gC, gD, and / or gE (or immunogenic fragment thereof) construct described herein. In some embodiments, guanosine / cytidine (G / C) content of a coding region is modified relative to a comparable coding sequence for an HSV gC, gD, and / or gE (or immunogenic fragment thereof) construct described herein, but the amino acid sequence encoded by the nucleotide sequence is not modified.

[0376] Without wishing to be bound by any particular theory, it is proposed that GC enrichment may improve translation of a payload sequence. Typically, sequences having an increased G (guanosine) / C (cytidine) content are more stable than sequences having an increased A (adenosine) / U (uridine) content. In respect to the fact that several codons code for one and the same amino acid (so-called degeneration of the genetic code), the most favorable codons for the stability can be determined (so-called alternative codon usage). Depending on the amino acid to be encoded by a nucleotide sequence, there are various possibilities for modification of the ribonucleic acid sequence, compared to its wild type sequence. In particular, codons which contain A and / or U nucleosides can be modified by substituting these codons by other codons, which code 280 11979815v1P-627574-PC for the same amino acids but contain no A and / or U or contain a lower content of A and / or U nucleosides.

[0377] In some embodiments, G / C content of a coding region of a nucleotide sequence described herein is increased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, or even more compared to the G / C content of the coding region prior to codon optimization, e.g., of the wild type RNA. In some embodiments, G / C content of a coding region of a nucleotide sequence described herein is decreased by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 6%, or even more compared to the G / C content of the coding region prior to codon optimization, e.g., of the wild type RNA.

[0378] In some embodiments, stability and translation efficiency of a nucleotide sequence may incorporate one or more elements established to contribute to stability and / or translation efficiency of the nucleotide sequence; exemplary such elements are described, for example, in PCT / EP2006 / 009448 incorporated herein by reference. In some embodiments, to increase expression of a nucleotide sequence used according to the present disclosure, a nucleotide sequence may be modified within the coding region, i.e., the sequence encoding the expressed peptide or protein, without altering the sequence of the expressed peptide or protein, for example so as to increase the GC-content to increase RNA stability and / or to perform a codon optimization and, thus, enhance translation in cells. Methods of Treatment and Uses of the Compositions

[0379] In some embodiments, the present disclosure provides methods of inhibiting an HSV oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of suppressing an HSV oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of reducing the incidence of an HSV oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of preventing an HSV oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of treating an HSV oral mucosal infection in a subject comprising administering a composition of the present disclosure.

[0380] In some embodiments, an HSV oral mucosal infection is an HSV-1 infection. In another embodiment, an oral mucosal infection is an HSV-2 infection. In other embodiments, the present 281 11979815v1P-627574-PC disclosure provides methods of treating an oral mucosal infection in a subject comprising administering a composition of the present disclosure.

[0381] In some embodiments, the present disclosure provides methods of inhibiting an HSV-1 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of suppressing an HSV- 1 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of reducing the incidence of an HSV-1 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of preventing an HSV-1 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of treating an HSV-1 oral mucosal infection in a subject comprising administering a composition of the present disclosure.

[0382] In some embodiments, the present disclosure provides methods of inhibiting an HSV-2 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of suppressing an HSV- 2 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of reducing the incidence of an HSV-2 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of preventing an HSV-2 oral mucosal infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of treating an HSV-2 oral mucosal infection in a subject comprising administering a composition of the present disclosure.

[0383] In some embodiments, the present disclosure provides methods of inhibiting HSV encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of suppressing HSV encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of reducing the incidence of HSV encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of preventing HSV encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present 282 11979815v1P-627574-PC disclosure provides methods of treating HSV encephalitis in a subject comprising administering a composition of the present disclosure.

[0384] In some embodiments, HSV encephalitis is an HSV-1 infection. In another embodiment, an oral mucosal infection is an HSV-2 infection. In other embodiments, the present disclosure provides methods of treating an oral mucosal infection in a subject comprising administering a composition of the present disclosure.

[0385] In some embodiments, the present disclosure provides methods of inhibiting HSV-1 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of suppressing HSV-1 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of reducing the incidence of HSV-1 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of preventing HSV-1 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of treating HSV-1 encephalitis in a subject comprising administering a composition of the present disclosure.

[0386] In some embodiments, the present disclosure provides methods of inhibiting HSV-2 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of suppressing HSV-2 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of reducing the incidence of HSV-2 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of preventing HSV-2 encephalitis in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of treating HSV-2 encephalitis in a subject comprising administering a composition of the present disclosure.

[0387] In other embodiments, the present disclosure provides methods of preventing establishment of a latent HSV infection in a subject comprising administering a composition of the present disclosure. In other embodiments, the present disclosure provides methods of treating a latent HSV infection in a subject comprising administering a composition of the present disclosure. In some embodiments, the latent HSV infection is an HSV-1 infection. In other embodiments, the latent HSV infection is an HSV-2 infection. 283 11979815v1P-627574-PC

[0388] In some embodiments, the latent HSV infection is in the dorsal root ganglia. In other embodiments, the latent HSV infection is in the trigeminal ganglia. In other embodiments, the latent HSV infection is in the brain. In other embodiments, the latent HSV infection is in the olfactory bulb. In other embodiments, the latent HSV infection is in any combination of dorsal root ganglia, trigeminal ganglia, brain, or olfactory bulb.

[0389] In some embodiments, the latent HSV infection is detected in the dorsal root ganglia. In other embodiments, the latent HSV infection is detected in the trigeminal ganglia. In other embodiments, the latent HSV infection is detected in the brain. In other embodiments, the latent HSV infection is detected in the olfactory bulb. In other embodiments, the latent HSV infection is detected in any combination of dorsal root ganglia, trigeminal ganglia, brain, or olfactory bulb. In some embodiments, the latent HSV infection is an HSV-1 infection. In other embodiments, the latent HSV infection is an HSV-2 infection.

[0390] In other embodiments, the present disclosure provides methods of suppressing or inhibiting an HSV infection of the dorsal root ganglia, trigeminal ganglia, brain, olfactory bulb, or a combination thereof in a subject comprising administering to said subject a composition of the present disclosure.

[0391] In other embodiments, the present disclosure provides methods of treating or inhibiting an HSV-1 infection in a subject comprising the step of administering a composition comprising one or more RNA encoding Herpes Simplex Virus-2 (HSV-2) proteins, or immunogenic fragments thereof. In some embodiments, the HSV-2 protein comprises an HSV-2 glycoprotein, or an immunogenic fragment thereof. In some embodiments, the HSV-2 glycoprotein comprises an HSV-2 glycoprotein D (gD) or an immunogenic fragment thereof, an HSV glycoprotein C (gC) or an immunogenic fragment thereof, and an HSV glycoprotein E (gE) or an immunogenic fragment thereof. For example, said RNAs can be one or more RNAs comprising a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 6.

[0392] In other embodiments, the present disclosure provides methods of inhibiting an HSV-1 infection in a subject comprising the step of administering a composition comprising one or more RNA encoding Herpes Simplex Virus-2 (HSV-2) proteins, or immunogenic fragments thereof. In other embodiments, the present disclosure provides methods of treating an HSV-1 infection in a subject comprising the step of administering a composition comprising one or more RNA encoding 284 11979815v1P-627574-PC Herpes Simplex Virus-2 (HSV-2) proteins, or immunogenic fragments thereof. In other embodiments, the present disclosure provides methods of suppressing an HSV-1 infection in a subject comprising the step of administering a composition comprising one or more RNA encoding Herpes Simplex Virus-2 (HSV-2) proteins, or immunogenic fragments thereof. In other embodiments, the present disclosure provides methods of reducing the incidence of an HSV-1 infection in a subject comprising the step of administering a composition comprising one or more RNA encoding Herpes Simplex Virus-2 (HSV-2) proteins, or immunogenic fragments thereof. For example, said RNAs can be one or more RNAs comprising a nucleotide sequence at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% identical to a sequence listed in Table 6.

[0393] In some embodiments, the present disclosure provides methods of vaccinating a subject against HSV and treating, impeding, inhibiting, reducing the incidence of, or suppressing an HSV infection or a symptom or manifestation thereof, comprising administration of a composition of the present disclosure.

[0394] In some embodiments, the present disclosure provides a method for treating an HSV infection in a subject, comprising contacting said subject with a composition comprising one or more RNAs, wherein each of said RNAs encodes an HSV glycoprotein or immunogenic fragment thereof.

[0395] In another embodiment, the present disclosure provides a method for suppressing an HSV infection in a subject, comprising contacting said subject with a composition comprising one or more RNAs, wherein each of said RNAs encodes an HSV glycoprotein or immunogenic fragment thereof.

[0396] In another embodiment, the present disclosure provides a ...

Claims

P-627574-PC CLAIMS What is claimed is:

1. A method of treating or inhibiting a herpes simplex virus (HSV) oral mucosal infection, an HSV encephalitis infection, or a combination thereof in a subject comprising administering to said subject: (a) a first composition comprising RNA encoding HSV glycoprotein D (gD) or an immunogenic fragment thereof, (b) a second composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and (c) a third composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof.

2. The method of claim 1, wherein said infection is a primary infection or a secondary infection.

3. The method of claim 1 or claim 2, wherein one or more of said RNAs comprise one or more ribonucleic acids that are nucleoside modified.

4. The method of claim 3, wherein the one or more nucleoside modified ribonucleic acids comprise one or more m5D (5-methyldihydrouridine) residues.

5. The method of claim 3, wherein the one or more nucleoside modified ribonucleic acids comprise one or more pseudouridine residues.

6. The method of claim 5, wherein said one or more pseudouridine residues comprise m1Ψ (1- methylpseudouridine).

7. The method of claim 6, wherein said one or more pseudouridine residues comprise m1acp3Ψ (1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine, Ψm (2′-O-methylpseudouridine, m3Ψ (3-methylpseudouridine), or any combination thereof.

8. The method of any one of claims 1-7, wherein: (a) the HSV gC or an immunogenic fragment thereof is an HSV-2 gC or immunogenic fragment thereof; (b) the HSV gD or an immunogenic fragment thereof is an HSV-2 gD or immunogenic fragment thereof; (c) the HSV gE or an immunogenic fragment thereof is an HSV-2 gE or immunogenic fragment thereof; or (d) any combination thereof. 349 11979815v1P-627574-PC 9. The method of claim 8, wherein: (a) the HSV-2 gC or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 28, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 241, or SEQ ID NO: 242; (b) the HSV-2 gD or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 110, SEQ ID NO: 234, or SEQ ID NO: 120; (c) the HSV-2 gE or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 17 or SEQ ID NO: 18; or (d) any combination thereof.

10. The method of claim 8, wherein: (a) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 25, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, or SEQ ID NO: 246; (b) the RNA encoding HSV-2 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 23, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 247; (c) the RNA encoding HSV-2 gE or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 27, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148; or (d) any combination thereof.

11. The method of claim 8, wherein: (a) the HSV-2 gC or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 224; (b) the HSV-2 gD or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 5; 350 11979815v1P-627574-PC (c) the HSV-2 gE or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 17; or (d) any combination thereof.

12. The method of claim 8, wherein: (a) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 246; (b) the RNA encoding HSV-2 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 247; (c) the RNA encoding HSV-2 gE or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 145; or (d) any combination thereof.

13. The method of claim 12, wherein: (a) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 246; (b) the RNA encoding HSV-2 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 247; and (c) the RNA encoding HSV-2 gE or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO:

145.

14. The method of any one of claims 1-7, wherein: (a) the HSV gC or an immunogenic fragment thereof is an HSV-1 gC or immunogenic fragment thereof; (b) the HSV gD or an immunogenic fragment thereof is an HSV-1 gD or immunogenic fragment thereof; (c) the HSV gE or an immunogenic fragment thereof is an HSV-1 gE or immunogenic fragment thereof; or (d) any combination thereof.

15. The method of claim 14, wherein: (a) the HSV-1 gC or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 240; (b) the HSV-1 gD or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 134; 351 11979815v1P-627574-PC (c) the HSV-1 gE or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 248, or SEQ ID NO: 140; or (d) any combination thereof.

16. The method of claim 14, wherein: (a) the RNA encoding HSV-1 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 24; (b) the RNA encoding HSV-1 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 22; (c) the RNA encoding HSV-1 gE or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 26; or (d) any combination thereof.

17. The method of any one of claims 1-16, wherein: (a) the immunogenic fragment of HSV gC comprises the ectodomain of HSV gC, (a) the immunogenic fragment of HSV gD comprises the ectodomain of HSV gD, (b) the immunogenic fragment of HSV gE comprises the ectodomain of HSV gE, or (c) any combination thereof.

18. The method of any one of claims 1-17, further comprising administering to the subject one or more RNAs encoding (a) HSV glycoprotein B (gB) or immunogenic fragment thereof, (b) HSV glycoprotein H (gH) or immunogenic fragment thereof, (c) HSV glycoprotein L (gL) or immunogenic fragment thereof, (d) HSV glycoprotein I (gI) or immunogenic fragment thereof, or (e) any combination thereof.

19. The method of any one of claims 1-18, wherein one or more of said RNAs further comprise a signal sequence encoding a signal peptide.

20. The method of claim 19, wherein the signal peptide comprises an amino acid sequence of any one of SEQ ID NO: 29-48 and 220-222.

21. The method of claim 19, wherein the signal sequence is or comprises any signal sequence listed in Table 4.

22. The method of claim 20, wherein the signal peptide comprises an IL-2 signal peptide.

23. The method of claim 20, wherein the signal peptide comprises a viral signal peptide. 352 11979815v1P-627574-PC 24. The method of claim 23, wherein the viral signal peptide comprises an HSV signal peptide.

25. The method of claim 24, wherein the HSV signal peptide comprises an HSV gD signal peptide.

26. The method of claim 25, wherein the HSV gD signal peptide comprises an HSV-1 gD signal peptide.

27. The method of claim 26, wherein the HSV-1 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO: 34 or SEQ ID NO:

35.

28. The method of claim 26, wherein the HSV-1 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO:

35.

29. The method of claim 25, wherein the HSV gD signal peptide is an HSV-2 gD signal peptide.

30. The method of claim 29, wherein the HSV-2 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO:

33.

31. The method of claim 30, wherein the HSV-2 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO: 29 or SEQ ID NO:

31.

32. The method of any one of claims 19-31, wherein the signal sequence is a codon optimized signal sequence.

33. The method of any one of claims 1-32, wherein one or more of said RNAs further comprise a poly-A tail.

34. The method of any one of claims 1-33, wherein one or more of said RNAs further comprise a cap.

35. The method of claim 34, wherein the cap is an m7GpppG cap, 3′-O-methyl-m7GpppG cap, or anti-reverse cap analog.

36. The method of any one of claims 1-35, wherein one or more of said RNAs further comprise a cap-independent translational enhancer.

37. The method of any one of claims 1-36, wherein one or more of said RNAs further comprise 5′ and / or 3′ untranslated regions.

38. The method of any one of claims 1-37, wherein one or more of said RNAs are formulated with a nanoparticle, lipid, polymer, cholesterol, cell penetrating peptide, or any combination thereof.

39. The method of claim 38, wherein said nanoparticle is a lipid nanoparticle. 353 11979815v1P-627574-PC 40. The method of any one of claims 1-39, wherein administration comprises intramuscular administration.

41. The method of any one of claims 1-39, wherein administration comprises subcutaneous administration.

42. The method of any one of claims 1-39, wherein administration comprises intradermal administration.

43. The method of any one of claims 1-39, wherein administration comprises intranasal, intravaginal, or intrarectal administration.

44. The method of any one of claims 1-39, wherein administration comprises topical administration.

45. The method of any one of claims 1-44, wherein the first composition, second composition, and third composition are different compositions.

46. The method of any one of claims 1-44, wherein the first composition, second composition, and third composition are the same composition.

47. The method of any one of claims 1-46, wherein administering to said subject comprises administering one or more doses of each of the first composition, second composition, or third composition.

48. The method of any one of claims 1-47, wherein said HSV oral mucosal infection, HSV encephalitis infection, or both are HSV-1 infections.

49. A method of preventing establishment of a latent Herpes Simplex Virus (HSV) infection in a subject comprising administering to said subject: (a) a first composition comprising RNA encoding HSV glycoprotein D (gD) or an immunogenic fragment thereof, (b) a second composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and (c) a third composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof.

50. The method of claim 49, wherein one or more of said RNAs comprise one or more ribonucleic acids that are nucleoside modified.

51. The method of claim 49 or claim 50, wherein the one or more nucleoside modified ribonucleic acids comprise one or more m5D (5-methyldihydrouridine) residues. 354 11979815v1P-627574-PC 52. The method of claim 49 or claim 50, wherein the one or more nucleoside modified ribonucleic acids comprise one or more pseudouridine residues.

53. The method of claim 52, wherein said one or more pseudouridine residues comprise m1Ψ (1-methylpseudouridine).

54. The method of claim 52, wherein said one or more pseudouridine residues comprise m1acp3Ψ (1-methyl-3-(3-amino-5-carboxypropyl)pseudouridine, Ψm (2′-O- methylpseudouridine, m3Ψ (3-methylpseudouridine), or any combination thereof.

55. The method of any one of claims 49-54, wherein: (a) the HSV gC or an immunogenic fragment thereof is an HSV-2 gC or immunogenic fragment thereof, (b) the HSV gD or an immunogenic fragment thereof is an HSV-2 gD or immunogenic fragment thereof, (c) the HSV gE or an immunogenic fragment thereof is an HSV-2 gE or immunogenic fragment thereof, (d) any combination thereof.

56. The method of claim 55, wherein: (a) the HSV-2 gC or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 28, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 241, or SEQ ID NO: 242; (b) the HSV-2 gD or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 110, SEQ ID NO: 234, or SEQ ID NO: 120; (c) the HSV-2 gE or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 17 or SEQ ID NO: 18; or (d) any combination thereof.

57. The method of claim 55, wherein: (a) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 25, SEQ ID NO: 119, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 123, SEQ ID NO: 124, SEQ ID NO: 125, SEQ ID NO: 126, SEQ ID NO: 127, SEQ ID NO: 128, SEQ ID NO: 129, SEQ ID NO: 130, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 218, SEQ 355 11979815v1P-627574-PC ID NO: 219, SEQ ID NO: 237, SEQ ID NO: 238, SEQ ID NO: 239, or SEQ ID NO: 246; (b) the RNA encoding HSV-2 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 23, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 247; (c) the RNA encoding HSV-2 gE or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 27, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 143, SEQ ID NO: 144, SEQ ID NO: 145, SEQ ID NO: 146, SEQ ID NO: 147, or SEQ ID NO: 148; or (d) any combination thereof.

58. The method of claim 56, wherein: (a) the HSV-2 gC or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 224; (b) the HSV-2 gD or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 5; (c) the HSV-2 gE or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 17; or (d) any combination thereof.

59. The method of claim 57, wherein: (a) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 246; (b) the RNA encoding HSV-2 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 247; (c) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 145; or (d) any combination thereof.

60. The method of claim 59, wherein: (a) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 246; (b) the RNA encoding HSV-2 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 247; and 356 11979815v1P-627574-PC (c) the RNA encoding HSV-2 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO:

145.

61. The method of any one of claims 49-60, wherein: (a) the HSV gC or an immunogenic fragment thereof is an HSV-1 gC or immunogenic fragment thereof, (b) the HSV gD or an immunogenic fragment thereof is an HSV-1 gD or immunogenic fragment thereof, (c) the HSV gE or an immunogenic fragment thereof is an HSV-1 gE or immunogenic fragment thereof, or (d) any combination thereof.

62. The method of claim 61, wherein: (a) the HSV-1 gC or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 8, SEQ ID NO: 9, or SEQ ID NO: 240; (b) the HSV-1 gD or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 2, SEQ ID NO: 3, or SEQ ID NO: 134; (c) the HSV-1 gE or immunogenic fragment thereof comprises an amino acid sequence at least 85% identical to SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 248, or SEQ ID NO: 140; or (d) any combinations thereof.

63. The method of claim 61, wherein: (a) the RNA encoding HSV-1 gC or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 24; (b) the RNA encoding HSV-1 gD or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 22; (c) the RNA encoding HSV-1 gE or an immunogenic fragment thereof comprises a nucleotide sequence at least 85% identical to SEQ ID NO: 26; or (d) any combinations thereof.

64. The method of claim 61, wherein: (a) the immunogenic fragment of HSV gC comprises the ectodomain of HSV gC, (b) the immunogenic fragment of HSV gD comprises the ectodomain of HSV gD, (c) the immunogenic fragment of HSV gE comprises the ectodomain of HSV gE, or (d) any combination thereof. 357 11979815v1P-627574-PC 65. The method of any one of claims 49-64, further comprising administering one or more RNAs encoding (a) an HSV glycoprotein B (gB) or immunogenic fragment thereof, (b) an HSV glycoprotein H (gH) or immunogenic fragment thereof, (c) an HSV glycoprotein L (gL) or immunogenic fragment thereof, (d) an HSV glycoprotein I (gI) or immunogenic fragment thereof, or (e) any combination thereof.

66. The method of any one of claims 49-65, wherein one or more of said RNAs further comprise a signal sequence encoding a signal peptide.

67. The method of claim 66, wherein the signal peptide comprises an amino acid sequence of any one of SEQ ID NO: 29-48 and 220-222.

68. The method of claim 66, wherein the signal sequence is or comprises any signal sequence listed in Table 4.

69. The method of claim 66, wherein the signal peptide is an IL-2 signal peptide.

70. The method of claim 66, wherein the signal peptide is a viral signal peptide.

71. The method of claim 70, wherein the viral signal peptide is an HSV signal peptide.

72. The method of claim 71, wherein the HSV signal peptide is an HSV gD signal peptide.

73. The method of claim 72, wherein the HSV gD signal peptide is an HSV-1 gD signal peptide.

74. The method of claim 73, wherein the HSV-1 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO: 34 or SEQ ID NO:

35.

75. The method of claim 74, wherein the HSV-1 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO:

35.

76. The method of claim 72, wherein the HSV gD signal peptide is an HSV-2 gD signal peptide.

77. The method of claim 76, wherein the HSV-2 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO: 29, SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, or SEQ ID NO:

33.

78. The method of claim 76, wherein the HSV-2 gD signal peptide comprises an amino acid sequence at least 85% identical to SEQ ID NO: 29 or SEQ ID NO:

31.

79. The method of any one of claims 66-78, wherein the signal sequence is a codon optimized signal sequence.

80. The method of any one of claims 49-79, wherein one or more of said RNAs further comprise a poly-A tail. 358 11979815v1P-627574-PC 81. The method of any one of claims 49-80, wherein one or more of said RNAs further comprise a cap.

82. The method of claim 81, wherein the cap is an m7GpppG cap, 3′-O-methyl-m7GpppG cap, or anti-reverse cap analog.

83. The method of any one of claims 49-82, wherein one or more of said RNAs further comprise a cap-independent translational enhancer.

84. The method of any one of claims 49-83, wherein one or more of said RNAs further comprise 5′ and / or 3′ untranslated regions.

85. The method of any one of claims 49-84, wherein one or more of said RNAs are formulated with a nanoparticle, lipid, polymer, cholesterol, cell penetrating peptide, or any combination thereof.

86. The method of claim 85, wherein said nanoparticle is a lipid nanoparticle.

87. The method of any one of claims 49-86, wherein said latent HSV infection comprises an HSV-1 infection.

88. The method of any one of claims 49-86, wherein said latent HSV infection comprises an HSV-2 infection.

89. The method of any one of claims 49-88, wherein administration comprises intramuscular administration.

90. The method of any one of claims 49-88, wherein administration comprises subcutaneous administration.

91. The method of any one of claims 49-88, wherein administration comprises intradermal administration.

92. The method of any one of claims 49-88, wherein administration comprises intranasal, intravaginal, or intrarectal administration.

93. The method of any one of claims 49-88, wherein administration comprises topical administration.

94. The method of any one of claims 49-93, wherein the first composition, second composition, and third composition are different compositions.

95. The method of any one of claims 49-93, wherein the first composition, second composition, and third composition are the same composition. 359 11979815v1P-627574-PC 96. The method of any one of claims 49-95, wherein administration to said subject comprises administering one or more doses of each of the first composition, second composition, or third composition.

97. The method of any one of claims 49-96, wherein said latent HSV infection is in the dorsal root ganglia, trigeminal ganglia, brain, olfactory bulb, or any combination thereof.

98. A method of treating or inhibiting a Herpes Simplex Virus (HSV) infection of the dorsal root ganglia, trigeminal ganglia, brain, olfactory bulb, or a combination thereof in a subject comprising administering to said subject: (a) a first composition comprising RNA encoding HSV glycoprotein D (gD) or an immunogenic fragment thereof, (b) a second composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and (c) a third composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof.

99. The method of claim 98, wherein said HSV infection is an HSV-1 infection.

100. A combination for use in treating or inhibiting a Herpes Simplex Virus (HSV) oral mucosal infection, an HSV encephalitis infection, or a combination thereof; or an HSV-1 infection, wherein the combination comprises: (a) a composition comprising RNA encoding HSV glycoprotein D (gD) or an immunogenic fragment thereof, (b) a composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and (c) a composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof, wherein the use comprises administering one or more doses of one or more of the compositions.

101. The combination of claim 100, wherein the infection is a latent infection, a primary infection, or a secondary infection.

102. The combination of claim 100, wherein the infection is in the dorsal root ganglia, trigeminal ganglia, brain, olfactory bulb, or any combinations thereof. 360 11979815v1P-627574-PC 103. Use of a combination for treating or inhibiting Herpes Simplex Virus (HSV) oral mucosal infection, encephalitis infection, or a combination thereof; or an HSV-1 infection, wherein the combination comprises: (a) a composition comprising RNA encoding HSV glycoprotein D (gD) or an immunogenic fragment thereof, (b) a composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and (c) a composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof, wherein the use comprises administering one or more doses of one or more of the compositions.

104. Use of a combination for the manufacture of a medicament for treating or inhibiting Herpes Simplex Virus (HSV) oral mucosal infection, an HSV encephalitis infection, or a combination thereof; or an HSV-1 infection, wherein the combination comprises: (a) a composition comprising RNA encoding HSV glycoprotein D (gD) or an immunogenic fragment thereof, (b) a composition comprising RNA encoding HSV glycoprotein C (gC) or an immunogenic fragment thereof, and (c) a composition comprising RNA encoding HSV glycoprotein E (gE) or an immunogenic fragment thereof, wherein the use comprises administering one or more doses of one or more of the compositions.

105. The use of claim 103 or 104, wherein the infection is a latent infection, a primary infection, or a secondary infection.

106. The use of any one of claims 103-105, wherein the infection is in the dorsal root ganglia, trigeminal ganglia, brain, olfactory bulb, or any combination thereof. 361 11979815v1

Citation Information

Patent Citations

  • Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast

    US20120121630A1

  • Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

    US20210386853A1

  • Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof

    WO2019035066A1

Cited By

  • HSV antigen fragments and related methods

    WO2026015882A1